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ABSTRACT
The concentrations of the galactoside-binding galectin-3 are greatly increased in 
the circulation of cancer patients and in particular those with metastasis. It shows 
here that galectin-3 at pathologically-relevant concentrations induces marked 
increase of cancer cell homotypic aggregation, heterotypic adhesion to vascular 
endothelium and trans-endothelial invasion in vitro under static and flow 
conditions and decreases the latency of experimental metastasis in athymic nude 
mice. These effects are shown to be a consequence of the interaction between 
galectin-3 and TF antigen on cancer-associated MUC1 by inducing MUC1 cell 
surface re-localization/polarization thus revealing the otherwise concealed cell 
adhesion molecules including CD44 and E-Cadherin. These findings suggest that 
interaction between circulating galectin-3 and cancer-associated MUC1 is an 
important mechanism in promoting haematogenous dissemination of tumour cells 
to remote sites.
It also shows here that peanut agglutinin, a-TF-binding lectin from peanut, at 
concentrations similar to that observed in the blood circulation of people who 
ingested 200g peanuts induces homotypic aggregation and heterotypic adhesion 
to vascular endothelial cells in vitro. The cell aggregates induced by PNA 
increases the survival and resistance of cancer cells to anoilds initiation under 
anchorage-independent conditions. These results suggest a detrimental effect of 
the presence of peanuts in the diet of cancer patients on patients' survival.
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CHAPTER 1
1. Introduction
1.1. Metastasis of epithelial cancers
1.1.1. Cancer and metastasis
Twenty-three per cent of all deaths in the US (US Mortality Data 2006. National 
Center for Health Statistics, Centers for Disease Control and Prevention, 2009. 
http://www.cdc,gov/ ) and 27% of all deaths in the UK are due to cancer (1-3). 
About 293,600 new cancer cases were diagnosed in the UK in 2006 (1, 2, 4). 
This means one new cancer case every two minutes in the UK. Metastasis is the 
main reason for cancer-related fatality. Although the mortality rate for all 
neoplasm fell by 10% in the UK from 1998 to 2007, cancer-associated casualty 
remains one of the major disease-associated mortality in UK (1-3).
1.1.2. The metastasis cascade
Cancer metastasis from primary to remote tumour sites is a sequential 
interrelated multi-stepped process (5). The major steps are as follows: (a) 
neoplastic cells transform and grow progressively at the primary tumour sites, 
(b) extensive vascularization occurs when the tumour mass exceeds 2 mm in 
diameter, (c) tumour cells invade through the host blood vessel wall into the 
blood/lymphatic circulation, (d) cancer cells survive in the circulation with 
formation of tumour microemboli, (e)tumour microemboli adhere to the blood
vessel wall endothelium at a distant site, (f) extravasion and growth of the 
tumour cells at the remote site (5).
Thus, homotypic cell-cell aggregation of cancer cells and their heterotypic 
adhesion to the vascular endothelium are two of the key steps in the cancer 
metastasis cascade.
a Primary tumour b Proliferation/ c Detachment/ d Embolism/circulation
angiogenesis invasion
venules.
capillaries Interaction with oiatotots.
lymphocytes OhC Other 
Mood cornponenls
e Extravasation Adherence to Arrest in organs Transport
vessel wall
Fig 1-1, Metastatic cascade (from Fidler 2003) (5)
1.1.3. Cancer cell heterotypic adhesion to endothelial cells
Cancer cell heterotypic adhesion to the vascular endothelium is facilitated by a 
variety of cell surface adhesion molecules (6) (7). Cancer metastasis often 
occurs in an organ-specific manner. For example, the regional lymph nodes, 
bone marrow, lung and liver are the specific metastasis organs for breast cancer.
whereas preferred metastatic sites for colon cancer are the lung, liver, brain, 
adrenal glands and skeleton (8).
Three mechanisms have been proposed in the past to explain the organ-specific 
manner of cancer metastasis: circulation patterns, mechanical trapping and cell 
adhesion.
The circulation pattern, for example the direction and connection of lymphatic 
or venous drainage, is clearly a significant factor determining the site of 
metastasis. However, direct connection alone provides only a partial explanation 
for organ-specific metastasis (5). For example, the preferred metastasis organs 
of breast cancer are the lungs, bones, liver and brain (9), some of which do not 
have a direct circulatory connection to the breast. Experimental intravenous 
injection of melanoma cells in animal models demonstrated that, although 
tumour cells reached the vasculature of all organs, metastases developed in the 
orthotopic and grafted lungs and ovaries, but not in the kidneys (10). Thus, 
cancer spread to secondary tumour sites cannot be explained solely by 
circulation patterns.
The mechanical trapping theory hypothesizes that the initial site of tumour 
arrest depends heavily on the relative size of the tumour cells and tumour cell 
clusters (11). Thus, cancer cell clusters/aggregates, by acting as microemboli, 
produce more metastases than single cell populations (12-14). However, it has 
been observed that colon carcinoma cells with different metastatic capacities 
preferentially arrest in lung and liver capillaries, although the diameters of
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involved microvessels were larger than the adherent tumour cells (8). This 
indicates that a mechanical trap alone cannot explain organ-specific metastasis 
of all types of cancers.
The cell adhesion mechanism suggests that the tumour cell arrest in the target 
organs in metastasis may be controlled primarily by the specific expression of 
cell adhesion molecules on cancer cells as well as on the vascular endothelial 
cells (15-17). In a recent study of breast cancer, 344 primary breast tumours of 
lymph node-negative patients were classified into different molecular subtypes 
(including luminal A) according to the intrinsic' gene list describing the 
subtypes. Luminal A subtype was abundant in bone relapse but absent in lung 
relapse,while focal adhesion was found up-regulated in the luminal A subtype 
but down-regulated in lung relapse (18). This indicates (a) that molecular 
subtypes cause preferential metastasis at different sites and (b) rate of metastasis 
in the lung is reduced as a consequence of down-regulation of local adhesion in 
the luminal A relapse. Although the exact adhesion molecules involved in 
cancer cell adhesion to endothelial cells are still unclear, four families of 
adhesion molecules, including E-selectin, cell adhesion molecules (CAMs) (19), 
CD44 (16) and integrins (17), are believed to be involved.
E-selectin is an important endothelial cell surface adhesion molecule whose 
physiological role is known to mediate the rolling of neutrophils, monocytes 
and memory T cells on the endothelium before their extravasation at sites of 
inflammation (20, 21). There is evidence that E-selectin is also involved in 
cancer-endothelial adhesion in metastasis (15, 22, 23). For example, E-selectin-
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mediated binding of colonic carcinoma cells to human and mouse endothelial 
cells has been shown to correlate with the metastatic potential of the cells (24). 
Addition chimeric molecules containing extracellular regions of E-selectin 
coupled with the Fc portion of human IgGl, inhibits colon carcinoma HT-29 cell 
adhesion to the endothelium monolayer and the formation of lung metastases, 
while control L-selectin-immunoglobulin had no effect, although it can still bind 
to the HT29 cells (25). Murine carcinoma H-59 cell adhesion to the endothelial 
cells pre-activated with tumour necrosis factor-alpha (TNF-cl a cytokine that 
stimulates the acute phase reaction) could be completely and specifically 
abolished by a neutralizing monoclonal antibody to murine E-selectin (MAb 
9A9) in vitro. The presence of the MAb 9A9 reduced the median number of 
liver metastases of Fl-59 cells by 97% in comparison to the control group in 
syngeneic mice (15).
Cell surface CD44 molecules have been shown to be involved cell-cell and 
cell-matrix interaction. The cell surface CD44 promotes tumour cell survival in 
invaded tissue (26) and metastasis. Several experiments using animal metastasis 
models have shown a correlation between increased CD44 expression and 
metastatic capability in cultured human melanoma (27), lymphoma cell lines 
(28) and rat pancreatic carcinoma cells (29). CD44 is also involved in the 
adhesion of cancer cells to a wide range of extracellular matrix (ECM) 
components (30). Hyaluronan (HA) is the major ligand of CD44 (31). There are 
many reports showing that the CD44-associated metastasis is linked to its 
binding to HA (32-35). Interactions between HA/CD44-stimulated p300 
(acetyltransferase) and resveratrol-activated SIRT1 (deacetylase) play critical
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roles in regulating the balance between cell survival and apoptosis, and between 
multi-drug resistance and sensitivity in breast tumor cells (36). Hyaluronan- 
mediated CD44 activation of RlioGTPase signalling and cytoskeleton function 
promotes tumour progression (37). Heregulin-mediated ErbB2-ERK signalling 
activates hyaluronan synthases leading to CD44-dependent ovarian tumour cell 
growth and migration (38).
There are also reports showing that the effect of CD44 on metastasis may not be 
dependant on its binding to HA(39, 40). The CD44 proteins have multiple 
protein isoforms as a result of their various splicing variants and it has been 
suggested that splicing variation and glycosylation play an important role in 
determining CD44-ligand binding (41). CD44 cross-linking with the CD44 
receptor on the human breast tumour cell line (MDA-MB-435s) has been shown 
to lead to the enhanced expression and relocation of MMP-9 in human breast 
tumour cells and increased tumour invasion and metastasis (42). There are also 
studies showing that the degradation products of tumour-associated ECMs 
(extracellular matrix components) interact with CD44 and are involved in 
CD44-mediated tumour progression (43).
1.1.4. Cancer cell homotypic aggregation in metastasis
There are strong links between the ability of tumour cells to form homotypic 
aggregation and metastasis. Homotypic cancer cell aggregation at the sites of 
their primary attachment to the endothelium has been shown in vitro, ex vivo 
and in vivo with metastatic breast and prostate carcinoma cells (44). It shows
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that cancer cells selected in vitro for an enhanced homotypic aggregation 
kinetics produce significantly higher in vivo experimental metastasis than the 
less aggregated parental cells, and also in vivo selection of tumour cells for high 
metastatic potential exhibiting increased homotypic aggregation properties (45- 
47). Aggregates of cancer cells have been shown to have higher survival rates in 
the blood circulation than single cells (13, 14). Intraportal injection of 
aggregated DHD/K12/TRb colon cancer cells into syngeneic BD IX rats 
produced over four times more liver metastases than injection with the same 
numbers of single cells (12).
It has been demonstrated that the aggregates of cancer cells arrest more 
efficiently in the small vasculature and increase metastasis (48). It has been 
suggested that the enhanced metastatic potential of cancer cell aggregates may 
be linked to resistance of the cells to the anoikis (suspension-induced apoptosis) 
(49). Anoikis is a specific type of apoptotic process induced by loss of cell 
adhesion or inadequate cell-matrix interactions (50). It has been suggested that 
anoikis is the dominant mechanism of removing disseminating tumour cells 
from the circulation (51).
It is well known that after invasion of the primary tumour cells into the 
circulation, only very few of them can survive in the circulation and eventually 
cause metastasis at remote organs in cancer patients (52, 53). Studies using 
cancer cell labelling with 125iodineiodo-deoxyuridine have shown that less than 
0.1% of tumour cells are still viable 24 hours after their injection into the animal, 
and that less than 0.01% of these cells can survive to eventually produce
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metastases (54). The ability of cancer cells to avoid destruction and survive 
from blood circulation would represent an important factor in the process of 
cancer metastasis (55). Prolonged survival of tumour cells in the circulation is 
directly associated with increased metastasis in BALB/c nude mice (56).
E-cadherin is a transmembrane glycoprotein that plays a major role in calcium- 
dependent, epithelial cell-cell interaction (57, 58). Several reports have shown 
that E-cadherin is expressed on the cell membrane of tumour cells at metastatic 
sites but not in the primary carcinoma sites (59-62). This indicates that E- 
cadherin may play different roles at different stages of cancer development.
1.1.5. Cancer cell extravasations (trans-endothelial invasion)
Cancer cell extravasations metastasis is a vital metastatic stage in which tumour 
cells penetrate the vascular wall at remote organs. It does not matter that some 
people add that extravasion starts from morphological change of the cells, such 
as flattening to increase contact areas, followed by migration through the 
vascular wall (63) and growth in the new organ.
1.1.6. Cancer cell anoikis in metastasis 
1.1.6.1. Anoilds
Anoikis, a Greek word meaning homeless, is an apoptotic process induced by 
loss or improper contact of the cells with the extracellular matrix (64). Anoikis 
is an important mechanism in removing disseminating tumour cells from the
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circulation (51, 65). Resistance to anoikis is an important feature of metastatic 
cancer cells (52, 66).
As a special type of apoptosis, anoikis-mediated cell death acts through the 
activation of either the intrinsic or extrinsic apoptosis pathways (67, 68). The 
intrinsic apoptosis pathway acts through mitochondria membrane 
permeabilization and cytochrome C release. Following cell detachment from the 
extracellular matrix (ECM) under the anoikis condition. Bid and Bim, members 
of the BH3-oniy family of proteins, are activated and promote the assembly of 
the pro-apoptotic Bax and Bak oligomers on the outer mitochondrial membrane 
(OMM) (69, 70). This creates channels on OMM (71) and the release of 
cytochrome C. Released cytochrome C then contributes to the apoptosome with 
caspase-9 and the cofactor apoptosis protease activating factor (Apaf), which 
activates the executioner caspases, caspase-3 (72-74). The anti-apoptotic Bcl-2 
protein protects OMM (70, 75, 76) or sequesters the activator Bid and Bim and 
prevents Bax and Bak oligomerization (77, 78). On the other hand, sensitizer 
BH3-only proteins such as Bad, Bik, Bmf, Noxa, Puma and Hrk inhibit the 
action of Bcl-2 by competing for the BH3 domain of Bcl-2, thus allowing the 
action of BH3-only proteins to induce Bax-Bak oligomer formation (79, 80).
The extrinsic apoptosis pathway acts through the extracellular death ligands on 
the cell surface and caspase-8. Following detachment of the cells from ECM, 
the extracellular death ligands, such as Fas Ligand (FasL) and tumour necrosis 
factor-a (TNF-a), bind to their transmembrane death receptors, namely Fas and 
TNF-a receptor (TNFR). This results in the assembly of the death-inducing
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signalling complex (DISC). The formation of DISC attracts other adaptor 
proteins such as the Fas-associated death domain protein (FADDf recruiting 
several molecules of caspase-8, which activate caspase-8? caspase-3 and ~7 and 
apoptosis (70, 81). There are cross-talks between the extrinsic and intrinsic 
apoptotic signalling in some cells (82). In such cases, activation of the death 
receptor ligand on the cell surface is not essential in anoikis initiation. Caspase- 
8 activation comes from activating the intrinsic pathway (83); the extrinsic 
apoptotic signalling could be induced by positive feedback from mitochondrial 
membrane damage (84, 85).
1.1 *6.2. Cell aggregation and anoikis
The majority of the cancer cells that have invaded the blood circulation are 
rapidly destroyed by anoikis or by the immune surveillance system and only a 
very small fraction of the invaded cells can survive and eventually cause 
metastasis at remote sites (54, 71).
It has been shown that cancer cells in aggregated forms develop the ability to 
evade anoikis. For example, aggregated human squamous carcinoma (HSC-3) 
cells shows less apoptosis than the single cell population when cultured for 36 
hours under suspension conditions (86). This enhanced ability of cell aggregates 
to evade anoikis has been suggested to be due to decreased FAK 
phosphorylation and increased p53 levels (86). Malignant pleural mesothelioma 
(MPM) cultured in suspension on poly-HEMA coated tissue culture plates form 
well-organized aggregates in which the cellular PI3K/Akt ERIC and SAPK/JNK
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signalling pathways are found to be inactivated. Impairment of cell aggregation 
by culturing the cells in suspension but under spinning conditions is seen to 
activate SAPK/JNK and Bim and induce anoikis (87). Claudia Hofmann et al. 
have revealed that colonic epithelial cell (CEC) crypts freshly isolated from 
surgical specimens and centrifuged into aggregation pellets show less anoikis in 
comparison to the CEC crypts liberated (passed over the mesh filter 80pm pore 
size) in suspension (88). Thus, formation of cell aggregates results in enhanced 
ability of the cells resistant to anoikis initiation.
1.2. Alteration of cell surface glycosylation in cancer 
1.2.1. General:
Glycosylation is a post-translational process in which sugar residues are 
attached to proteins or lipids. Altered glycosylation occurs in neoplastic and 
inflammatory conditions such as cancer, Crohn's disease, rheumatoid arthritis 
and tuberculosis. It is believed that more than half of the mammalian proteins 
are modified by glycosylation of O- or AMinked glycans (89). //-linked 
glycosylation occurs via attachment of complex and diverse sugar chains 
through ALacetylglucosamine (GlcNAc) to the amide group of asparagine 
residues, //-linked glycosylation occurs on a large number of membrane- 
associated and secreted proteins in eukaryote cells (90). AMinked glycans 
share a common branched trimannosyl core
M i-iri VtarL
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Fig. 1-2 The trimannosyl core, common to all AMinkecl glycans(89)
Man3GlcNAc2-Asn (Fig. 1-2), which may be elaborated to form a diversity of 
heterogeneous, often quite large and bulky, bi-, tri- or tetra-antennary glycans 
(89).
CMinked glycosylation occurs in many cell membrane and secreted proteins. 
The 0-1 inked glycans tend to be smaller and less branched than /V-linked 
glycans. O-glycans are more diverse than /V-linked glycans. The mucin-type 
O-glycans are the most common O-linked glycans and are characterized by 
the attachment of a-/V-acetylgalactosamine (a-GalNAc) to serine and 
threonine residues of proteins. Mucin type O-linked glycosylation is seen in 
(amongst others) epithelial cells, leukocytes and vascular endothelia (90, 91). 
Membrane-bound and secreted mucins carry many O-linked glycans which 
typically comprise more than 50% of the mucin molecular weight (92).
Glycans modulate various aspects of the proteins they attach to, for example
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O-glycans may confer protease resistance of the proteins by protecting 
thermolysin-sensitive regions of the polypeptide (93).
At least eight different core structures have been reported to occur on mucin 
type glycans. All these core structures are based on the core-a-GalNAc 
residue, which is further substituted at C3, C6 or at both positions with (3- 
galactose (Gal) at C3, f3-GlcNAc at C3 and/or C6, and a-GalNAc at C3 or C6 
(Fig 1-3 (94)). This results in the formation of either core 1, core 2 or core 3 
structures. Some of the mucin-type 0-linked glycans are cancer-associated 
antigens, this includes GalNAc- (Tn), sialyl-GalGAc (sialyl-Tn) and 
Gal[31,3GalNAc- (Thomsen-Friedenreich or TF) antigens (95). Some of these 
carbohydrate antigens have been studied as therapeutic targets for cancer 
treatment (96).
BaiNAc 4
GlcNAcBI '6GalNAc 6
Ga!NAca1»6GalNAe 7
Ga!tt1-3GalNAc 8
Fig 1-3: Core structure of the Mucin-Type O-Glycans
(94)
1.2.2. TF antigen
1.2.2.1. TF expression and carrier proteins
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The TF disaccharide (also called the Thomsen-Friedenreich, TF or T antigen) 
is the core I structure of O-linlced mucin-type glycans. It is concealed in 
normal epithelium by sialic acids, sulphates or other sugar chains that form 
branched and complex <9-glycans (97). In cancer, unsubstituted Gaipi- 
3GalNAc occurs in about 90% of all human cancers, including colon, breast, 
bladder, prostate, liver, ovary and stomach, (98) Cancer-associated MUC1 is 
to date one of only two cell surface proteins known to carry the unsubstituted 
TF disaccharide; the other is the high molecular weight splice variant of the 
cell surface adhesion molecule CD44v6 (99). Alternative splicing of CD44 
can produce a large number of ditferent isoforms, some of which are 
overexpressed during colorectal tumorigenesis. Overexpression of CD44v6, 
one of the high molecular weight variant CD44 isoforms, is associated with 
poor prognosis (100). CD44v6 is shown to express TF antigen and sialyl-Tn 
in HT29 human colon cancer cells (99).
Cancer-associated MUC1 is the predominant carrier of the TF antigen in 
mammary, gastric, pancreatic and colorectal adenocarcinomas, thyroid, renal 
and bladder carcinomas (101, 102). Investigations by Baldus et al. with anti- 
MUC1 antibody BW835 [(which defines a site-specific Thomsen- 
Friedenreich disaccharide linked to threonine within the VTSA motif of 
MUC1 tandem repeats (103)] and HMFG-2 and anti-TF antibody A78G/A7 
[specific for both anomeric forms of this disaccharide (TF alpha and TF beta, 
including related structures on glycolipids)(104)] and TF-binding PNA have 
shown that the anti-MUCl and anti-TF antibodies reacted significantly more
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strongly with adenoma of high grade dysplasia while faintly or negatively 
with adenomas of low grade dysplasia in 45 colorectal adenomas and 48 
carcinomas. Mucins extracted from three individual moderately differentiated 
native cancer specimens of colorectal origin show relative binding activity 
with all three reagents of BW835 and HMFG-2 and A78G/A7 (105). Baldus 
et al. have also shown that TF antigens may be. at least in part, carried by 
MUC1 peptide cores in gastric carcinomas after staining 208 specimens from 
primary gastric adenocarcinoma patients with BW835 and A78G/A7 (106).
I.2.2.2. TF in cancer metastasis
TF expression correlates with cancer progression and metastasis (97). TF 
expression on MUC1, as revealed by immunohistochemical studies using an 
antibody (BW835) specific for TF on MUC1(103), correlates with the 
presence of lymph node metastases and an unfavourable prognosis in patients 
with gastric cancer (106) and with increased Pathological Tumor-Node- 
Metastasis (pTNM) Staging, histologic grading and lower survival probability 
in patients with colorectal carcinoma (107), Investigations of the specimens 
from 264 patients with colorectal carcinoma using primary monoclonal 
antibodies (MAbs) A78-G/A7, which bind to TF-alpha and TF-beta antigens, 
the latter present in glycolipids, irrespective of the carrier, and BW835, which 
detects TFalpha on MUC1 repeat peptide, show that BW835 reactivity 
exhibited a significant correlation with increasing pTNM staging and 
histologic grading. In univariate survival analysis, reactivity with A78-G/A7 
anti-TF antibody correlated significantly with increasing pTNM staging,
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histological grading and lower survival probability (107). A similar study 
using 208 specimens from primary gastric adenocarcinoma patients 
demonstrated that BW835 binding correlated with tumour progression from 
pTl to pT2, from pTNM stage I to stage II, and that the presence of lymph 
node metastases decreased survival probability in stage I and tubular/papillary 
carcinomas (106).
I.2.2.3. The effects of TF expression in cancer metastasis
The TF antigen is a natural ligand of a group of dietary TF binding lectins, 
including that from peanut (Arachis hypogea) (PNA) (108, 109), Amaranth 
(Amaranthus caudatus) (110), mushroom Agavkus bisporus (ABL) (111) and 
jackfruit (jacalin) (110). Interaction of cancer-associated TF with TF-binding 
PNA and amaranth stimulates human colonic cancer cell proliferation 110, 
112), while TF interaction with other TF-binding ABL and jacalin inhibits cell 
proliferation 110, 111).
The TF antigen is also a ligand of the mammalin galactoside-binding galectins 
and the interaction between TF and cancer-associated galectin-3 expressed by 
cancer cells and endothelial cells has been shown to promote cancer cell 
proliferation, adhesion and aggregation (97). Galectin-3 promotes cancer cell 
proliferation in vitro when added exogenously (113, 114). Down-regulation of 
galectin-3 expression by antisense technology suppresses cancer cell 
proliferation in human breast carcinoma MDA-MB-435 cells in soft agar and 
in nude mice (115). Interactions of cancer-associated-TF with galectin-3
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expressed in human breast carcinoma MDA-MB-435 cells and by endothelial 
cells have been reported to increase cancer cell adhesion to the monolayer of 
the vascular endothelium and to enhance homotypic cancer cell aggregation 
(116). Highly metastatic human breast carcinoma MDA-MB-435 cells which 
express high levels of both TF and galectin-3 show significantly increased 
adhesion to the endothelial monolayer under static and sheer flow conditions 
and increased homotypic cell-cell aggregation. The MDA-MB-435 cells were 
shown to produce a high rate of metastasis when transplanted into nude mice 
by allografts when compared with less TF-expressing MDA-MB-468 cells 
(116). It was reported that initial attachment of the cancer cells to the 
endothelial monolayer causes rapid clustering of endothelial-associated 
galectin-3 at the cancer endothelium contacts, whilst the cancer-associated 
galectin-3 is accumulated at the homotypic cancer—cancer cell contacts (44, 
116).
Introduction of a TF antigen-binding peptide (HGRFILPWWYAFSPS), or a 
synthetic TF antigen-mimicking peptide (lactulosyl-l-leucine) or TF antigen­
expressing glycoproteins (117, 118), significantly inhibits rolling and stable 
adhesion of MDA-MB-435 cells to the endothelial monolayer under static 
(119, 120) and flow conditions (121). In v/vo, intravenous co-inoculation of 
breast or prostate cancer cells together with antibodies against either TF or 
galectin-3 decreases the formation of cancer cell deposits in mouse lung and 
bones (97). Treatment of colon 26 carcinoma cells (BALB/c-derived tumor 
cells subcultured by subcutaneous implantation) with neuraminidase led to the 
exposure of TF, and consequently to a higher frequency of liver metastases in
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syngeneic Balb/c mice. This effect could be prevented by an antibody to TF 
(A78-G/A7), but not by a control antibody (122). These studies suggest that 
metastatic cancer cell adhesion to target organ microvessels and homotypic 
cancer cell aggregation at the cancer-endothelium adhesion sites are regulated 
by the interaction of cancer-associated TF antigen with endothelial- and 
cancer-associated galectin-3 (97).
1.2.3. Molecular mechanism of altered glycosylation in cancer
Alteration of cellular glycosylation is a common feature in cancer cells. 
Alteration of N-glycosylation in tumours includes increased expression of f31- 
6 branched complex-type sugar chains (123) and increased expressions of the 
three p-W-acetylglucosaminyltransferases GnT-III, -IV and -V are reported in 
cancer cells (124).
The molecular mechanism of the changes in 0-linked glycosylation in cancer 
is much more complex. Cancer cells are normally shown to carry shorter and 
less branched 0-linlced carbohydrate chains, with increased sialylation and 
reduced sulfation (125-127). Altered expressions or activities of the relevant 
glycosyltransferases was initially thought to be the primary reason causing 
altered 0-linked glycosylation in cancer. Brockhausen and colleagues found 
that many glycosyltransferase activities present in the normal mammary cell 
line are also expressed at variable levels in breast cancer cells (128). The 
activity of a sialyltransferase (CMP-sialic acid Gal beta l-3GalNAc alpha 3- 
sialyltransferase) was increased several-fold in three breast cancer cell lines,
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BT20, MCF-7 and T47D. The Gal beta l-3GalNAc (GlcNAc to GalNAc) beta 
6-GlcNAc-transferase activity was found to be lacking in mammary cancer 
cell lines BT20 and T47D but expressed in MCF-7 breast cancer cells (128).
The expressions of Tn (GalNAca-Ser/Thr), sialosyl-Tn and TF antigens are 
often increased in cancer cells. Interestingly, it was found that the levels of the 
relevant glycotransferases that control the biosynthesis of Tn, sialosyl-Tn and 
T antigens were similar in paired specimens of normal and cancerous tissues 
(129). Furthermore, in cancerous tissues, the enzyme activities of the 
glycotransferases were found not to be in correlation with tumour location, 
stage or histologic type (129). Those studies suggest that the expressions of 
the glycosyltransferase alone may not account for the altered glycosylation 
changes in cancer cells.
There are reports showing that redistribution of the glycotransferases in the 
Golgi apparatus may contribute to the abnormal glycosylation of proteins (130) 
(131).
Several studies suggest that the inappropriate Golgi pH may be responsible for 
altered glycosylation potential (132-134). Perturbing of the Golgi pH causes 
increased expression of some cancer-associated carbohydrate antigens and 
also causes structural disorganization of the Golgi apparatus in otherwise 
normally glycosylating cells. Disturbance of the Golgi pH has been shown to 
cause altered glycosylation in colorectal cancer cells in vitro and in vivo (in 
patients) (132). Elevation of the Golgi pH by treatment of the cells with 
bafilomycin A or pH calibration buffers has been shown to induce an increase
19
of TF antigen expression in breast and colorectal cancer cells (133, 134). All 
those studies indicate that altered glycosylation in cancer cells is attributed to 
relocalization of glycosyltransferases within the Golgi (135).
TF antigen on colon cancer cells has been shown to be expressed specifically 
on high molecular weight splice variants (CD44v6) of the adhesion molecule 
CD44, but not on the standard CD44 from both normal and colon cancer 
tissues (99). This suggests that splicing of CD44 may be involved in altered 
cell surface glycosylation in cancer cells. Tumour necrosis factor alpha (TNF- 
«) is a pre-inflammatory cytokine and can induce cancer-associated 
glycosylation changes in cancer cells (136). Addition of TNF-a in cell culture 
results in aberrant mucin expression, increased expression of TF and 
decreased sulphation in cultured goblet cell-differentiated colon cancer cell 
lines (137). TNF-a has also been shown to increase expression of the cancer- 
related sialyl Lewis-x antigen in human lung cancer cell lines QG-95 (136) 
and Lewis-y on the surface of the colorectal carcinoma cell lines HT29, LoVo 
and SW480 (138). Interestingly, the expression of CD44vlO has been shown 
to be significantly up-regulated by recombinant human interferon-gamma and 
rTNF-alpha in colon carcinoma cells (139).
1,2.4. Roles of altered glycosylation in cancer
The beta 1 -6 branched AMinked oligosaccharides are consistently increased in 
neoplasias of human breast and colon and have been shown to correlate with 
the pathological staging of human breast and colon neoplasia (140). While
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tumour growth and metastasis were inhibited in Mgat5-deficient mice, Golgi 
betal,6N-acetylglucosaminyltransferase V (MGAT5) is required in the 
biosynthesis of betal,6GlcNAc-branched N-linked glycans (141). The 
increased expression of the highly branched A-glycans at cell surface is 
correlated with the rapidity of tumour formation and altered adhesive 
properties of tumour cells in vivo (142). Increased expression of cell surface 
A-glycans has been shown to contribute directly to reducing contact-inhibition 
cell growth in an immortalized lung epithelial cell line (143). Overexpressions 
of sialyl-Le\ sialyl-Le‘n and sialyl-Lex on the surface of tumour cells, 
including human adenocarcinoma of colon (144, 145), breast cancer (146) et 
ah, were used as a marker for tumour diagnosis (145, 147). The increased cell 
surface expression and binding to E-selectin of sialyl-Lex have been shown to 
correlate with the metastatic potential of human colon cancer cells (148). 
Several clinical studies have shown that the expressions of sialyl-Lea and 
sialyl-Lex in tumours are correlated to enhanced cancer progression and 
metastasis (124).
Alteration of cellular glycosylation is a common characteristic of human 
cancer (149-151). Amongst the commonest glycosylation changes are the 
increased occurrence of GalNAcal-Sei7Thr(Tn antigen), Neu5Aca2-6GalNAc 
(sialyl-Tn antigen) and Galf31-3GalNAcal-Ser/Thr (TF or T antigen) (97). 
Sialyl-Tn antigen is expressed in breast cancer patients but not in normal 
mucosa (152). Overexpression of sialyl-Tn has been shown to be related to 
resistance of the cancer cells to chemotherapy (153). In experimental mouse
models, inhibition of sialylation (154) and enhancement of mucin 
glycosylation (155) reduce cancer cell metastasis.
1.3. MUC1 in normal and cancer epithelia
1.3.1. Mucin protein
The surface of epithelial cells is covered and protected by a layer of mucus 
(156). The major content of mucus is mucins. Mucins are high molecular 
weight glycoproteins with a tandem repeat peptide rich in threonine, serine 
and proline (157). Mucins carries a large number of short oligosaccharides 
(which account for 50-90% of the molecular weight of mucins) that are O- 
glycosidically linked to the serine and threonine residues. By cDNA cloning, 
at least 18 human mucin genes have been identified. They are MU Cl, MUC2, 
MUC3A, MUC3B, MUC4, MUC5AC, MUC5B, MUC6, MUC7, MUC8, 
MUC12, MUC13, MUC15, MUC16, MUC17, MUC19, MUC20 and MUC21 
(158, 159). Secreted gel-forming mucins (MUC2, MUC5AC, MUC5B, 
MUC6, MUC19) and transmembrane mucins (MUC1, MUC3A, MUC3B, 
MUC4, MUC12, MUC17 and MUC21) are two structurally and functionally 
distinct classes of mucins. Some MUC gene products do not fit well into 
either class (MUC7, MUC8, MUC13, MUC15, MUC 16, MUC20) (157-161). 
cDNAs designated MUCH and MUC 12 may be derived from two closely 
related genes or may be parts of the same gene. Murine MuclO and Mucl4 as 
yet have no human counterparts. MUC9, encoding the mucin-like 
glycoprotein oviductin, has been renamed OVGP1. MUC 18, now named
MCAM, was the original designation of a cell adhesion molecule in the 
immunoglobulin gene superfamily, not a mucin (157).
1.3,2. MUC1 structure
MUC1 is a large, heavily glycosylated transmembrane mucin protein. It has a 
large extracellular domain, a transmembrane region and a short cytoplasmic 
tail (162). The extracellular domain of MUC1 consists of variable numbers of 
20-amino acid tandem repeat peptides (VNTR) that are rich in serines, 
threonines and prolines and are heavily glycosylated with complex O-glycans 
(150, 163). 50-90% of the molecular mass of MUC1 comes from 
carbohydrates. The MUC1 protein has a very large extracellular domain (1000 
to 2200 amino acids) made of a variable number of highly conserved tandem 
repeats (25-125) of 20 amino acid residues (HGVTSAPDTR- 
PAPGSTAPPA). Its cytoplasmic domain is made of 72 amino acids that 
contain signalling motifs (164). The extracellular domain of MUC1 can 
extend 200 to 500 mn above the plasma membrane (165).
The tandem repeats of MUC1 extracellular domains are rich in serines, 
threonines and prolines and are heavily glycosylated with complex O-glycans 
(151, 163). The initial glycosylation occurs by addition of an N- 
acetylgalactoside residue to serine or threonine residues (Tn antigen). The Tn 
antigen is then modified by either a Galactose (Gal) residue to form a core 1 
structure (GalBl, 3GalNAc-0-Ser/Thr), an N-acetylglucosamine residue to 
form a core 3 structure, or a sialic acid residue for chain termination. Then
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core 1 and core 3 structures are further modified by other carbohydrate 
residues to form branched complex glycans or core 2 glycans (166).
The O-glycosylation of MUC1 is a step-by-step process occurring in the cis to 
trans Golgi. Each MUC1 VNTR contains five potential O-glycosylation 
sites(167). There are unique active site conformations for each member of 
distinct GalNAc-transferases. The extended backbone conformations assigned 
to the VTSA motif are preferable for the GalNAc-Tl; polyproline II—like 
conformations assigned to the GTSA motif are primarily recognized by the 
GalNAc-T2; and relatively folded conformations assigned to y -turn-like 
structure of the PDTR motif are required for the efficient recognition and 
binding by the GalNAc-T4(168). The recombinant polypeptide N- 
acetylgalactosaminyltransferase rGalNAc-Tl(169? 170), rGalNAc-T2, 
rGalNAc-T4(171) preferentially glycosylates Tin- within the VTSA peptide 
motif, Tin' in GST A, Ser within the VTSA and Tin* within the PDTR motif 
separately.
The addition of GalNAc to the five potential O-glycosylation positions of the 
MUC1 tandem repeat include two pathway. Addition of Gal or GlcNAc 
residue to GalNAc forms core 1 or core 2 structures and exerts inhibitory 
effects on initial glycosylation at proximal sites. This pathway results in the 
low-density glycosylation as found on human milk mucin. In breast cancer 
cells on the other hand, a deletion or under-expression of the core2-specifIc 
(36-GlcNAc-transferase and a concomitant over-expression of the a3- 
sialyltransferase could account for the higher degree of site substitution by the 
concerted action of the ppGalNAc-Ts(167).
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1.3.3. MUC1 distribution in normal epithelium
MUC1 is normally expressed on the apical surface of most normal secretory 
epithelial cells, including those in the mammary gland (172) and the 
gastrointestinal, respiratory, urinary and reproductive tracts (173). MUC1 
expression is generally investigated by MUC1 immimohistochemistry using 
anti-MUCl antibodies. MUC1 detected by 139H2 (Mouse Mab anti-core 1 
protein) and DF3 anti-MUCl antibody (Mouse Mab anti-core 1 protein ± 
carbohydrate) was seen to be expressed on the apical membranes of most 
secretory epithelial tissues, such as the ductular and glandular tissue of 
bronchus, breast, pancreas, prostate and uterus, and less frequently in gastric 
surface epithelium, gallbladder, small and large intestinal epithelium (173).
The lack of activity of the 139H2 anti-MUCl antibody in intestinal tissue, 
which however shows relatively high levels of steady-state MUCI mRNA, 
suggests that immunohistochemical detection of MUCI may be largely 
influenced by MUCI glycosylation, which could result in concealment of 
antibody recognition sites (173).
1.3.4. MUCI in epithelium cancer
Compared with the MUCI in normal epithelium, cancer-associated MUCI 
loses its apical membrane polarization and becomes over-expressed around 
the entire cell surface (174, 175). The MUCI mRNA and detectable protein 
levels are frequently shown to be altered in adenocarcinomas compared with
25
corresponding normal tissues (173, 176). MUC1 overexpression is found in 
more than 80% of breast, gastric, colonic, pancreatic and prostate 
adenocarcinomas, bile duct neoplasms, esophageal squamous cell carcinomas 
and 50% of ovarian mucinous cystadenocarcinomas (173, 176). This 
increased MUC1 expression is seen to be associated with high metastatic 
potential and poor prognosis (155, 176, 177).
Interestingly, cancer-associated MUC1 was found to be overexpressed on the 
entire cell surface of tumour cells compared to polarization of MUC1 on the 
apical surface in the normal epithelium (162, 174, 175). Recently, Yonezawa 
has reported that MUC1 in invasive ductal carcinoma of the pancreas (IDC) 
by MUC1/DF3 immunohistochemistry was not only expressed at the cell apex 
but also at the cytoplasm and lateral membrane, in comparison to the MUC1 
expression only at the cell apex in the normal tissues (176).
Cancer-associated MUC1 also shows reduced expression of complex O- 
glycans and increased expression of short oligosaccharides such as GalNAca- 
(Tn antigen), sialylated GalNAca- (sialyl-Tn) and Gal|31,3GalNAca- (T or TF 
antigen) (127). MUC1 in cancer cells is shown to carry more core 1-related O- 
glycans while it carries predominatly core 2-related O-glycans in normal 
tissue (178, 179).
1.3.5. The function of MUC1 
1.3.5.1. Anti-adhesive
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Overexpression of cancer-associated MUC1 has been shown to inhibit cancer 
cell-cell and cancer-extracellular matrix interactions (174, 180). A normal 
mammary epithelial cell line (HBL-100) and a melanoma cell line (A375) 
transfected with cDNA-encoding MUCl/episialin have been shown to 
undergo less cell aggregation in comparison to their control cells which do not 
express MUC1 (181). MUC1 overexpression in transfectants of a melanoma 
cell line (A375), a ras-transformed Madin-Darl-canine kidney cell line 
(MDCK-ras-e) and a human breast epithelial cell line (HBL-100) reduces 
integrin-mediated adhesion to the extracellular matrix (174). Furthermore, E- 
cadherin-mediated adhesion of two breast cancer cell lines, YMB-S and ZR- 
75-IS, was functionally suppressed by overexpression of MUC1 but resumed 
after MUC1 expression was reduced by MUC1 antisense oligonucleotide 
(180). Thus, MUC1 expression on the cell surface inhibits cell adhesion.
MUC1-mediated inhibition of cell adhesion may be a result of its shielding of 
the small adhesion molecular cell membrane due to its massive size. This may 
also be contributed to by the negative charge of its heavy content of sialic 
acids and/or sulphates (182). The anti-adhesive property of MUC1 may also 
involve competition of its cytoplasmic tail with adhesion molecules for 
cytoskeletal components. The latter is, however, less likely as truncated 
MUCl/episialin which does not express its cytoplasmic tail is still able to 
inhibit cell adhesion (174). The contribution of the negative charge of the 
sialic acids may also be limited, as removal of the MUC1 sialic acid residues 
by neuraminidase only partly restores cell adhesion (181).
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MUC1 is known to protrude 200-500 nm above the plasma membrane (165). 
In contrast, the typical cell adhesion molecules extend less than 30 nm above 
the plasma membrane (183, 184). Hence the typical adhesion molecules are 
likely to be largely concealed by the large and long MUC1 molecules on the 
cell surface. MUC1 transfectants of cL929 fibroblast cells that contain three 
tandem repeats showed a comparable level of aggregation in comparison with 
the MUC1 negative control cells. However, the MUC1 transfectants that 
contain eight repeats (LUD8/B1 and LUD8/D4), 15 repeats (LUD 15/4.2) and 
36 repeats (LUE6/10 and LUE6/15) displayed decreasing levels of cell-cell 
interactions. These results strongly support a role of the extracellular domain 
of MUC 1 in its anti-adhesion functions (175).
1.3.5.2. Adhesive properties of MUC1
MUC1 has also been shown to mediate cell adhesion. MUC1 has been shown 
to interact with intercellular adhesion molecule-1 (ICAM-1) and increase 
adhesion of cancer cells to HUVEC cells in cell culture under static conditions 
(185, 186) and under fluid flow conditions (187), and enhances cancer cell 
transendothelial migration (188). Migration of human breast cancer MCF7 
cells across a gelatin-coated transwell membrane could be increased by the 
sequential addition of ICAM-1-expressing cells (primary human breast 
fibroblasts and primary human umbilical vein endothelial cells) (188). 
Antibodies against MUC1 or ICAM-1, but not a control antibody, could 
abrogate cell migration in those cases (188). It has also been demonstrated 
that MUC1-ICAM1 interaction initiates Src-CrkL-Racl/Cdc42-Mediated
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Actin Cytoskeletal Protrusive Motility, an effect that can be exclusively 
abrogated by an anti-ICAM-1 antibody (189). MUC1-ICAM1 interaction has 
also been shown to enhance cancer cell interaction with B lymphocytes (190) 
and fibroblasts (Rahn et ah, 2004) in cell culture under static conditions.
Thus, cell surface MUC1 can act as an anti-adhesive molecule by preventing 
cancer cell adhesion and can also act as an adhesion molecule by interaction 
with ICAM1 and increase cell-cell interactions. The anti-adhesive property 
of MUC1 has been shown to promote epithelial tumour cell adhesion to the 
basement matrix at the primary tumour sites and their subsequent invasion 
into the circulation (181).
I.3.5.3. Signal transduction by MUC1
MUC1 is also a signalling protein and can transduce extracellular signals into 
the cells through interaction of its cytoplasmic domain with intracellular 
signalling proteins, such as P53 and b-catenin.
p53 is a tumour suppressor and its expression is up-regulated in response to 
various stresses such as DNA damage, hypoxia and oncogene activation. 
Activated p53 initiates several different transcriptional programs that can 
result in either cell cycle arrest, cellular senescence or apoptosis (191). The 
MUC1 COOH-terminal subunit (MUC1-C) can interact with p53 through 
binding to the PE21 element in the p53 proximal promoter and suppress p53 
activation (192).
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The MUC1 cytoplasmic tail can also interact with p-catenin (193) and 
transduce cell signalling through the Wnt/p-catenin signalling pathway and 
regulate the expressions of a number of downstream genes essential for cell 
proliferation and differentiation (194). The Wnt/b-catenin signalling pathway 
is known to be perturbed in a number of disease conditions such as cancers, 
bone diseases (differentiation of osteoblasts and regulation of bone mass) and 
cardiovascular diseases (194). The MUC1 cytoplasmic tail (MUC1CT) has 
also been shown to be involved in several other signalling pathways, such as 
those involved in Ras, pi20 catenin and estrogen receptor (195). Furthermore, 
MUC1 expression has been shown to regulate intracellular oxidant levels, and 
to decrease the apoptotic response of the cells to oxidative stress (196).
Thus MUC1 is involved in signal transduction via interaction of its 
cytoplasmic tail with important intracellular signalling proteins such as p53 
(Wei et al, 2005) and p-catenin (Yamamoto et ah, 1997; Singh and 
Hollingsworth, 2006) and suppresses cellular apoptosis in response to DNA 
damage (Ren et ah, 2004; Raina et ah, 2006; Yin et ah, 2007).
1.4. Galectins and cancer 
1.4.1. Galectin structure
Galectins are a family of animal lectins that have binding affinity for p- 
galactosides and share conserved carbohydrate recognition domains (CRDs). 
The CRDs of galectins are about 130 amino acids and are responsible for 
recognition of galectins to carbohydrates (120). To date, 15 mammalian
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galectins have been identified which are subdivided into prototype galectins 
(galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15), which have one CRD and 
exist as monomers or non-covalent homodimers, a chimera-type galectin 
(galectin-3) that is composed of a non-lectin domain connected to one CRD, 
and tandem-repeat-type galectins (galectin-4, -6, -8, -9 and -12) that consist 
of two CRDs in a single polypeptide chain (197). Galectins are either bivalent 
or multivalent in their carbohydrate-binding activities as a result of molecular 
polymerization. In this way, galectins can form ordered arrays/lattices of 
complexes when they bind to multivalent glycoconjugates (120).
1.4.2. Galectin-3
Galectin-3 is a chimera type of galectin containing one-CRD domain which is 
fused to a stretch of unusual tandem repeats of short amino-acid stretches 
(198).
1.4.3. Distribution of galectin-3
Galectin-3 is expressed by a wide variety of mammalian cells. These include 
monocytes and macrophages (199), gastric epithelium (200), colonic 
epithelium (201), mammary epithelium (202), prostatic cells (203) and a range 
of neoplastic tissues, including anaplastic large cell lymphoma (204), thyroid 
carcinoma (205), breast carcinoma (202, 206), gastric carcinoma (200), colon 
carcinoma (201), ovarian carcinoma (207), prostate carcinoma (203) and
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melanoma (208). Galectin-3 is found inside cells, extracellularly (but cell 
surface associated) and in the circulation (209, 210).
1.4.4. Role of galectin-3 in cancer
There is increasing evidence showing that galectin-3 contributes to cancer cell 
transformation, development and metastasis (120, 211).
I.4.4.I. Intracellular galectin-3:
Intracellular galectin-3 is an apoptosis inhibitor (212, 213). Tumour cells 
transfected with a cDNA-encoding galectin-3 reduced cellular apoptosis(212). 
cells transfected with a gene encoding an amino-terminal truncated galectin-3 
increased cell sensitivity to apoptotic stimuli (120). Repression of galectin-3 
by homeodomain-interacting protein kinase 2 (HIPK2) activated tumour 
suppressor gene p53 is required in p53-induced apoptosis (214). Galectin-3 
acts as a selective binding partner of activated K-Ras, an important Ras 
oncoprotein (215). NF-kB (nuclear factor kB) is known to play a role in 
tumour cell resistance to apoptosis (216). Galectin-3 expression has been 
shown to regulate the expression of NF-kB transcription factor (217, 218). 
Galectin-3-mediated inhibition of apoptosis has been shown to be involved in 
protecting mitochondrial membrane integrity by preventing cytochrome c 
release and caspase activation in human breast carcinoma cells (219).
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Intracellular galectin-3 is also an mRNA splicing promoter (220). Cell-free- 
splicing assays using HeLa cell nuclear extracts and 32P-labelled MINX as 
the pre-mRNA substrate demonstrate that galectin-3 is required in pre-mRNA 
splicing (220). In this splicing assay, the addition of carbohydrates with high 
galectin-3 binding affinity inhibits product formation of the splicing 
complexes, while the addition of carbohydrates without galectin-3 binding 
affinity does not. Nuclear extracts that are depleted of galectin-3 are deficient 
in splicing activity. This splicing deficiency could be restored by the addition 
of recombinant galectin-3, but not other lectins with a similar saccharide 
binding specificity (soybean agglutinin) or with a different specificity (wheat 
germ agglutinin) (220).
Galectin-3 is involved in tumour cell transformation. Inhibition of galectin-3 
expression suppresses the phenotypes of transformation of human breast 
carcinoma cells and thyroid papillary carcinoma cells in cell culture (115, 
221). Conversely, galectin-3 overexpression by transfection of galectin-3 
cDNA in a normal thyroid follicular cell line induces the phenotypes of 
transformation (222). It has been suggested that galectin-3-mediated cell 
transformation is related to its interaction with -Ras (215), an oncogenic 
protein that plays a vital role in transformation (223, 224).
1.4.4.2, Cell surface-associated galectin-3
Cancer cell-associated galectin-3 is reported to play an important role in
tumour cell heterotypic adhesion to endothelium and cancer cell homotypic
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aggregation. It was found that the highly metastatic human breast carcinoma 
cells of MDA-MB-435 that express higher levels of galectin-3 show a higher 
level of adhesion to monolayers of endothelial cells in vitro compared to their 
nonmetastatic counterparts MDA-MB-468 (116). Addition of synthetic 
galectin-3 carbohydrate recognition domain-specific peptides significantly 
inhibited rolling and stable heterotypic adhesion of human MDA-MB-435 
breast carcinoma cells to endothelial cells under flow conditions, as well as 
homotypic tumor cell aggregation in vitro (Zou et ah, 2005). Addition of the 
galectin-3 inhibitor - synthetic lactulose amine prevents galectin-3-mediated 
homotypic cell aggregation (225). Liver metastasis of adenocarcinoma cell 
lines XK4-A3 and RPMI4788 was reduced by alpha-lactose and anti-galectin- 
3 treatment (226),
Cancer cell-associated galectin-3 has also been shown to increase cancer cell 
adhesion and invasion. Overexpression of galectin-3 in lung cancer cells 
enhances the cell motility and invasiveness in vitro (227), Overexpression of 
galectin-3 in human breast carcinoma cells results in the remodelling of the 
cellular cytoskeletal elements that are associated with cell spreading (228, 
229). Introduction of recombinant galectin-3 inhibits the adhesion of tumour 
cells to extracellular matrix proteins of various human cancer cells (230-232). 
This effect of galectin-3 has been suggested to be related to its interaction 
with the adhesive molecular integrinalpl (229). Galectin-3 when added 
exogenously in solution or when bound within a three-dimensional matrix 
markedly enhanced the migration of the primary tumour cell lines through a 
Matrigel barrier (233). By contrast, another study showed that exogenously
34
added galectin-3 (Matrigel-coated with 0.15[ag/cm2 gal-3) reduced the 
migration of human colon cancer cell lines (234).
Reduction of galectin-3 expression in LsiM6 and HM7 human colon cancer 
cells is associated with decreased liver colonization and spontaneous 
metastasis in athymic mice after splenic-portal inoculation, whilst elevation of 
galectin-3 expression in low metastatic LS174T colon cancer cells results in 
increased liver metastasis (Bresalier et ah, 1998). Thus, cell-associated 
galectin-3 contributes to cancer cell motility and invasiveness by interaction 
with the cell-surface proteins expressed on the same or adjacent cells.
1.4.4.3. Circulating galectin-3
The concentration of circulating galectin-3 has been shown to be increased up 
to fivefold in the sera of patients with breast, colorectal and lung cancers (209), 
melanoma (235), thyroid malignancy (236), bladder cancer (237) and head 
and neck squamous cell carcinomas (HNSCCs) (238).
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Serum galectin-3 concentrations in various cancers (Tablel-i)
Normal
individuals
Non
metastasis
Metastasis Total of
malignant
Reference
Breast 62 ng/ml 40 ng/ml 170 ng/ml 100 ng/ml lurisci et al.
cancer (20-313) (20-170) (20-620) (20-620) 2000
Gastrointesti 62 ng/ml 75 ng/ml 320 ng/ml 185 ng/ml lurisci et al.
nal cancer (20-313) (20-328) (20-950) (20-950) 2000
Lung cancer 62 ng/ml 171,5 ng/ml lurisci et al.
(20-313) (20-807) 2000
Head and 2.39 ng/ml 3.2 ng/ml Saussez et al.
neck (1.3-6.4) (0.8-7.9) 2008
squamous
cell
carcinoma
Bladder 584 pg/ml 1068 pg/ml Sakaki et al.
(range 259- (range 551- 2008
1262) 2028)
Melanoma 6.9 ng/ml 12 ng/ml Vereecken et
(5.9-8) (9.4-15.5) al. 2006
Thyroid 2.22 ng/ml 3.4 ng/ml Saussez et al.
cancer (1.4-3.1) (2.4-7.8) 2008
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Interestingly, the increased galectin-3 concentration in the circulation of 
cancer patients is seen to be closely correlated with cancer progression. Those 
patients with metastatic disease have significantly higher circulation of 
galectin-3 than those with localized tumours (209, 239). Until very recently, it 
remained unknown whether this increased circulation of galectin-3 had any 
functional implications in cancer progression.
Recent studies in our group have demonstrated that the cancer-associated 
transmembrane mucin protein MUC1 is a natural ligand of galectin-3 in 
human cancer cells (Yu et ah, 2007). The interaction between galectin-3 and 
MUC1 is via binding of galectin-3 to the Thomsen-Friedenreich oncofetal 
carbohydrate (Gal|31,3GalNAc-, T or TF) antigen on MUC1. The interaction 
between exogenously introduced galectin-3 and MUC1 increases cancer cell 
adhesion to the monolayer of human umbilical vein endothelial cells 
(HUVECs) in culture. It was found that binding of galectin-3 to MUC1 causes 
MUC1 cell surface polarization and consequent revealing of the smaller 
adhesion molecules that are otherwise concealed by the large size and length 
ofMUCl (Yu et ah, 2007).
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CHAPTER 2
2. Hypothesis and aims
2.1 Hypothesis
The huge size and heavy glycosylation of the transmembrane mucin protein 
MUC1, which protrudes over 10 times higher from the surface of the 
epithelial cancer cells than classical adhesion molecules, may shield these 
adhesion molecules and thus prevent interaction of disseminating cancer cells 
with each other and with endothelial cells. Binding to MUC1, via the 
oncofetal Thomsen-Friedenreich (Gaipi,3GalNAcal, TF) antigen, of 
circulating galectin-3, whose concentration is markedly increased in the 
circulation of cancer patients, causes MUC1 polarization and subsequent 
exposure of the smaller adhesion molecules thus increasing cancer cell 
homotypic aggregation, heterotyic adhesion to endothelium and trans- 
endothelial invasion (extravasation) hence promoting cancer metastasis.
2.2 The aims of the study
To investigate the effects of MUC1 expression and MUC1-galectin-3 
interaction on cancer cell homotypic aggregation (see chapter 5), heterotypic 
adhesion to vascular endothelial cells and trans-endothelial migration and on 
metastasis (see chapter 4).
To assess the effects of the TF-binding peanut agglutinin (PNA) on cancer
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cell-cell interaction and metastasis (see chapter 6).
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CHAPTER 3
3. Materials and methods.
3.1. Materials.
Full-length recombinant galectin-3 (Cat No. 1154-GA/CF, carrier free), 
monoclonal antibodies against CD44H (Cat No. BBA10), E-cadherin (Cat No. 
MAB1838) and E-selectin (Cat No. BBA16), ICAM-1 (Cat No. BBA3), 
VCAM-1 (Cat No. BBA5), integrin-|3 (Cat No. MAB17782), anti-human 
galectin-3 antibody (Cat No.MAB1154) and biotinylated anti-human galectin- 
3 antibody (Cat No. BAF1154) were all from R & D Systems Europe Ltd 
(Abingdon, United Kingdom). B27.29 anti-MUCl antibody, which binds to 
the epitope RPAP within the tandem repeat region (240), was kindly 
provided by Dr. Mark Reddish (Biomira Inc., Edmonton, Canada). CT-2 anti- 
MUCl cytoplasmic tail antibody was from NeoMarkers (Fremont CA). Anti- 
TF antibody (TF5) was kindly provided by Dr. Bo Jansson (Bioinvent 
Therapeutic, Lund, Sweden) (241). Peanut agglutinin (PNA) was purchased 
from Sigma. Florescence-conjugated peanut lectin, peroxidase-conjugated 
PNA, AMCA anti-mouse IgG(H+L) made in horse (Cat No. CI-2000), 
AMCA anti-hamster IgG(H-i-L) made in goat (Cat No. CI-9100) and mounting 
medium for fluorescence HI200 with DAPI were purchased from Vector 
Laboratories Ltd (Peterborough, UK). Streptococcus pneumoniae Endo-V- 
acetyl-galactosaminidase (EC 3.2.1.97), O-glycanase, was obtained from 
Prozyme Inc (Oxford, UK). The trypsin-EDTA solution (10x) with 5% 
porcine trypsin, 2% EDTA (Cat No. T4174, dilute to lx with PBS before
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using) and the Non-Enzymatic Cell Dissociation Solution were from Sigma. 
The Vybrant DIO (octadecyl oxacarbocyanines) and Dil (1,10 -dioctadecyl- 
3,3,30 ,30 -tetramethylindocarbocyanine perchlorate) Cell-labelling Solutions 
were from Molecular Probes (Cambridge, UK). Calcein (AM) was obtained 
from Invitrogen. The 24 wells Cell culture insert was from BD (CAT No. 
(35)3097). Asialofetuin was bought from Sigma.
3.2. Medium (All were from Sigma except where particularly 
specified)
a) Dulbecco's modified Eagle's medium (DMEM). A) Complete culture 
medium contains 10% PCS (fetal calf serum), penicillin lOOU/ml, 
streptomycin 100 pg/ml, glutamine 2 mM. B) Serum-free DMEM contains 
0.5% bovine serum albumin, penicillin lOOU/ml, streptomycin 100 pg/ml, 
glutamine 2 mM. C) Antibiotic-free DMEM contains 10% PCS, glutamine 
2 mM. D) Antibiotic-free and serum-free DMEM contains glutamine 2mM. 
The cell lines HT-29, HT29-5F7, HCA1.7+, HCA1.7-, ACA19+, ACA19- 
and SW620 were cultured with this medium.
b) McCoy's 5a. A) Complete medium contains 10% FCSpenicillin lOOU/ml, 
streptomycin 100 pg/ml, glutamine mM. B) Antibiotic-free medium 
contains 10% PCS, glutamine 2 mM, The cell lines HCT116 were cultured 
with this medium.
c) Endothelial growth media (EGM) supplemented with BBE 2 ml, liEGF 0.5 
ml, Hydrocortisone 0.5ml, PBS 25 ml, GA-1000 0.5 ml (EGM Bullet kit,
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Cambrex Bio Sciences, UK) were used for the culture of human umbilical 
vein endothelial cells (HUYEC).
d) EGM-2 endothelial growth media supplemented with FBS 25 ml, hEGF 
0.5 ml Hydrocortisone 0.2ml hFGF-B 2ml VEGF 0.5ml R3-IGF-1 0.5ml 
ascorbic acid 0.5ml GA-1000 0.5 ml (EGM-2 Bullet kit, Cambrex Bio 
Sciences, UK) were used for human microvascular lung endothelial cells 
(HMVEC-Ls)
3.3. Cell lines
HT-29 and HT29-5F7: The HT-29 human colon cancer cell line was obtained 
from the European Cell Culture Collection via the Public Health Laboratory 
Service (Porton Down, Wiltshire, UK). HT29-5F7 cells, kindly provided by 
Dr. Thecla Lesuffleur (INSERM U560, France), are enterocyte-like 
subpopulations of HT29 cells that express mainly MUC1 and MUC5B and 
were isolated as a consequence of their resistance to 5-fluorouracil The cells 
were cultured in DMEM supplemented with 10% FCS, 100 units/ml 
penicillin, lOOpg/ml streptomycin and 4mM glutamine at 37°C in a 
humidified atmosphere of 5% CCK The culture medium was changed two to 
three times a week.
HUVECS and HMVEC-L: Human umbilical vein endothelial cells (HUVECs) 
and human microvascular lung endothelial cells (HMVEC-L) were obtained 
from Cambrex Bio Sciences Wokingham Ltd (Wokingham, UK). HUVEC 
cells were cultured in endothelial growth media (EGM Bullet kit, Cambrex 
Bio Sciences, UK). HMVEC-L cells were cultured in EGM-2 endothelial
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growth media (EGM-2 Bullet kit, Cambrex Bio Sciences, UK). Less than five 
passages of the cells were used in all the experiments. The culture medium 
was changed every two days.
HCA1.7+/HCA1.7- and ACA19+/ACA19-: MUC1 transfection of HBL-100 
human breast epithelial cells and human melanoma A375 cells with full- 
length cDNA encoding MUC1 either variant A or B with about 40 repeats, 
which is similar to the amount present in the small allele of T47D cells(l 82), 
and the subsequent selection of the MUC1 positive transfectants HCA1.7+, 
ACA19+ and the negative revertants HCA1.7- and ACA19- were as described 
previously(174).
SW620: Human colon cancer cells were obtained from the European Cell 
Culture Collection via the Public Health Laboratory Service (Porton Down, 
Wiltshire, UK).
HCT116: Human colon carcinoma cells were from the European Collection of 
Cell Cultures. HCT116 cells are malignant cells isolated from a male with 
colonic carcinoma. HCT116 cells are tumourigenic in nude mice and form 
colonies on agarose. Growth and plating efficiency are enhanced by using a 
feeder layer of murine fibroblasts (242).
3.4. Cell thawing and plating
The cell culture medium was warmed to 37°C in the waterbath (about 30 
minutes) before use. The freezing vial of cells from the N2 cell bank was 
warmed up at 37°C in the waterbath. The cell suspension was then added into 
10ml pre-warmed cell culture medium in a 15ml tube. (For defrosting
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HUVEC cells, the cells were added directly into one or two T25 cell culture 
flasks.) After centrifugation of the cell suspension for 5 minutes at 
lOOORCF(xg), the supernatant was discard. The cell pellet was re-suspended 
in 10ml pre-warmed cell culture medium and seeded into a T25 cell culture 
flask. The cells were incubated at 37°C in a humidified atmosphere of 5% 
CCb. The culture medium was changed two to three times a week.
3.5. Detachment of the cells with trypsin or non-enzymatic cell 
dissociation solution
Sub-confluent cells in T-25 cell culture flasks were rinsed twice with 10ml 
each time PBS before 2ml Trypsin (with 0.5% porcine trypsin and 0.2% 
EDTA) or non-enzymatic cell dissociation solution (NEEDS) was added into 
each T25 flask for 5-10 minutes at 37°C until the cells became detached from 
the flasks. After addition of 10ml pre-warmed culture medium, the cell 
clumps were dispersed by sucking up and blowing down the cell suspension 
10 times using a 10ml pipette, to produce a single cell suspension.
3.6. Cell aliquoting
After detachment of the cells with trypsin (see cell detachment), 10ml 
complete cell culture medium was added. The cell numbers were counted and 
re-suspended in 5x105/ml concentration in complete culture medium. 1ml 
(0.5ml for HCA1.7- cells) was added into each T25 flask 10ml complete
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culture medium and the cells were incubated at 37°C in a humidified 
atmosphere of 5% CCb.
3.7. Cell freezing
After detachment of the cell with trypsin 10ml complete cell culture medium 
was added. The cell suspension was centrifuged at lOOORCF(xg) for 5 
minutes. After removal of the supernatants, the cell pellet was re-suspended 
in cell freezing medium (20% PCS, 7% Dimethyl sulfoxide (DMSO) in 
culture medium) at cell density foloVnil for HT-29. HT29-5F7, HCA1.7+, 
HCA1.7-, SW620, HCT116. 3xl05/ml for HUVEC and HMVEC-L cells. One 
10ml cell suspension was transferred into a Cryotube. The cells were stored at 
-80°C overnight before being transferred to a N2 cell bank.
3.8. Cell counting
Cell numbers were counted using a haemacytometer. The number of cells was 
obtained with the following equation: Cells Density (cells/ml) = number of 
cells per square x 104.
3.9. Assessment of cell aggregation by flow cytometry
3.9.1. After detachment of the cells with 2 ml cell dissociation solution at 
37°C for 5—10 mins, 10ml serum-free DMEM medium was added and cell
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clumps were dispersed by sucking up and blowing down the cell suspension 
several times using a 10ml pipette. The cells were then washed twice with 
PBS 10ml each time. The PBS was removed by spinning the cell suspension 
for 5 minutes at lOOOg (RCF). After cell counting, the cells were removed 
then diluted to l><106/ml cells with serum-free medium. 0.2ml cell suspension 
was taken and diluted into 5x 105/ml with 1ml serum-free medium to be used 
as unstained control cells in later flow cytometry analysis. Two aliquots of 
(2ml or more according to the experiments needed) 1x10 6/ml cells were 
transferred into two 15ml tubes. One tube was added in 5ul/ml Dil cell- 
labelling solution and another in 5ul/ml DiO cell-labelling solution. After 30 
mins incubation at 37°C\ 10ml PBS was added into each tube; after 
centrifugation of the cell suspension for 5 minutes at lOOOrpm, the 
supernatants were removed. The cells were washed a second time with PBS. 
The cell pellets were re-suspended at about 1 xl06/ml with serum-free DMEM 
medium. The cell numbers were re-counted and the cells were diluted with 
serum-free medium to 5xl05/ml. 500 pi of each cell suspensions were taken 
as unmixed Dio- and Dil- labelled cells for later use to identify the single dye- 
labelled cell population by flow cytometry. 1.5ml of each cell suspension was 
then mixed by gently sucking up and blowing down the cell suspension 
several times with a pipette. The cell suspension was then divided into 
different tubes with 1 ml/tube (5xl05/ml) and incubated with the presence or 
absence of recombinant galectin-3, antibodies, lactose or PNA in a rotating 
incubator (Julabo Temp SW23, Julabo labortechnic GMBH, Seelbach, 
Germany) at 100 REVS /min at 37°C for 1 hour.
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3.9.2. At the end of the incubation, the cell suspension was cooled on ice 
and cell aggregation was analysed by flow cytometry (Becton-Dickinson 
FACS Vantage SE). Unlabelled cells and cells labelled with Dil- or DiO- only 
dye were used to identify the position of the unlabelled (bottom-left), DiO- 
labelled (top-left) and Dil-labelled (bottom-right) cell populations in the bi­
variant correlation plot. The cell population containing both DiO and Dil 
fluorescence (upper-right) in the correlation plot was defined as cell 
aggregates in this study. The percentage of each cell population was obtained 
using the FACS software (Cell Quest).
It should be mentioned that this method measures cell aggregates containing 
both DiO- and Dil-labelled cells. Although this method may underestimate the 
total cell aggregates by having eliminated the aggregates formed by the cells 
labelled with the same fluorescent dye, it more accurately measures the 
percentage of cell aggregates formed after the two cell populations (DiO- and 
Dil-labelled) are introduced together (which is a key part of this study) by 
reducing experimental errors potentially caused due to 1) cell aggregation 
formed before introduction of recombinant galectin-3 and 2) differences in the 
abilities of the cells to be labelled with the two fluorescent dyes.
When assessing the cell aggregation, a 200pM nozzle was selected because 
the larger sizes of cell aggregation easily clog the nozzle.
3.10. Epithelial cell-endothelial adhesion - Method one:— counting cell 
numbers
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a) After detachment of the endothelial cells from a T25 flask with Trypsin, 
5ml endothelial culture medium was added and the cell clumps were 
dispersed by sucking up and blowing down the suspension 10 times with a 
10ml pipette. The cell numbers were counted with a haemocytometer and 
the cells were diluted into 5x104/ml in endothelial culture medium.
b) 13mm glass cover slides were inserted into the wells of a 24-well cell 
culture plate followed by gentle addition of the endothelial cell suspension 
(1 ml/well). The culture medium was changed the next day and the cells 
were added with or without lOng/ml TNF-a for 12 hours at 37°C before the 
adhesion assay.
c) Sub-confluent cancer cells or MUC1 transfectants were released from the 
culture flasks by 2ml cell dissociation solution as discussed earlier. After 
the cell clumps were dispersed by pipetting, cell numbers were counted 
with a haemocytometer.
d) The cells were then diluted to 1 x106/ml cells with serum-free medium and 
added to 5ul/ml DIO cell-labelling solution at 37°C for 30 minutes.
e) The cells were washed twice with 10ml PBS each time by centrifugation 
for 5 minutes at lOOORCF(xg).
f) The cells were then re-suspended into about 2x 106/ml with serum-free 
DMEM medium. Re-count the cells with a haemocytometer and dilute the 
labelled cells into 5><104/ml with serum-free medium.
g) The endothelial monolayer was washed twice with PBS 1 ml/well. 250ul 
cancer cells suspension (1.25><104/well in serum-free medium) was then 
incubated with or without galectin-3 for 30 min at 37°C before addition of 
the whole cell suspension into the monolayer of endothelial cells for 1 hr at
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37°C. The medium was removed and the ceiis were washed twice with 
1 ml/well PBS and fixed with 2% paraformaldehyde 0.5ml/well for 15 
minutes at room temperature.
h) After removal of the paraformaldehyde and washing once with 0.5ml 
PBSAvelf the glass cover slides were taken out from the wells and 
mounted with mounting medium for fluorescence (HI200 with DAPI from 
VECTOR). The cover slides were covered with a new 22mm cover slide. 
The slides were blinded with tapes and fluorescence-labelled cells 
remaining on the endothelial monolayer were counted in 10 random fields 
of view (FOV) under fluorescence microscopy (Olympus B51 fluorescence 
microscope).
3.11. Epithelial cell-endothelial adhesion -Method two: Calcein-AM 
labelling
a) After detachment of the cells and washing with PBS. the cells were diluted 
into IX 106/ml cells with serum-free medium before addition of lOpl/ml 
Calcein AM cell labelling solution at 37°C for 30 minutes. The cells were 
washed twice with 10ml PBS each time by centrifugation for 5 minutes at 
1000RCF(xg).
b) The cells were then re-suspended into about IxloVml with serum-free 
DMEM medium. Re-count the cells with a haemocytometer and dilute 
labelled cells into 5x 104/ml with serum-free medium.
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c) The endothelial monolayer was washed twice with PBS 1 ml/well. 100j.il 
cancer cells suspension (5><103/well in serum-free medium) was then 
incubated with or without galectin-3 for 30 min at 37°C before addition of 
the whole cell suspension into the monolayer of endothelial cells.
d) After 1 hour s incubation of the ceils at 37°C; the medium was removed 
and the cells were washed twice with PBS Iml/well before 0.1 ml/well cell 
lysis buffer (2xsample buffer without Bromthymol blue) was added. After 
30 minutes shaking of the plate at speed 200REVS/minute on Orbital 
shaker S03 at room temperature;, the fluorescence density of the cell 
lysates was measured using a TECAN infinite F200 microplate reader with
Excitation Wavelength 485 nm
Emission Wavelength 535 mn
Excitation Bandwidth 20 nm
Emission Bandwidth 25 nm
Gain 50 Manual
The background (from medium and endothelial monolayer) was deducted 
before analysis of the data.
3.12. Cell adhesion under flow conditions
3.12.1. This was assessed with a flow-based video-microscopic model (243, 
244). Human umbilical vein endothelial cells (HUVECs) were isolated from 
freshly obtained human umbilical cords by collagenase digestion of the 
interior of the umbilical vein (245). The cells were maintained in medium 199
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(Ml99; Invitrogen, Paisley, UK) containing 20% fetal calf serum, 28jag/mL 
gentamicin, 2.5jig/mL amphotericin B, and 1 ng/mL epidermal growth factor 
(all from Sigma) until confluent (246). The cells were dissociated with 
trypsin/EDTA (ethylenediaminetetraacetic acid) and seeded approximately at 
4x 10 /ml (a total of 45pl) into rectangular glass capillaries (microslides; 
internal width 3 mm, depth 0.3 mm) which had been coated with 
collagen/gelatin (bovine skin gelatine from Sigma in deionized water at 1% 
w/v) for 24 In's at 37°C to allow the cells to form a monolayer. The HUVEC 
monolayer was stimulated with lOOU/ml TNF-a for 24 hrs at 37°C before 
being used in the cell adhesion experiments. (All these were conducted by 
Philip Stone at Birmingham University.)
3.12.2. Sub-confluent ACA19+/- cells were detached from the T25 cell 
culture plate 5ml/flask with non-enzyme cell dissociation solution. After 
washing with 10ml PBS twice, the ceils were re-suspended in 5ml serum-free 
medium and the cell numbers were counted using a haemocytometer. The 
cells were then diluted into IxloVml with serum-free DMEM and incubated 
with or without 1 pg/ml recombinant galectin-3 for 30 mins at 37°C before 
being perfused through the microslides at the chosen volumetric flow rate to 
deliver a desired wall shear stress. After 4 minutes of washing with PBS, the 
micro slides were video-recorded and the number of the adhered cells was 
quantified and normalized by the number of cells perfused.
3.13. Electrophoresis and lectin/immimoblotting
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3.13.1. Cell lysis: up to 90% confluence cells in a T25 flask were washed 
with PBS 10ml twice. 0.7ml/T25 flask SDS(sodium dodecyl sulfate)-sample 
buffer was added and incubated for 20 minutes at room temperature. The cell 
lysates were collected into 1.5ml tubes and kept at -20°C until use.
SDS-Sample buffer:
2 fold 4 fold
Stacking buffer 2.5ml 0ml
Glycerol 1.0ml (20%) 2ml
Mercaptoethanol 0.5ml (10%) 1ml
20% SDS 1.0(4%) 2ml
1% Bromthymol blue 50 pi 0.1ml
3.13.2. Gel preparation:
Separating gel 4% 7.50% 10% 15%
Deionized water 6ml 4.85ml 4.20ml 2.35ml
1.5M Tris-HCL resolving gel buffer 2.5ml 2.5 ml 2.5 ml 2.5ml
10% (w/v) SDS lOOul lOOul lOOul lOOul
30% acrylamide/bisacrylamide 1.35ml 2.5ml 3.33ml 5ml
TEMED 5 pi 5 pi 5 pi 5 pi
10% ammonium persulfate 65 pi 50pl 50 pi 50pl
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Stacking gel 3.75% 4.00%
Deionized water 3.09ml 3.05ml
0.5M Tris-Hcl stacking gel buffer 1.25ml 1.25ml
10% (w/v) SDS 5 Oul 5 Oul
3 0% acrylamide/bisacrylamide 0.625ml 0.665ml
TEMED lOpl lOpl
10% ammonium persulfate 65 pi 50pl
After the glass plates and spacers (1.0mm thick) were assembled, the running 
gel was poured to about 1cm below the wells of the comb (~4.9ml). Then 80ul 
water-saturated butanol-1 was added on top of the gel (adding from the corner 
of the gel). When the gel had set (~ 40 mins), the butanol was poured off and 
the gel was rinsed with about 2ml deionized water three times. Stacking gel 
was added and the 1.0mm thick comb inserted immediately. When the 
stacking gel had set, the glass plates were placed in a gel rig and immersed in 
buffer. Prior to running the gel, the wells were flushed out thoroughly with 
running buffer.
Running buffer:_____________
Tris-Base 30.67
Glycine 64.04
SDS 2.2
Make up 4L
3.13.3. Running the gels
The samples were heated at 100°C for 10 mins before being loaded to the gels.
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The proteins separated on the gels were transfered to nitrocellulose 
membrane using a transfer buffer compounded of following ingredients. 
Transfer buffer
Tris-Base 12.12g
Glycine 57.65g
Methanol 800ml
Make up 4L
The gel was sandwiched as negative pole (black) - Sponge - filter paper - gel 
- nitrocellulose membrane - filter paper ~ sponge - positive pole (white) and 
transferred at 100V for 1 hr.
After electrode transfer, the nitrocellulose membrane was stained with 
Ponceau S (0.1% Ponceau S in 1% acetic acid) solution for 2-3 minutes to 
visualize the protein bands. To get a clearer view of the bands, the blots were 
washed several times with 1% acetic acid. The Ponceau staining was 
removed by washing the blot several times with PBS.
3.13.4. Immunobloting
The membrane was blocked in Blocking Buffer (1% BSA in 1% TWEEN20 
in PBS) for 30 minutes at room temperature or 4°C overnight.
The first antibody in 1% BSA in TWEEN20 in PBS was then applied to the 
membrane according to the concentrations specified in the results section for 1 
hour at room temperature. The blot was washed three times with 1% 
TWEEN20 in PBS lOOml/time with rolling on a rolling machine for 10 
minutes per time. After removal of the solution, the secondary antibody
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diluted in 1% BSA in TWEEN20 in PBS was applied for 1 hour at room 
temperature. After 3-5 times with 1% TWEEN20 in PBS 100ml each time, 
the binding was visualized using enhanced chemiluminescence (ECL).
3.14. MUC1 and E-Cadherin cell surface localization
a) Sub-confluent cells were released from culture plates with 2ml non- 
enzymatic cell dissociation solution for 5-10 minutes at 37°C until the 
cells became detached from the flask.
b) 10ml serum-free DMEM medium was added and the cell clumps were 
dispersed by sucking up and blowing down the cell suspension several 
times using a 10ml pipette. The cells were then re-suspended in 5 ml 
serum-free DMEM medium and cell numbers were counted with a 
haemocytometer.
c) For MUC1 localization in single cells, the cells were diluted into 5* 105/ml 
with serum-free medium; go to step h) directly.
d) For the MUC1 localization in cell aggregation, the cells were diluted into 
lxl06/ml cells with serum-free medium. Two aliquots (2ml each) of lx 
106/ml cells suspension were taken into two 15ml tubes. To one was added 
5pl/ml DiL cell-labelling solution and to the another was added DiO 5 
pl/ml cell-labelling solution for 30 mins at 37°C.
e) The cells were washed twice by 10ml PBS each tube and centrifuged for 5 
minutes at 1000RCF(xg) to remove the supernatants.
f) Each cell pellet was re-suspended into 5xl05/ml (4ml) with serum-free 
medium. The two cell suspensions were then mixed by gently sucking up
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and blowing down several times with a pipette and divided into several 
tubes with 1 ml/tube.
g) The cell suspension was then incubated in the presence or absence of 
recombinant galectin-3 Ipg/mL anti-MUCl (B27.29) antibodies Ipg/ml in 
a rotating incubator (Julabo Temp SW23, Julabo labortechnic GMBH, 
Seelbach, Germany) at 100 REVS /min at 37°C for 1 hr.
h) Two 1cm diameter circles were drawn on poly-lysine-coated glass slides 
with thin black marker pen. lOOpl cell suspensions were dropped in the 
marked circle on the poly-lysine coated slides for 30 minutes at room 
temperature.
i) After gentle removal of the medium from the slides, 150pl 2% 
paraformaldehyde was applied to fix the cells for 15 minutes at a flow hood 
at room temperature. The paraformaldehyde was removed and the cells 
were washed twice with PBS. lOOpl 5% normal goat serum/PBS was 
applied to block the non-specific binding for 30 minutes at room 
temperature.
j) After removal of the solution, lOOul/circle of primary antibody diluted in 
1% goat serum in PBS (anti-MUCl B27.29 (5mg/ml) 1:2000, anti-E- 
Cadherin antibody (1 mg/ml) 1:400) was applied for 1 In- at room 
temperature.
k) The slides were rinsed with PBS in a tank. Tissues were used to dry the 
slide around the circle, lOOul/circle FITC- (1:400) or AMCA- (1:400) 
labelled secondary antibody in 1% goat serum in PBS (for the purpose of 
counting the MUC1 localization % in single cells, using anti-mouse 
immunoglobin FITC; for MUC1 localization or E-Cadherin distribution on
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the cell membrane of cell aggregation, using anti-mouse immunoglobin 
AMCA) were applied for 1 In- at room temperature. The slides were 
washed three times by rinsing with PBS and mounted in a mounting 
medium H-2000 (Vector Laboratories Ltd), then the slides were covered 
with another cover slide. The slides were blinded and the MUC1 
localization was observed under a fluorescent microscope with the same 
microscope settings. The percentage of cells lacking a continuous rim of 
MUC1 in 500 cells was scored in randomly selected low power fields with 
15X objective under fluorescent microscopy, as previously described (Yu 
et ah, 2007).
3.15. Cell surface expressions of MUC1, E-Cadherin, E-selectin and
CD44
Sub-confluent cells were released by 2ml non-enzymatic cell dissociation 
solution incubated for 5-10 minutes at 37°C and washed twice with PBS 10ml 
each time. After removal of the supernatant, 5ml 2% paraformaldehyde was 
added to fix the cells for 15 minutes at room temperature. After washing the 
cells twice with 10ml PBS and centrifugation at 1500RCF(xg) to remove the 
supernatants, the cells (106/ml) were incubated with 5% goat serum for 30 
minutes at room temperature on the roller mixer. After removal of the 
supernatant following centrifugation at 1500RCF(xg) for 5 mins, the cells 
were re-suspended into 106/ml in the 1% goat serum in PBS and divided 
1 ml/tube in 1.5ml tubes. Antibodies against E-Cadherin (Img/ml), E-selectin 
(1 mg/ml) or CD44H (1 mg/ml) were all in 1:400. Anti-MUCl antibody B2729
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(5mg/ml) in 1:2000 working concentration was applied to the cells solution 
for 1 hr at room temperature on the roller (or overnight at 4°C). After washing 
twice with PBS. fluorescence-conjugated secondary antibodies (1:400 in 1% 
BSA in PBS) were applied for 1 hour at room temperature. After three washes 
with PBS. the cells were re-suspended in PBS in 0.5ml/tube. The cell surface 
expression of MUC1. E-selectin. E-Cadherin or CD44H was analysed by flow 
cytometry. Fluorescent conjugated secondary antibody was used as a negative 
control in all the experiments.
3.16. siRNA MUC1 and E-Cadherin transfection
Plate Format
Tube 1
Volumes per well
Tube 2
Volumes per well
Plating
Volume
(pL/well)
Plating
Format(
wells/pla
te)
Surface
Area
(cnrAvel
1)
2 pM
siRNA
(pL)
Serum-
free
Medium
(pL)
DharmaF
ECT (pL)
Serum-
free
Medium
(pL)
Transfecti
on
Medium
96 0.3 5 5 0.05-0.5 9.95-9.5 100
24 2 25 25 0.5-2.0
49.5-
48.0
500
All steps of the protocol were performed in a laminar flow cell culture hood 
using sterile technique. Each experiment included the following samples in 
triplicate: mock-transfection (without siRNA). non-specific control siRNA
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(iCONTROL™ Non-Targeting siRNA, Cat. # D-001210-01-05) and test 
siRNA.
The cells were released by trypsinization and cell numbers were counted. The 
cells were diluted in antibiotic-free complete medium to 5.0 x 104 cells/mL 
(ACA19+ cells 3.0 x 104 cells/ml). 100 pL cell suspension was seeded into 
each well of a 96-well plate, or 1 ml/well for a 24-well plate. The cells were 
incubated at 37°C with 5% CCb overnight. Transfection (all calculations are 
shown for triplicate samples in 96-well format. 24-well cell plate format 
adjusted by a 10 fold increase) 20 pM siRNA stock siRNA was diluted into 2 
pM siRNA solution in lx siRNA buffer. In separate tubes, the appropriate 
amount of 2 pM siRNA (Tube 1) and DharmaFECT 4 (Tube 2) was diluted 
with antibiotic-free and serum-free medium as follows: a. Tube 1 - Add 17.5 
pL of 2 pM siRNA to 17.5 pL serum-free medium. The total volume was 35 
pL. b. Tube 2 — Add 1.4 pL of DharmaFECT 4 to 33.6 pL serum-free 
medium. The total volume was 35 pL. The contents of each tube was mixed 
gently by pipetting carefully up and down and incubate for 5 minutes at room 
temperature. Contents of Tube 1 were added to Tube 2. In this example, the 
total volume was 70 pL. The contents were mixed by pipetting carefully up 
and down and incubate for 20 minutes at room temperature. 280pL antibiotic- 
free complete medium was added to the mix in step 4 for a total volume of 
350 pL transfection volume. The complete culture medium were removed 
from the wells of the 96-well plate and 100 pL of the appropriate transfection 
medium replaced to each well. The cells was incubated at 37°C in 5% C02 for 
48-96 Ill's for protein analysis. After transfection, the cells were either lysed 
and the expressions of the target protein were analysed by immunoblotting or
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the cells were labelled with DiO and Dil followed by the assessment of cell 
aggregation or adhesion in the presence or absence of recombinant galectin-3, 
as described in the earlier protocol.
3.17. Cell viability, caspase assays
The CellTiter-Glo® Buffer was thawed, and equilibrated to room temperature 
prior to use. The lyophilized CellTiter-Glo® Substrate was equilibrated to 
room temperature prior to use. All of the CellTiter-Glo® Buffer was 
transferred into the amber bottle containing CellTiter-Glo® Substrate to 
reconstitute the lyophilized enzyme/substrate mixture. This formed the 
CellTiter-Glo® Reagent.
Mixed by gently vortexing, swirling or by inverting the contents to obtain a 
homogeneous solution. lOOul/well of cells solution in concentration 2^105/ml 
was added to each flat white (block) transparent 96-well plate. The control 
wells were added with medium only to obtain a value for background 
luminescence. The plate and its contents was equilibrated at room temperature 
for approximately 30 minutes. lOOul CellTiter-Glo® Reagent was added to 
the cell culture medium present in each well. Contents was mixed for 2 
minutes on an orbital shaker to lyse the cells. The plate was allowed to 
incubate at room temperature for 30 minutes to equilibrate.
Luminescent reading with Tecan infinite 200 (Note: Uneven luminescent 
signal within standard plates can be caused by temperature gradients, uneven
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seeding of cells or edge effects in multi wall plates.)
Application:
Device:
System
Plate
Mode
Attenuation 
Integration Time 
Settle Time
Corning 96 Flat bottom Transparent Polystyrol
Luminescence
NONE
500ms
0ms
Tecan i-Control, 1.3.3.0 
infinite 200 
MED17-86467C
3.18. Anoikis detection by Annexin V-FITC cell surface binding
The cells were released by NECDS and either treated or not treated, after 
suspension in a poly-HEMA coated cell culture plate for the desired time (see 
Chapter 5 and Chapter 6). Collect 2.5 x 105 cells by centrifugation. The cells 
were re-suspended in 500 pi of IX Binding Buffer (from Biovision) at a 
concentration of 5 x 105 cells/ml. 5 pL of Annexin V-FITC and 5 pL of 
propidium iodide (PI 50pg/ml) were added into 0.5ml cell solution and 
incubated at room temperature for 5 mins in the dark before analysis of 
annxin-V cell surface binding by flow cytometry (Ex = 488 nm; Em = 530 
nm) using FITC signal detector (usually FL1) and PI staining by the 
phycoerythrin emission signal detector (usually FL2).
Cell without staining and cells stained only with Annexin V-FITC or 
propidium iodide(PI) were used to identify the position of without staining 
(bottom-left panel), Annexin V-FITC (bottom-right panel) and PI (upper-right 
panel) labelled cell populations in the bivariate correlation plot. Annexin-V 
positive and PI negative (early apoptotic, at the bottom right in the bivariate 
correlation plot) and Annexin-V positive and PI positive (late apoptotic, at the 
top right in the correlation plot) cells are considered as apoptotic cells (Fig3-
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Fig 3-1. An example of flow cytometry plots from the anoikis assessments 
of HT29-5F7 cells. Annexin-V positive and PI negative (early apoptotic, at 
the bottom right in the bivariate correlation plot) and Annexin-V positive and 
PI positive (late apoptotic, at the top right in the correlation plot) cells are 
considered as apoptotic cells.
ht2y5f7 cluster control.017
FL1-H
3.19. Trans-endothelial invasion
The trans-endothelial invasion assays were performed in transwell cell culture 
inserts (BD Falcon. MA) with 8-pm pore filters. HUVEC cells were cultured 
in the inserts 50000/well for 3 days to allow tight formation of the cell 
monolayer. The monolayer integrity and permeability were monitored by
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measuring the trans-endothelial electrical resistance (TEER) using a 
voltohmmeter (EVOM, World Precision Instruments, UK).
Epithelial cells were released by Non-Enzymatic Cell Dissociation solution, 
labelled with DiO-fluorescent dye 5j.il/ml (l><106/ml in serum-free medium) 
for 30 mins at 37°C. Then the cells were washed twice with PBS and diluted 
into 5xl04/ml in serum-free medium, and incubated with or without 
recombinant galectin-3 for 30 mins at 37°C before the cells were applied to 
the E1UVEC monolayer. The cancer cells 250jil/well were added directly 
(without removing the endothelial culture medium) on the ETUVEC monolayer 
for 16 hrs at 37°C. The cells inside the inserts were scraped with cells scraper 
(reformed from 16cm 2-position blade cell scraper from Sarstedt, Inc. 
Newton, NC 28658) and removed from the upper side of the transwell 
membrane with a cotton swab. The transwell membrane of the insert was 
fixed with 2% paraformaldehyde at room temperature for 15 minutes in the 
fume hood. The inserts membrane was then cut down from the insert housing 
and put on glass slides, bottom side up. The slides were sealed with mounting 
medium for fluorescence (HI200 with DAPI from VECTOR) and the 
fluorescent cells migrated to the bottom side of the transwell membrane were 
counted under fluorescence microscopy.
3.20. Assessment of secreted galectin-3 from cells by ELISA
The Anti-Gal3 antibody (RD MAB1154 from R&D) was diluted to 2.5pg/ml 
with coating buffer (1.6 Na2C03, 1.46g NaHC03 in 1L, PH9.6). lOOul/well 
was added into an ELISA plate. The plate was sealed with Parafilm and
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incubated overnight at room temperature. The wells were washed 3 times with 
300ul/well PBS with complete removal of the liquid at each step. After 
removing the solution in the last wash, the plate was inverted and blotted 
against paper towel to remove the residue of the solution.
The wells were then added in 300pL/well of 5% BSA in PBS (Blocking 
Buffer) at room temperature for a minimum of 1 hour. The wells were washed 
three times with PBS before addition of the testing samples. Both samples to 
be tested and standard recombinant galectin-3 were diluted in polypropylene 
tubes. 100 pL of samples or standard of recombinant galectin-3 
(250,125,62.5,31.25,15.6,7.8,3.9,2,l,0.5,0.25pg/ml) in 1% BSA in PBS was 
added. The solution was mixed by gently tapping the plate frame for 1 minute. 
The plate was covered and incubated for 2 hours at room temperature. The 
plate was washed with 300j.il/well PBS three times. 100 pL (0.4pg/ml in 1% 
BSA/PBS) of the biotinylated anti-Gal3 antibody (BAF 1154 from R&D) was 
added to each well for 2 hours at room temperature. The plate was then 
washed with 300pl/well PBS three times. 100 pL of Extra Avidin-HRP (R&D 
Systems, dilute 1:1000 in 1% BSA in PBS) was added into each well for 20 
minutes at room temperature. The plate was washed with 300ul PBS three 
times.
100 pL SigmaFAST OPD (Sigma) Solution was added into each well for 20- 
30 minutes at room temperature. 50 pL 4M sulphuric acid was then added into 
each well to stop the reaction. The plate was gently tapped to ensure thorough 
mixing before the optical density (O.D.) was read (within 30 minutes) with a 
Sunrise microplate reader at 452 mn. Wavelength correction set to 540 or 570 
mn. The concentration of the testing samples was obtained from the standard
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curve.
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CHAPTER 4.
4. Effects of galectin-3 on cancer cell heterotypic adhesion to
endothelium and trans-endothelial migration
4.1. Aims
To assess the influence of cell surface MUC1 expression and MUCl-galectin- 
3 interaction with recombinant galectin-3 at pathologically-relevant 
circulating galectin-3 concentrations on cancer cell heterotypic adhesion to 
vascular endothelial cells and trans-endothelial migration.
4.2. Introduction
One of the critical steps in cancer metastasis is the adhesion of disseminating 
tumor cells to the blood vessel endothelium in distant organs. This process is 
thought to be regulated by the mechanical properties of the cancer cells and 
also by the specific expression of various adhesion molecules and/or ligands to 
adhesion molecules on the surface of cancer cells and endothelial cells (247).
Previous studies from our group have shown that MUC1 is a natural ligand of 
galectin-3 in human cancer cells. Binding of recombinant galectin-3 to cancer- 
associated MUCl, via the TF antigen, induces MUC1 cell-surface polarization, 
thus revealing underlying adhesion molecules on the cell surface, and 
increases the adhesion of human epithelial cells to human umbilical vein 
endothelial cells (HUVEC) under static cell culture conditions(248). Previous 
investigations have indicated that the great size and length of MUC1 allows it 
to form a protective shield on the cell surface and inhibit cancer cell-cell and
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cancer cell-matrix interactions (174, 175). We therefore investigated the 
effects of MUC1 expression and MUCl-galectin-3 interactions on cancer cell 
heterotypic adhesion to endothelial cells.
4.3. Materials and methods
Materials. Recombinant full-length human galectin-3 and monoclonal 
antibodies (mAh) against human CD44H (BBA10) and E-selectin (BBA16) 
were from R&D Systems. B27.29 anti-MUCl mAh was kindly provided by 
Dr. Mark Reddish (Biomira, Inc.). Nonenzymatic Cell Dissociation Solution 
was from Sigma. Vybrant DiO Cell-Labeling Solutions were from Molecular 
Probes.
Cell lines. Human colon cancer HT29 and HT29-5F7 cells. Macrovascular 
HUVECs and human micro vascular lung endothelial cells (HMYEC-L) Cells 
that had been passaged less than five times were used in the experiments. 
ACA19h, and ACA19_,all as described in chapter 3
Cancer cell-endothelial adhesion. Cancer cell-endothelial adhesion was 
assessed as described at chapter 3. At the end of the experiments, the samples 
were blinded and the fluorescently labeled cells remaining on the endothelial 
monolayer were counted in 10 randomly selected fields of view using 
fluorescent microscopy (Olympus B51). The ability of the cells to be labeled 
by the fluorescent dye was different between any two human cell lines tested
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ill our pilot experiment. As comparison of the cell adhesion between different 
MUC1-expressing cells is an important part of this study, the actual number of 
the fluorescently labeled cells adhered to endothelial monolayer, rather than 
the reading of the fluorescent density, was used as the end point.
Small interfering RNA MUC1 knockdown. ACA19+ cells 
(3x104/ml, 1 ml/well in 24Wells cell culture plate after 24 hours cultured in 
incubator at 37°C in Anti-biotic free complete DMEM )were transfected with 
100 nmol/L MUC1 small interfering RNA (siRNA) or scrambled control non­
targeting siRNA (siCONTROL, Dharmacon) for 48 h at 37°C in serum-free 
and anti-biotic free DMEM medium. The cells were lysed and the expression 
of MUC1 was assessed by MUC1 immunoblotting with the B27.29 anti- 
MUC1 antibody (5mg/ml 1:15000 in 1%BSA in PBS) followed by goat anti­
mouse HRP-conjugated antibodyl:1000 in 1% BSA in PBS. See in details at 
chapter 3.
Cell adhesion under flow conditions (Experiment performed in University 
of Birmingham in collaboration with Prof G Nash, I traveled there to do part 
of those experiments with them together). HUYECs, cultured in flattened 
glass capillaries for 24 h at 37°C to allow the cells to form monolayers as 
described previously(243), were unstimulated or stimulated with 10 ng/mL 
tumor necrosis factor-n (TNF-a) for 24 h at 37°C before the introduction of 
cancer cells. ACA19 i/_ cells were incubated with or without 1 pg/mL galectin- 
3 for 30 min at 37°C. The cells were then perfused through glass capillaries at 
a flow rate to deliver 0.05-Pa shear wall stress. After 4 min of washing with 
PBS, the capillaries were video-recorded and the number of adherent cells was
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quantified and expressed as the number of adherent cells per square millimeter 
per 106 cells perfused.
Cell-surface expressions of E-selectin and CD44. Cells released with 
Nonenzymatic Cell Dissociation Solution were fixed with 2% 
paraformaldehyde for 0.5 h, blocked with 5% normal goat serum/PBS for 0.5 
h, and incubated with antibodies against E-selectin (1 mg/ml 1:400 in 1%BSA 
in PBS)or CD44H(1 mg/ml 1:400 in 1%BSA in PBS) for 1 h at room 
temperature. After application of fluorescence-conjugated secondary antibody 
1:400 for 0.5 h, the expression of cell-surface E-selectin or CD44 was 
analyzed by flow cytometry (Cells treated without primary anti-E-selectin or 
anti-CD44H antibody used as control in the cytometry analysis).
Trans-endothelial invasion. HUVECs (50000/ml, 0.5ml/well in EBM 
medium) were cultured in Transwell inserts with 8-pm-pore filters (BD Falcon) 
for 3 d to allow tight formation of cell monolayers. Monolayer integrity was 
monitored by measuring transendothelial electrical resistance using a volt-ohm 
meter (EVOM, World Precision Instruments), and monolayers with 
transendothelial electrical resistance >800 ft /cm2 were used for 
transendothelial assessment. Epithelial cells (l><106/ml in serum-free medium), 
labeled with DiO (5j.il/ml), were incubated with or without galectin-3 
(concentrations)for 30 min at 37°C before application of the cells to the 
HUVECs for 16 h at 37°C. The cells at the upper side of the Transwell 
membrane were removed with a cotton swab and fluorescent cells migrated to 
the bottom side of the Transwell membrane were counted using an Olympus
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B51 fluorescence microscope after removal of the transwell membrane from 
the trails well inserts.
Measurement of galectin-3 concentration in the cell culture supernatant 
by ELISA:
Sample preparation: HT295F7 cells (5.0 xlO5 cells/mL) in serum-free 
DMEM medium were incubated for 1.5 hours at 37°C. The cells suspension 
was spun at 1500RCF(xg) for 5 minutes. Then the supernatant was collected 
and froze at -20oC for galectin-3 test.
100 pL/well of Anti-Gal3 antibody 2.5pg/ml(RD MAB1154 from R&D) in 
coating buffer(1.6 Na2C03, 1.46g NaHC03 in 1L? PH9.6) in PBS, use 
immediately) was transferred to an ELISA plate. The plate was sealed and 
incubated overnight at room temperature. Each well was aspirated and 
washed 3 times by forcefully filling each well with PBS (300 pL) using a 
multi-channel pipette. The liquid was completely removed at each step. After 
the last wash, the remaining PBS was removed by inverting the plate and 
blotting it against clean paper towelling. The plates was blocked by adding 
300 pL of 5% BSA in PBS of Blocking Buffer to each well and incubated at 
room temperature for a minimum of 1 hour. After washing, the plates was 
ready for sample addition. Dilutions of unknowns and standards was carried 
out in polypropylene tubes. 100 pL of sample or standards of Recombinant 
Galectin-3 in 1% BSA in PBS was added per well. The samples were mixed 
by gently tapping the plate frame for 1 minute. The plate was covered with an 
adhesive strip and incubated 2 hours at room temperature. The plate was 
washed 3 times by forcefully filling each well with PBS (300 pL) using a
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multi-channel pipette. 100 pL of the Biotinylated anti-Gal3 antibody(BAF 
1154 from R&D) O^pg/mlj diluted in 1%BSA in PBS, was added to each 
well. The plate was covered with a new adhesive strip and incubated for 2 
hours at room temperature. The plate was washed 3 times by forcefully filling 
each well with PBS (300 pL) using a multi-channel pipette. 100 pL of Extra 
Avidin-HRP (R&D Systems, dilute 1:1000 in 1% BSA in PBS) was added to 
each well. The plate was covered and incubated for 20 minutes at room 
temperature. The plate was avoided placing in direct light. The plate was 
washed 3 times by forcefully filling each well with PBS (300 pL) using a 
multi-channel pipette. 100 pL SigmaFAST OPD ( from Sigma-Aldrich) 
Solution was added to each well. The plate was incubated for 20 - 30 minutes 
at room temperature. The plate was avoided placing in direct light. 50 pL 4M 
sulphuric acid was added to each well. The plate was gently tapped to ensure 
thorough mixing. The optical density (O.D.) of each well was determined 
within 30 minutes. The Sunrise microtiter plate reader was set to 452 mn. 
wavelength correction set to 540 or 570 mn. The values of the unknown 
samples were assigned in relation to the standard curve. Various methods 
(c.g., linear, semi-log, log/log, 4 parameter logistic) in Excel were tried to see 
which curve best fits the data. One way to determine if the curve fit is correct 
is to back fit the standard curve O.D. values. To do this, the standard curve 
was first plotted. Next, standards were treated as unknowns and interpolate the 
O.D. values from standard curve. The readings were close to the expected 
values (+/-10%). The data reduction method that gave the best correlation (r) 
value and backfitted was used.
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Statistical analysis. Paired or impaired t test for single-comparison, one-way 
ANOVA followed by Newman-Keuls' test for multiple comparisons, X2 test, 
and Kaplan-Meier analysis followed by log-rank test (StatsDirect for
Windows, StatsDirect) were used where appropriate. Differences 
considered significant when 2-tailed P < 0.05
were
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4.4. Results
4.4.1 Effect of MUC1 expression and MUCl-galectin-3 interaction on 
cancer-endothelial adhesion under static conditions
Immuno/lectin blots of MUC1-positive transfectants ACA19+ and MUC1- 
negative transfectants (AC A IQ") cells of A375 human melanoma cells with 
B27.29 anti-MUCl mAh (5mg/ml 1:15000 in 1%BSA in PBS) and TF- 
binding PNA (1 mg/ml 1:1000 in 1%BSA in PBS) showed that MUC1 in 
ACA19+ cells is abundantly decorated with TF antigens (Fig4-1). MUC1- 
positive transfectants ACA19+ showed abundant expression of MUC1 while 
the negative transfectants ACA19- showed no detectable expression of MUC1 
(Fig4-1).
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MUC1(B27.29) TF/MUC1(PNA biotin)
Molecular ACA19- ACA19+ 
Marker
— 200
—122
— 86
ACA19- ACA19+ Molecular
Marker
ACA19- ACA19+
Fig4-1 Expression of MUC1 and MUCl-associated TF in ACA19+/- 
transfectants. Immunoblots of ACA19+/- cell lysates were probed with 
biotinylated TF-binding peanut agglutinin (PNA), B27.29 anti-MUCl antibody 
or anti-tubulin antibody (1 mg/ml 1:1000 in 1%BSA in PBS).
HUVEC cells (Red) were seeded on the glass cover slipes inserted in 24 well 
culture plates till confluence after three days (Fig4-2). The ACA19" and 
ACA19 were labeled with DiO (green) fluorescence labeling solution 
separately for 30minutes before applied HUVEC monolayer (Only for 
presentation purposes HUVEC prelabelled with DiL for 30minutes, not 
labeled in every real adhesion experiment).
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AC A19- ACA19+
Fig 4-2. ACA19+ cells adhere less than ACA19- cells to monolayer of 
HUVECs. ACA19+or- cells (green) were labeled with DiO and dropped on the 
HUVEC monolayer (red) on the slides for 1 hour at 37°C , The cells were 
washed and the adhesion cells on the HUVEC monolayer were counted under 
fluorescence microscope.
ACA19 cells showed significantly less adhesion to unstimulated and TNF-o— 
prestimulated HUVECs compared with the ACA19“. (Fig 4-2, and 4-3)
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□ ACA19- ■ ACA19+
Untreated HUVEC TNFa-treated HUVEC
Fig 4-3. Effects of MUC1 expression on cancer cell-HUVEC adhesion 
under static conditions. ACA19+ cells adhere less than ACA19" cells to 
HUVECs. Columns, mean of triplicate determinations from three independent 
experiments; bars, SE. P < 0.05; **, P < 0.01; ***, P < 0.001 (one-way 
ANOVA compare means).
To determine the effect of circulating galectin-3 on cancer cell adhesion to 
endothelium, we pretreated the cells with recombinant galectin-3 at several 
pathologically relevant circulating galectin-3 concentrations. Earlier 
investigation by lurisci and colleagues (209) has shown that the concentration 
of circulating galectin-3 increases up to 5-fold in the sera of cancer patients 
with melanoma, breast, or gastrointestinal cancer (range, 20-950 ng/mL) 
compared with healthy people. Our own investigation has indicated that the
76
concentrations of circulating galectin-3 in the sera of colorectal cancer patients 
are > 14-fold higher (up to 5 pg/mL) than in healthy people (Barrow et al, 
unpublished data). We found that pretreatment of the cells with galectin-3 at 
concentrations >100 ng/mL resulted in significant increase of ACA19+, but 
not ACA19“ cell adhesion to HUYECs (Fig4-4).
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Fig4-4. Effects of MUCl-galectin-3 interaction on cancer cell- 
HUVEC adhesion under static conditions. Pretreatment of the cells 
with galectin-3 increases ACA19+. but not ACA19~, cell adhesion to 
HUVECs. Columns, mean of three independent experiments; bars, SE. *, 
P < 0.05; **, P < 0.01; ***, P < 0.001 (one-way ANOVA followed by 
Newman-Keuls' test for multiple comparisons).
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Treatment of ACA19+ with MUC1 siRNA results in 63% reduction of MUC1 
expression in comparison with cells treated with control siRNA (fig 4-5).
MUC1
(B27.29)
Tubulin-P
Fig4-5. siRNA MUC1 suppression in ACA19+ cells. ACA19+cells were 
treated with siRNA MUC1 or control non-targeting siRNA for two or three 
days before the cellular mucl expression was determined by B27.29 
immunoblotting. Selected representative blots of three experiments.
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Suppression ot MUC1 expression by siRNA in ACA19 cells was seen to be 
associated with 47% increased adhesion of the cells to HUVECs(Fig4-6). and 
this prevented the increase of cell adhesion in response to galectin-3 (Fig4-7).
175 n
150 -
125 ■
100 ■
No siRNA Con-siRNA MUCIsiRNA
Fig4-6 Effects of MUC1 expression on cancer cell-HUVEC adhesion 
under static conditions. MUC1 suppression increases ACA19+ cell 
adhesion, mean of three independent experiments; bars, SE. P < 0.05; **, 
P < 0.01; ***,/>< 0.001. (one-way ANOVA to compare means).
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Fig4-7 SiRNA MUC1 suppression in ACA19+ cells. MUC1 suppression 
abolishes galectin-3-induced cell adhesion. Columns, mean of three 
independent experiments; bars, SE. *, P < 0.05; **, P < 0.01; ***. P < 0.001. 
(one-way ANOVA compare means).
Thus, the presence of extracellular free galectin-3, by its interaction with 
MUC1. counteracts the antiadhesive effect ofMUCl expression on cancer cell 
adhesion.
To determine whether MUC1-galectin-3 interaction has similar effects on cell
8!
adhesion in cancer cells that naturally express MUCK we compared the 
adhesion ot human colon cancer HT29 andHT29-5F7 cells in the presence or 
absence of recombinant galectin-3. HT29-5F7 is a FIT29 subline selected by 
its resistance to 5-fluorouracil and has much greater MUC1 than the parental 
HT29 cells (249)(Fig 4-8).
MUC1 (B27.29)
MUC1 (CT2) 
Tubulin-P
HT29 HT295F7
Fig4-8 Expression of MUC1 in HT29 and HT29-5F7 cells. Higher MUC1 
expression in HT29-5F7 than in parental HT29 cells. HT-29 and HT29-5F7 
cell lysates were probed with B27.29 anti-MUCl antibody(5mg/ml, 
1:15000), CT-2 anti-MUCl antibody against the cytoplasmic tail of MUC1 
(0.5mg/ml, 1:1000. NeoMarkers, Fremont, CA) or anti-fK-tubulin antibody 
(1 mg/ml, 1:1000).
HT29 cells showed significantly more adhesion to unstimulated and TNF-o- 
prestimulated HUVECsthan HT29-5F7 cells (Fig4-9).
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□ HT29-5F7
Untreated HUVEC TNFa-treated HUVEC
Fig4-9 Effects of MUC1 expression on HT29 and HT29-5F7 ceil 
adhesion to HUVECs. HT29-5F7 cells show less adhesion than HT29 cells 
to HUVECs unstimulated or pre-stimulated with lOng/ml TNFa for 16 hr. 
Data are expressed as total number of the adhered cells/FOV as mean ± SEM 
from two independent experiments. The difference was analysed by unpaired 
t test.
Pretreatment of the cells with galectin-3 significantly increased adhesion of 
HT29-5F7, but not HT29. cells to HUVECs(Fig4-10), and this effect was 
abolished by the presence of TF-expressing Asialofetuin (Fig4-11).
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200 t
HT29 HT29-5F7
Fig4-10 Effects of MUCl-galectin-3 interaction on HT29 and HT29-5F7 
cell adhesion to HUVECs. Galectin-3 (Ijag/ml) treatment increases adhesion 
of HT29-5F7 but not HT29 cells to HUVECs. Data are expressed as percentage 
of the adhered cells compared to that in the controls (mean ± SEM of triplicate 
determinations from three independent experiments). The difference was 
analysed by paired t test. *p<0.05, **p<0.01, ***p<0.001. (one-way ANOVA 
compare means).
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Control (BSA) +Gal3 +Gal3 +ASF +ASF
4-11 Effects of MUCl-galectin-3 interaction on HT29 and HT29-5F7 cell 
adhesion to HUVECs. Galectin-3-induced cell adhesion was blocked by the 
presence of galectin-3-binding ligand asialofetuin (ASF). HT29-5F7 cells were 
treated without or with 1 pg/ml galectin-3 in the presence or absence of 
20pg/ml ASF before the assessment of cell adhesion. Data are as percentage of 
the adhered cells compared to that in the controls (mean ± SEM of triplicate 
determinations from six independent experiments). The difference was 
analysed by ANOVA, Newman and Keuls. *p<0.05, **p<0.01, ***p<0.001.
To see whether the effects of MUCl-galectin-3 interaction on cancer cell 
adhesion to HUVECs also occur with microvascular endothelium, a model 
that is probably closer to the in vivo situation in metastasis, we analyzed cell
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adhesion to HMVEC-L. Again. ACA19+ cells showed significantly less 
adhesion to unstimulated and INF- a- -prestimulated FIMVEC-Ls than 
ACA19 cells (Fig 4-13).
□ ACA19- **
Untreated HMVEC-L TNFa-treated HMVEC-L
Fig 4-13. Effects of MUC1 on cancer cell-HMVEC-Ls adhesion under static 
conditions.ACA19+ cells adhere less than ACA19- cells to FIMVEC-Ls 
prestimulated with or without TNF-<*. Columns, mean of three independent 
experiments; bars, SE. P < 0.05; **, P < 0.01; ***, P < 0.001. (one-way 
ANOVA compare means).
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Pretreatment ot the cells with galectin-3 (1 jag/mL) increased adhesion of 
ACA19+ cells but not of ACA19 cells comparing with control(Fig 4-14)
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Figure 4-14. Effects of MUCl-galectin-3 on cancer cell-HMVEC-Ls 
adhesion under static conditions: Galectin-3 (1 pg/mL) increases ACA19+, 
but not ACA19—. cell adhesion to HMVEC-Ls. Columns, mean of two 
independent experiments; bars. SE. *, P < 0.05: **, P < 0.01; ***, P < 0.001. 
(one-way ANOVA compare means).
Collectively, these results indicate that MUC1 expression prevents cancer cell 
adhesion to macrovascular and microvascular endothelium and that MUC1- 
galectin-3 interaction reduces this protective effect of MUC1.
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4.4.2 Assessment of galectin-3 secretion.
We also assessed whether galectin-3 is secreted into the medium by the cancer 
cells. SxloVml cells suspension 1ml of HT295F7, HT29, ACA19+ or 
ACA19- cell were incubated for 1.5 hour at 37°C. the culture medium 
(Serum-free DMEM)was collected after spin of the medium at 1500RCF(xg) 
tor 5 min and the concentrations of galectin-3 in the medium was assessed 
by ELISA. Recombinant galectin-3 was used to generate a standard curve (Fig 
4-12)
1.8 n
y = 0.5595x- 1.4381.6 -
1.4 -
0.8 ■
0.6 -
Log Galectin-3 pg/ml
Fig4-12 Standard curve of recombinant Galectin-3 tested by 
ELISA(T riplicate)
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It was found that galectin-3 secrected into the medium with the 1.5 hr 
incubation time was all less than 0.325 ng/mL ( the detectable limit of the 
assay) Thus, the contribution of endogenously secreted galectin-3 to 
recombinant galectin-3—mediated cell adhesion in these assessments is 
minimal.
4.4.3 Effect of MUC1 and MUCl-galectin-3 interaction on cancer- 
endothelail adhesion under sheer flow conditions
106 cells were perfumed through HUVEC monolayers pre-treated with 
TNFa for 24 hours on glass capillaries in PBS at 0.5 ba for 4 mins. The 
HUVEC monalyers were washed by PBS for 1 minutes before video-recorded. 
The numbers of adhesion cells per square millimeter per 106 cells perfused 
was calculated. The results are shown in Fig4-15. Under 0.05 Pa shear flow 
conditions, very few ACA19+ or ACA19' cells showed adhesion to 
unstimulated HUVECs, but their adhesion was markedly (68%) increased 
when HUVECs were pretreated with TNF- VFig 4-15).
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Figure 4-15. Effects of MUC1 expression on cancer cell-HUVEC adhesion 
under flow conditions.ACA19+ cells adhere less than ACA19- cells to 
HUVECs at 0.05-Pa shear stress flow conditions. Columns, mean of seven 
independent experiments; bars, SE. *,P< 0.05; **, P < 0.01; ***. P < 0.001. 
(one-way ANOVA compare means).
Moreover. ACA19 cells showed 68% less adhesion than ACA19- cells to 
TNF-a-stimulated HUVECs under such conditions. Pretreatment of the cells 
with 1 pg/mL galectin-3 resulted in 55% increased adhesion of ACA19+ cells 
but not of ACA19“ cells(Fig 4-16)
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Fig 4-16. Effects of MUC1-galectin-3 interaction on cancer cell-HUVEC 
adhesion under flow conditions, galectin-3 (1 jig/mL) treatment increases 
adhesion of ACA19+, but not ACA19~, cells to HUVECs under flow 
conditions. Columns, mean of five ACA19+ and six ACA19- independent 
assessments; bars, SE. *,P < 0.05; **, P < 0.01; ***, P < 0.001.
Thus. Cancer cell-endothelial adhesion under flow conditions is inhibited by 
MUC1 expression but increased by MUC 1-galectin-3 interaction. The effects 
of MUC1 expression and galectin-3-MUCl interaction on cancer cell- 
endothelial adhesion seen under static conditions also hold true under flow 
conditions.
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4.4.4 Effect of Galectin-3 and B27.29 anti-MUCl mAb on MUC1 cell-
surface polarization and on cell adhesion.
Previous studies in our group has shown shown that galectin-3-MUC1 
interaction induces change in MUC1 cell-surface localization (248). To see 
whether this change in MUC1 localization is associated with altered cell 
adhesion to endothelium, we compared MUC1 cell-surface clustering in 
response to galectin-3 and cell adhesion to HUVECs.
It was found that 10% (48 of 500) ACA19+ cells showed spontaneous 
clustering of MUC1 on the cell surface, as illustrated by discontinuity of 
MUC1 cell-surface staining when cultured in suspension for 1 h at 37°C 
(Table4-1).
Table 4-1. Galectin-3 and B27.29 anti-MUCl antibody induce 
discontinuous MUC1 cell surface localization on ACA19+ cells.
Control Gal-3 (Ipg/ml) B27.29 (Ipg/ml)
%(n) % (ft) % (n)
37°C 10(48) 14(68)* 26(128)**
Pre-fixed 7(36) 8(39) 9(43)
After pretreatment with galectin-3 (1 pg/mL) at 37°C for 1 h, 40% more (68 
of 500; P < 0.05) cells showed MUC1 cell-surface polarization than control 
cells. Introduction of B27.29 anti-MUCl mAb also resulted in significant 
increase (128 of 500; P < 0.01) in the number of cells showing MUC1 cell-
92
surface polarization. This effect of B27.29 on MUC1 cell-surface polarization 
is in keeping with previous reports that the presence of 214D4 anti-MUCl 
mAh, which also recognizes the VNTR region of MUC1, induces MUC1 cell- 
surface polarization in MUC1-transfected human melanoma cells (175). The 
B27.29 mAh recognizes the PDTRPAP epitope in the VNTR region of 
MUC 1(250), and nuclear magnetic resonance analysis has indicated an 
enhanced binding affinity of B27.29 to MUC1 in the presence of short sugar 
chains within the VNTR region(251).
It was found that the increases in MUC1 cell-surface polarization in response 
to galectin-3 and to B27.29 mAh are both associated with increased adhesion 
of ACA19 cells to HUVECs (Fig 4-17 ). Furthermore, introduction of 
galectin-3 or B27.29 mAb to paraformaldehyde-prefixed cells, which would 
be unable to undergo changes in the MUC1 cell-surface localization, failed to 
induce cell adhesion to HUVECs compared with the control cells. These 
results support a direct link between discontinuous cell-surface localization of 
MUC1 and increased cell adhesion in response to galectin-3 and B27.29 mAb.
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□ Control(BSA) 
■ Gal3
37°C Pre-fixed
Fig 4-17. GaIectin-3 and B27.29 anti-MUCl mAb both induce 
increased adhesion to HUVECs of live, but not prefixed, ACA19+ 
or ACA19" cells. Live or paraformaldehyde-prefixed ACA19+/“ cells 
were pretreated with 1 pg/mL recombinant galectin-3, B27.29 mAb, 
bovine serum albumin (BSA), or control mouse IgG before adhesion to 
HUVECs. Columns, mean of four independent experiments; bars, SE.
*, /* < 0.05(one-way ANOVA ).
4.4.5 Aassessment of the cell adhesion molecules involved in galectin- 
3-mediated cancer-endothelial adhesion.
Since the galectin-3 caused MUC1 localization, the effect of the presence of 
antibodies against the cell surtace adhesion molecules was tested. The 
presence ot 25 pg/mL anti-CD44H mAb (BBA10), which recognizes all 
CD44 isoforms, caused 26% {P < 0.05) inhibition of ACA19-, but not
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ACA19+> adhesion to HUVECs, but largely blocked ACA19+ cell adhesion 
induced by galectin-3(Fig 4-18).
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□ control (BSA)
□ anti-E-Sel
□ anti-CD44H
■ Gal3
Banti-E-Sel+Gal3
■ anti-CD44H+Gal7
ACA19- ACA19+
Fig4-18. Involvement of cell-surface CD44 and ligand(s) to endothelial-E- 
selectin in galectin-3—induced cancer cell-endothelial adhesion. The
presence of 25 pg/mL anti-CD44H, but not anti-E-selectin mAb reduces 
ACA19 cell adhesion and adhesion of ACA19+ cells induced by 1 pg/mL 
galectin-3. Columns, mean of three independent experiments; bars, SE. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. (one-way ANOVA followed by Newman- 
Keuls' test for multiple comparisons)
The presence of 25 pg/mL anti-E-selectin antibody, however, failed to block 
the adhesion ot either ACA19 or ACA19+ cells and also showed no 
significant inhibition (/>= 0.47) of galectin-3-induced ACA19+ adhesion(Fig
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4-17). The presence of either anti-CD44H or anti-E-selectin antibody inhibited 
HT29 cell adhesion to HUVECs(Fig 4-19)
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4-19. Involvement of cell-surface CD44 and ligand(s) to endothelial-E- 
selectin in gaIectin-3—induced cancer cell-endothelial adhesion, the
presence of 25 pg/mL anti-CD44H or anti-E-selectin antibody inhibits HT29 
and HT29-5F7 cell adhesion and adhesion of HT29-5F7 cells induced by 1 
pg/mL recombinant galectin-3. Columns, mean of three independent 
experiments; bars, SE. P < 0.05; **, P < 0.01; ***, P < 0.001. (one-way 
ANOVA followed by Newman-Keuls' test for multiple comparisons)
Neither of these antibodies at this concentration showed significant inhibition 
ot HT29-5F7 cell adhesion to HUVECs, but their presence completely
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prevented the increase of HT29-5F7 cell adhesion in response to galectin- 
3(Fig4-18).
Antibody binding followed by flow cytometry analysis showed similar CD44 
cell-surface expression and antibody accessibility between HT29 and HT29- 
5F7 and between ACA19 and ACA19+cells (Fig4-20)
10° 101 102 1 03 1 04 1 0° 101 102 103 104
Fluorescence Intensity
Fig 4-20. Expression of cancer cell-surface CD44 and E-selectin. cell- 
surface expression of E-selectin and CD44 are similar between HT29 and 
HT29-5F7 cells and between ACA19+ and ACA19' cells. Green, CD44; red, 
E-selectin; purple, isotype control.
Thus, the lack of effect of the anti-CD44H antibody on the adhesion of HT29- 
5F7 and ACA19+ cells to HUVECsis likely due to the inability of cell-surface
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CD44 to gain access to its receptor on HUVECs as a result of functional 
concealment of cell-surface CD44;, for example, by the presence of adjacent 
MUC1. The inhibition by the anti-CD44H antibody of galectin-3—induced cell 
adhesion, in which cell-surface CD44 is functionally exposed following 
MUC1 cell-surface polarization, supports this conclusion. The relatively 
modest inhibition of the anti-CD44 antibody at 25 pg/mL on AC A19“ 
adhesion indicates that cell-surface CD44 may represent just one of several 
cell adhesion molecules involved in melanoma cell-endothelial adhesion.
We found that anti-CD44H antibody pretreatment of HT29 cells, but not of 
HUVECs, caused a significant inhibition of subsequent HT29 cell adhesion to 
HUVECs (Fig4-21).
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Fig4-21. Involvement of cancer cell-surface CD44 in galectin-3-mduced 
cancer cell-endothelial adhesion. Pretreatment of HT29 cells, but not of 
HUVECs, with 25 ^g/mL anti-CD44H antibody inhibits HT29 cell adhesion to 
HUVECs. Columns, mean of three independent experiments; bars, SE. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. (one-way ANOVA)
This indicates the involvement of HT29-associated, but not HUVEC- 
associated. CD44 molecules in HT29-endothelial interaction and in galectin- 
3—mediated cancer cell-endothelial adhesion. This is in keeping with earlier
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reports of a role for cancer-associated CD44 in the initial endothelial adhesion 
of human prostate, breast, and colon cancer cells(252, 253). Neither 
HT29/HT29-5F7 nor ACA197ACA19+ cells express E-selectin on their cell 
surface (Fig4-19). The HT29 adhesion to HUVECs and the HT29-5F7 
adhesion to HUVECs induced by galectin-3 were, however, inhibited by the 
presence of the anti-E-selectin antibody(Fig4-18). This suggests the 
involvement of endothelial-E-selectin in these cell adhesion events. The 
different effects of the anti-E-selectin antibody on HT29/HT29-5F7 and 
ACA19 /+adhesions to HUVECs likely reflect differences in the expression of 
E-selectin ligands on the surface of HT29 colon and ACA19 melanoma cells.
4.4.6 Assessment of effects of MUC1 and MUCl-galectin-3 interaction 
on Cancer cell transendothelial invasion
The HUVECs were cultured in an invasion chamber (Fig 4-23) and the 
monolayer integrity of the cells were measured by transendothelial electric 
resistance with a vol-ohm meter (Fig4-22) . Good monolayers were seen 
under microscope to be achieved after 3 days culture of the cells.
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Fig4-22. Transendothelial electric resistance of HUVEC monolayers at 
different times.
Then, the tumor cells labeled with Dio cell labeling solution were dropped on 
the HUVECs and incubated for 16 h at 37°C(Fig4-23).
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HUVEC
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through
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Membran 2 with
Cancer cells after invasion
Cell culture Medium
Fig4-23. The set up of the invasion chamber.
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ACM9" cells showed less trans-HUVEC invasion than ACM9“ cells (Fig4- 
24) after 16 hr culture.
ACA19 ACA19+
Fig4-24. Effects of MUC1 expression on cancer cell transendothelial 
invasion. ACA19+ cells showed less trans-HUVEC invasion than ACA19' 
cells (Picture ot the bottom outside of the Transwell membrane after 16 hr).
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ACA19 showed 46% greater trans-HUVEC invasion than ACA19+ 
cells(Fig4-25)
> o>
200 -
ACA19- ACA19+
Fig4-25. Effects of MUC1 on cancer cell transendothelial 
invasion.ACA19+ cells show less trans-HUVEC invasion than ACA19- 
cells. Columns, mean of triplicate determinations from six independent 
experiments; bars, SE. P < 0.05; ***, P < 0.0001. (one-way ANOVA 
compare means (bonferroni))
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Pretreatment of the cancer cells with galectin-3 (1 (ag/mL) before their 
application to the HUVEC monolayers resulted in 64% increased invasion of 
ACA19+ cells but not of ACA19“cells (Fig4-26).
ACA19- ACA19+
Fig4-26. Effects of MUCl-galectin-3 on cancer cell transendothelial 
invasion, galectin-3 (1 pg/mL) pretreatment increases ACA19+, but not 
ACA19 , cell trans-HUVEC invasion. Columns, mean of six independent 
experiments; bars, SE. *, /> < 0.05; ***, P < 0.0001. (one-way ANOVA 
compare means)
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This effect of galectin-3 was completely prevented by the presence of 
lactose(Fig4-27).
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Fig4-27. Lactose inhibition of the galectin-3 induced cancer cell 
transendothelial invasion. Galectin-3-mediated transendothelial invasion 
of ACA19+ is inhibited by the presence of (10 pg/mL) lactose. Columns, 
mean of four independent assessments; bars, SE. *, P < 0.05; ***. P < 
0.0001. (one-way ANOVA followed by Newman-Keuls' test for multiple 
comparisons).
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4.4.7 Effect of MUC1 expression and MUCl-galectin-3 interaction on 
metastasis in vivo in nude mice see appendix l.(this part of the study was 
conducted by Pr Xiuliguo et al in Shangdong University of China)
4.5 Discussion:
This study shows that overexpression of cell-surface MUC1 is associated with 
reduced cancer cell-endothelial adhesion under static and flow conditions and 
with decreased cancer cell transendothelial invasion. Work by our 
collaboratiors subsequently showed (appendix 1) that increased MUC1 
expression correlated with and increased survival of athymic nude mice 
inoculated i.v. with malignant melanoma cells. The interaction of cell-surface 
MUC1 with circulating galectin-3 at pathologically relevant concentrations 
reduces the protective effects of MUC1 on cancer cell adhesion, 
transendothelial invasion, and metastasis. These effects of galectin-3 are 
mediated by MUC1 cell-surface clustering and the consequent exposure of 
cell-surface adhesion molecules including CD44 and the ligand(s) for 
endothelial-E-selectin. Thus, the enhanced molecular interaction between 
circulating galectin-3 and cancer-associated MUC1 in the bloodstream of 
cancer patients, occurring as a result of the increased expression of MUC1 by 
cancer cells, the increased expression of the galectin-3-ligand TF antigen by 
cancer-associated MUC1, and the increased concentration of circulating 
galectin-3, all of which are common features in cancer, promotes metastasis.
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Cancer cell adhesion to endothelium is a vital step in metastasis and is 
mediated by a range of adhesion molecules and their ligands, including 
selectins and integrins expressed on cancer cells and endothelial cells, which 
in turn are regulated by circulating molecules such as cytoldnes(247). The 
inhibitory effect of MUC1 expression and the stimulatory effect of galectin-3- 
MUC1 interaction on cancer cell-endothelial adhesion shown in this study 
suggest that MUC1 cell-surface polarization, which leads to uncovering of the 
smaller adhesion molecules and/or ligands to adhesion molecules, represents 
an essential first step in the process of cancer cell-endothelial adhesion. Given 
the variable expression of MUC1 in different cancer cell lines(254), the lack 
of inhibitory effect of anti-selectin antibodies on cancer cell-endothelial 
adhesion observed in several previous investigations (255) maybe, to a large 
extent, due to the concealment of the cell-surface selectin ligands by MUC1.
MUC1 can carry sialyl Lewis-related carbohydrate structures that act as 
ligands for selectins (256). However, an interaction between cancer-associated 
MUC1 and endothelial-E-selectin will probably not induce tight cell adhesion, 
a process that is believed to require the involvement of cell-surface integrins 
as has been well established for leukocyte-endothelial adhesion (257). Tight 
cancer cell-endothelial adhesion may only occur after MUC1 cell-surface 
polarization and exposure of integrins and other smaller cell adhesion 
molecules. Our previous demonstration (248)that MUC1 is absent at the 
cancer cell-endothelial contact point supports this.
The protective effect of the MUC1 "shield" and the "deprotective" effect of 
the galectin-3-TF/MUCl interaction on cancer cell adhesion provide
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explanations at the molecular level for several recent clinical and experimental 
observations related to metastasis;, for example, the correlation between 
increased apical MUC1 cell-surface polarization and increased lymphatic 
invasion, recurrence rate, and lower overall survival in breast cancer patients 
(258). The correlation of increased concentrations of circulating anti-TF 
antibodies, which would inhibit galectin-3-mediated TF/MUC1 interactions, 
with improved prognosis in gastric cancer(259) is also consistent with our 
model. The association of MUC1 sialylation with a better prognosis in breast 
cancer(260) is also in keeping with a reduced galectin-3-TF/MUCl interaction 
as a consequence of concealment of TF by sialic acid, thus inhibiting MUC1- 
galectin-3 interaction(248). The significant extension of animal survival 
induced by i.p. coinjection of an anti-TF antibody with metastatic 4T1 breast 
cancer cells(261) could be the consequence of the blockade of the galectin-3- 
TF/MUC1 interaction.
Because increased occurrence of the TF glycan is one of the commonest 
glycosylation changes in cancer(97), this study also highlights the functional 
importance of cancer-associated changes in cellular glycosylation (151, 
262)and indicates a potential for glycan profiling in predicting cancer 
metastasis and prognosis. Furthermore, as the increased concentrations of 
circulating galectin-3 in cancer patients are probably produced not only by the 
tumor cells but also by the peritumoral inflammatory and stromal cells(209), 
this also reinforces the importance of the tumor microenvironment for 
metastasis(263, 264).
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It should be emphasized that this study focuses on the role of circulating 
galectin-3 on cancer cell adhesion and metastasis. The functional importance 
of cancer cell-associated galectin-3 in metastasis is well documented (120, 
211). For example, antisense suppression of galectin-3 in metastatic LSLiM6 
human colon cancer cells before inoculation of the cells into athymic mice 
results in reduced liver colonization and metastasis(265), whereas suppression 
of galectin-3 expression by short hairpin RNA in melanoma cells reduces 
tumor cell invasiveness and capacity to form tube-like structures on collagen, 
so-called vasculogenic mimicry(266). Similarly, reduction of galectin-3 
expression in highly malignant human breast cancer MDA-MB-435 cells leads 
to loss of serum- and anchorage-independent growth in vitro and tumor 
growth in nude mice(l 15).
Thus, galectin-3 released into the bloodstream of cancer patients promotes 
cancer cell hematogenous dissemination by its interaction with TF-expressing 
MUC1 on cancer cell surface. This provides insight into the molecular 
regulation of metastasis and has important implications for the development of 
therapeutic strategies to prevent metastasis.
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CHAPTER 5
5. Effects of galectin-3 on cancer cell homotypic aggregation
5.1. Aims
To assess the effect of MUC1 expression and MUC1-galectin-3 interaction at 
pathologically relevant concentrations on tumour cell homotypic aggregation
5.2. Introduction
Formation of tumour cell aggregation/emboli in the circulation prolongs the 
survival of tumour cells and allows their physical trapping in the micro­
vasculature and contributes to cancer cell hematogenous dissemination (5, 
267).
Our discovery that the interaction between cancer-associated MUC1 and 
galectin-3 increases cancer cell adhesion to endothelium as a consequence of 
the MUC1 cell surface polarization and exposure of the cell surface adhesion 
molecules led us to speculate that change of MUC1 cell surface localization 
in response to galectin-3 binding may expose a range of cell surface adhesion 
molecules, some of which may be essential to cancer cell homotypic 
interactions. Thus an increased interaction between circulating galectin-3 and 
cancer-associated MUC1 in the circulation of cancer patients may promote the 
formation of cancer cell aggregates/emboli that would prolong the survival of
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disseminated tumour cells in the circulation and thus contribute to
haematogenous metastatic spread.
We thus investigated the effect of recombinant galectin-3 at pathologically- 
relevant concentrations on cancer cell homotypic aggregation
5.3. Materials and Methods 
Cell aggregation
Subcontinent cells were released from the culture flask with NECDS 2ml/T25 
flask (which releases the cells while keeping the cell membrane proteins 
intact) and were dispersed in serum-free DMEM containing 0.5mg/ml bovine 
serum albumin (BSA), Two 0.5 ml (IxlO6 cells) aliquots of the cell 
suspension were incubated, separately, with 5pl/ml DiO and Dil Cell 
Labelling Solution for 30 min at 37°C. The DIO- and Dil-labelled cells were 
then mixed in the presence or absence of recombinant galectin-3, antibodies or 
lactose in DMEM in a rotating incubator (Julabo lab GMBH, Seelbach, 
Gemerney) at 100 rpm/min at 37°C for 1 hi* followed by analysis with flow 
cytometry (Becton-Dickinson FACS Vantage SE).
Fig 5-1 Cell aggregation assessed by flow cytometry: The top left(green) 
and bottom right(red) are cell population labelled with DiO or Dil cell 
labelling solution separately. The top right in the bivariate correlation plot is 
the cell population containing cell aggregates that contain both DiO- and Dil- 
labelled cells and that are defined in this study as cell aggregates.
Cells labelled only with Dil or DiO were used to identify the position of DiO- 
(upper-left panel) and DiI-(bottom-right panel) labelled cell populations in the 
bivariate correlation plot and cell populations containing both DiO and Dil 
fluorescence (top-right panel) in the correlation plot were defined as cell 
aggregates(Fig5-l).
This method measures cell aggregates containing both DiO- and Dil-labelled 
cells and does not include cell aggregates formed only by DIO- or Dil-labelled 
cells. Although this may underestimate the total cell aggregates, it provides a
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more accurate assessment of the effect of exogenous galectin-3 by reducing 
the variations hence the experimental errors due to the differences of initial 
numbers of cell aggregates in each individual assessment.
Reduction of TF expression by 0-gIycanase treatment
HCA1.7+ cells (105 cells) were incubated with 0.02U/ml 0“glycanase(which 
is specific for unsubstituted TF) for 2 hr at 37°C. The cells were either lysed 
directly with SDS-sample buffer 100pi for blotting with PNA(1 mg/ml, 1:500) 
following extra-evidin(l :1000) for the purpose testing TF expression, or 
labelled with DiO and Dil and incubated with recombinant galectin-3 for 1 hr 
at 37°C before the cell aggregation assessments.
Electrophoresis and lectin/immunoblotting
SDS-PAGE (4% miming gel and 3.5% stack gel for MUC1 blotting and 10% 
miming gel and 4% stack gel for E-Cadherin blotting) electrophoresis and 
immune/lectin blotting were performed as previously described (248).
MUC1 cell surface localization
Cells released with NECDS were labelled, separately, with DiO and Dil as 
described above. Two equal cell populations (5xl05) of the labelled cells were 
mixed in the presence or absence of 1 pg/ml galectin-3, B27.29 antibody or 
BSA for 1 hr at 37°C. The cell suspensions were applied to poly-lysine coated 
slides, fixed with 2% paraformaldehyde for 15 min, blocked with 5% normal 
goat serum for 0.5 In-, probed with B27.29 anti-MUCl antibody (1:2,000 
dilution in 1% goat serum/PBS) and followed by fluorescent-labelled 
secondary antibody (1:400 dilution in 1% goat serum/PBS). The slides were 
blind labelled and the number of cells lacking a continuous rim of MUC1 or
the number of small or large aggregates in 500 adjacent cells in randomly 
selected low power fields was counted using an Olympus B51 fluorescent 
microscope with 20x objective. To show MUC1 on the cell membrane, cell 
aggregates labelled with Dio(green colour) and Dil(red colour) were selected, 
and the localization of MUC1 (blue colour)on the cell membrane was 
recorded using 25X high power field.
E-Cadherin cell surface distribution
Cells released with NECDS were labelled, separately, with DiO and Dil as 
described above. Two equal cell populations (5x105) of the labelled cells were 
mixed in the presence or absence of 1 pg/ml galectin-3 or BSA for 1 In at 
37°C. The cell suspensions were applied to poly-lysine coated slides, fixed 
with 2% paraformaldehyde for 15 min, blocked with 5% normal goat serum 
for 0.5 In-, probed with anti-E-Cadherin antibody (1:400 dilution in 1% goat 
serum/PBS) and followed by fluorescent-labelled secondary antibody (1:400 
dilution in 1% goat serum/PBS). The slides were examined using an Olympus 
B51 fluorescent microscope with 20x objective. The cell aggregate labelled 
with Dio(green colour) and Dil(red colour) was selected, the localization of 
E-Cadherin(blue colour)on the cell membrane was photographed using a high 
power 25X objective.
E-Cadherin cell surface expression
Cells released with NECDS were fixed in 2% paraformaldehyde for 15 min, 
blocked with 5% normal goat serum for 0.5 hr, incubated with anti-E- 
Cadherin antibody (1:1000 dilution with 1% goat serum in PBS) or isotype 
control immunoglobulin and followed with fluorescent-conjugated secondary
antibodies (1:400 dilution in 1% goat serum/PBS). The cell surface expression 
of E-Cadherin was analysed by flow cytometry.
siRNA E-Cadherin transfection
HT29-5F7 cells were treated with commercially available siRNA constructs 
(lOOnM) against E-Cadherin or scrambled control non-targeting siRNA 
(siCONTROL non-targeting siRNA, Dhamacon) for 48 hr at 37°C. The cells 
were either lysed and the expressions of E-Cadherin was analysed by 
immunoblotting or the cells were labelled with DiO and Dil followed by the 
assessment of cell aggregation in the presence or absence of 1 pg/ml galectin- 
3 as described above.
Cell viability in single and aggregated cells under anchorage-independent 
condition
96 or 24 well plates were coated twice with 200 pl/well (96-well plates) or 5 
ml/well (6-well plates) of lOmg/ml poly-2-hydroxyethyl methacrylate (poly- 
HEMA, Sigma) in 95% ethanol over night at room temperature. After 
washing, the cells were treated with Ipg/ml recombinant galectin-3 or BSA 
under suspension culture in serum-free medium for various times at 37°C. 
The cells in suspension were collected and passed three times through a 40- 
pm cell strainer (BD Biosciences). The viability of the cells that did and did 
not pass through the strainers was measured by the CellTiter-Glo“ 
Luminescent Cell Viability Assay (Promega).
Cell anoikis in single and aggregated cells under anchorage-independent 
condition
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For the measurement of cellular anoikis, after separation of the cells by cell 
strainers as above, the cells were resuspended in FITC-Annexin-V 1 * binding 
buffer and the apoptotic cells were measured FITC-Amrexin-V apoptosis 
detection kit (Cambridge Biosciences, Cambridge, UK) by flow cytometry as 
the manufacture's instructions.
Statistical analysis
The statistical analyses were performed using the unpaired / test for single 
comparison, one-way analysis of variance (ANOVA) followed by Newman 
and Keuls test for multiple comparisons or Chi-Square test (StatsDirect for 
Windows, StatsDirect Ltd; Sale, UK) where appropriate. Differences were 
considered significant when p<0.05.
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5.4. Results
5.4.1 Effect of MUC1 expression and MUCl-galectin-3 interaction on 
cancer cell hoinotypic aggregation
To test the effect of MUC1 expression on cancer cell homotypic aggregation, 
we first compared the adhesive properties of human colon cancer HT29 and 
HT29-5F7 cells.
It was found that spontaneous aggregation of HT29 human colon cancer cells 
was 2.8-fold greater than that of HT29-5F7 cells (Fig 5-2and Fig5-3),
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Fig 5-2 MUC1 expression prevents and MUCl-gaIectin-3 interaction
promotes homotypic aggregation of human colon cancer cells:
Representative flow cytometry plots from the aggregation assessment of
human colon cancer HT29-5F7 and HT29 MUC1 cells in the presence or
absence of Ipg/ml recombinant galectin-3. The top right in the bivariate
correlation plot are the cell population containing both DiO- and Dil-labelled
cells that are defined in this study as cell aggregates.
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Fig5-3. MUC1 expression prevents homotypic aggregation of human 
colon cancer cells. The more strongly MUC1-expressing HT29-5F7 cells 
show less spontaneous cell aggregation than the parental HT29 cells. Data are 
expressed as mean ± SEM of triplicate determinations from three independent 
experiments, (one-way ANOVA compare means)
Pre-treatment of HT29-5F7 cells with recombinant galectin-3 at various 
pathologically-relevant circulating galectin-3 concentrations in the sera of 
colorectal cancer patients (209) resulted in a dose-dependent increase of 
HT29-5F7 but not HT29 cell aggregation (Fog 5-4).
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Fig5-4.MUCl-gaIectin-3 interaction promotes homotypic aggregation of 
human colon cancer cells. Recombinant galectin-3 treatment induces a 
dose-dependent increase of HT29-5F7 but not HT29 cell aggregation. Data 
are expressed as mean ± SEM of triplicate determinations from four 
independent experiments. **p<0.01, ***p<0.001. (one-way ANOVA 
followed by Newman-Keuls' test for multiple comparisons)
At l.Opg/ml, galectin-3 caused 69% increased aggregation [169.2±24.7 (mean 
± SEM). pO.Ol] of HT29-5F7 but not HT29 cells (9l.4±5.9. p=0.2) (Fig 5-2 
and Fig5-5)
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Fig5-5. MUC1 expression prevents and MUCl-galectin-3 interaction 
promotes homotypic aggregation of human colon cancer cells.
Recombinant gaIectin-3 at l.Opg/ml induces increase of HT29-5F7 but not 
HT29 cell aggregation. Data are expressed as mean ± SEM of triplicate 
determinations from three independent experiments. **p<0.01, ***p<0.001. 
(one-way ANOVA compare means (bonferroni))
In the flow cytometry plots, the cell population shown at the upper-right 
quadrant (blue)representative the aggregation cells. The aggregation 
population ot HCA1.7+(Fig 5-6 upper right picture) was significantly less
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comparing to HCA1.7- (Fig 5-6 upper left picture ) without treatment after 1 
hr incubation at 37°C.
Dil fluorescence Intensity ---->
Fig5-6. MUC1 expression prevents and MUCl-galectin-3 interaction 
promotes homotypic aggregation of MUC1 positively but not negatively 
transfected human breast epithelial cells. Representative flow cytometry 
plots from the aggregation assessment of MUC1 positive- transfectants 
(HCA1.7+) and negative-revertants (HCA1.7-) of HBL-100 human breast 
epithelial cells in the presence or absence or Ijig/ml recombinant galectin-3.
Spontaneous aggregation of FIBL-100 human breast epithelial cells with 
MUC1-positive transfection (HCA1.7+) (5.1 ± 0.4%) was significantly less 
comparing to MUC-1-negative transfection (HCA1.7-) (8.0 ± 0.3. pO.OOl) 
(Fig 5-6 and Fig5-7).
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Fig 5-7. MUC1 expression prevents homot^pic aggregation of MUC1 
positively but not negatively transfected human breast epithelial cells.
HCA1.7+ cells show less spontaneous cell-cell aggregation than HCA 1.7- 
cells. Data are expressed as mean ± SEM of triplicate determinations from 
four independent experiments. Data are expressed as mean ± SEM of 
triplicate determinations from two independent experiments. *p<0.05, 
**p<0.01, ***p<0.001. (one-way ANOVA compare means (bonferroni))
Pre-treatment of the cells with galectin-3, l.Opg/mL caused 36% increased 
aggregation of HCA1.7+ (136.6±7.0. p<0.01) but not HCA 1.7- cells (94.2±4.2, 
p=0.2) (Fig 5-8).
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Fig5-8. MUCl-galectin-3 interaction promotes homotypic aggregation of 
MUC1 positively but not negatively transfected human breast epithelial 
cells. Galectin-3 (l|ig/ml) increases HCA1.7+ but not HCA1.7- cell 
aggregation. Data are expressed as mean ± SEM of triplicate determinations 
from four independent experiments. Data are expressed as mean ± SEM of 
triplicate determinations from two independent experiments. *p<0.05, 
**p<0.01, ***p<0.001. (one-way ANOVA compare means (bonferroni))
The effect of galectin-3 on HCA1.7+ cell aggregation was dose-dependent 
(Fig 5-9) and was prevented by the presence of 10 pM lactose (Fig 5-10).
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Fig5-9. MUCl-galectin-3 interaction promotes homotypic aggregation of 
MUC1 positively transfected human breast epithelial cells. Galectin-3 
induces dose-dependent aggregation of HCA1.7+ cells. Data are expressed as 
mean ± SEM of triplicate determinations from two independent experiments. 
*p<0.05, **p<0.01, ***p<0.001. (one-way ANOVA followed by Newman- 
Keuls' test for multiple comparisons)
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Fig5-10. The effect of MUCl-galectin-3 interaction promotes homotypic 
aggregation of MUC1 positively transfected human breast epithelial cells 
blocked by lactose. The presence of lactose (lOpM) blocks the increase of 
HCA1.7+ cell aggregation induced by Ipg/ml galectin-3. Data are expressed 
as mean ± SEM of triplicate determinations from two independent 
experiments. *p<0.05) **p<0.01, ***p<0.001. (Two-way ANOVA followed 
by Newman-Keuls' test for multiple comparisons)
5.4.2 Effect of TF expression in galectin-3-mediated cell aggregation
Pre-treatment ot MCAl.7+ cells with streptococcal O-glycanase, that 
specifically removes the unsubstituted TF disaccharide, caused a 58%
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reduction of TF expression on MUC1 as assessed by the TF-binding PNA 
blotting (Fig5-11) and attenuated the effect of galectin-3 on cell aggregation 
(Fig5-12).
MUC1 (B27.29)
TF/MUC1 (PNA)
O-Glycanase
Fig5-ll. Effects of O-glycanase treatment on TFexpression. PNA blot 
show reduction of TF on MUC1 by O-Glycanase treatment of HCA1.7+ cells. 
Data are selected from two independent experiments.
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Fig5-12. Effects of TF expression on galectin-3-mediated cell aggregation.
Reduction of TF-expression by O-glycanase treatment abolishes the effect of 
galectin-3 (Ijig/ml) on HCA1.7+ cell aggregation. Data are expressed as 
mean ± SEM of triplicate determinations from two independent experiments. 
* p<0.05. (one-way ANOVA followed by Newman-Keuls' test for multiple 
comparisons)
5.4.3 Effects on B27.29 anti-MUCl mab on MUC1 cell surface 
polarization and on cell-cell aggregation
Our previous study demonstrated that B27.29 anti-MUCl mAh. directed 
against the PDTRPAP epitope (250) within the VNTR region of MUC1.
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induces MUC1 cell surface polarization and increases human melanoma cell 
adhesion to endothelium(268). The B27.29 anti-MUCl mAh is blown to have 
an enhanced binding affinity to MUC1 when short sugar chains within the 
VNTR region are present(251). It was found here that introduction of B27.29 
mAb also caused a dose-dependent increase of HCA1.7+ cell aggregation 
(Fig5-13),
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Fig5-13. Galectin-3 and B27.29 anti-MUCl mAb both induce increase of 
cell aggregation. B27.29 mAb induces dose-dependent increase of HCA1.7+ 
cell aggregation. HCA1.7+ cell aggregation was measured after pre­
incubation of the cells with or without various concentrations of B27.29, or 
Ipg/ml control mouse immunoglublin or CT-2 anti-MUCl antibody. Data are 
expressed as mean ± SEM of triplicate detenninations from three independent 
experiments. *p<0.05,**p<0.01, ***p<0.001. (one-way ANOVA followed by 
Newman-Keuls' test for multiple comparisons)
regardless of the presence or absence of recombinant galectin-3 (Fig5-l4).
300 *** ***
S 150
Control Gal3 Gal3+ B2729 Control 
(BSA) B27.29 IgG
Fig5-14. Galectin-3 and B27.29 anti-MUCl mAb both induce increase of 
cell aggregation. B27.29 mAb increases HCA1.7+ cell aggregation 
regardless of the presence or absence of recombinant galectin-3. HCA1.7+ 
cell aggregation was measured after pre-incubation of the cells with or 
without 1 jig/ml recombinant galectin-3 in the presence or absence of 1 pg/ml 
B27.29, BSA or control immunoglublin. Data are expressed mean ± SE of 
triplicate determinations from three independent experiments. 
*p<0.05.**p<0.01, ***p<0.001. (Two-way ANOVA followed by Newman- 
Keuls' test for multiple comparisons)
When the cell aggregates were further analysed, it was found that B27.29 
mAh not only induced more cell aggregates but also larger aggregates than 
recombinant galectin-3 (Table5-1). Because cells may aggregate before 
treated, in order to make sure the cell aggregates really happen after cells
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treated. We defined the aggregates as small or larger one according to the 
number of cells trom different cell groups labelled with different florescence 
colour rather than total numbers of the whole aggregates. The larger clusters 
mean no less than two red as well as two green florescence labelling cells. The 
small clusters contain either one red with one or more green cells or one green 
cell with one or more red cells. There were 8.8%(including 4.6% of large and 
4.2% small ) spontaneous HCA1.7+ cell clusters in the 500 consecutive events 
counted on the slides, when cultured in suspension for 1 hour at 37°C , whilst 
16.2 % (include 8.6% of large and 7.6% small. P=0.0004. Chi-square test) or 
29.4% (include 18.4% of large and 11% small PO.OOOl) more HCA1.7+ 
cells clusters, respectively, than control BSA-treated cells clusters after 
incubation with Ipg/ml recombinant galectin-3 or B27.29 mAb for 1 hr at 
37°C.
Table 5-1. Characteristics ot the HCA1.7+ cell aggregates in response to 
galectin-3 and B27.29 anti-MUCl antibody
Groups* Control r-Gal3 B27 29
% of total events (events) % (n) % (n) % (n)
Total 8 8(44) 16.2(81) 29.4(147)
Large clusters (no less than 
two green as well as two 
red cells)
4.6(23) 8.6 (43) 18.4(92)
Small clusters (one green with 
one or more red, or one red 
with one or more green cells)
4.2(21) 7.6 (38) 11.0(55)
*500 events per group were counted
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MUC1 is distributed around the whole cell surface in single HCA1.7+ cells 
without treatment with galectin-3 or b27.29 mab (Picture 5-1 left, blue) After 
treatment with galectin-3 or b27.29 anti-MUCl antibody, many cells showed 
loss ot continuous MUC1 cell surface localization .We used MUC1 
discontinuity as the criterion for quantifying MUC1 clustering (Picture 5-1 
right) in our experiment.
HCA1.7+ Without treatment Treated with B27.29
Picture 5-1. MUC1 homogenous distribution on cell surface in single 
HCA1.7+ cells(Left) showing discontinuity (Right) after addition of 
MUC1 anti-body(B27.29) implying cell surface clustering.
Fourteen percent (71/500) HCA1.7+ cells showed spontaneous clustering of 
MUC1 on the cell surface, when cultured in suspension for 1 hour at 37°C 
whilst 57% (112/500. P<0.01, Chi-square test) or 93% (133/500. PO.01) 
more HCA1.7+ cells, respectively, than control BSA-treated cells 
demonstrated MUC1 cell surface clustering after incubation with Ipg/ml 
recombinant galectin-3 or B27.29 mAb for 1 hr at 37°C. Introduction of 
galectin-3 or mAb B27.29 to the cells at 4°C or to paraformaldehyde pre-fixed 
cells had no effect on MUC1 localization(Table 5-2) and no significant effect 
on cell aggregation(Fig 5-15) compared with the control BSA-treated cells.
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which suggest liquidity of the cell membrane is important in HCA1.7+ cells 
MUC1 clustering induced by galectin-3 and B27.29.
Table 5-2. Galectin-3 and B27.29 anti-MUCl antibody induce 
discontinuous MUC1 cell surface polarization of HCA1.7+
37°C 4°C Pre-fixed
%(n) %(n) %(n)
Control (BSA) 14(71) 7(37) 3(16)
Galectin-3 (Igg/ml) 22(112)** 8(38) 3(14)
B27.29 (Ijig/ml) 27(133)** 10(49) 3(15)
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Fig 5-15. GaIectin-3 and B27.29 anti-MUCl mAb both induce increase 
of cell aggregation. Galectin-3 or B27.29 mAb at 1 ng/ml fails to induce 
HCA1.7+ cell aggregation at 4°C or to paraformaldehyde-prefixed cells. 
Data are expressed as mean ± SE of triplicate determinations from four 
independent experiments. *p<0.05?**p<0.01, ***p<0.001. (one-way
ANOVA followed by Newman-Keuls' test for multiple comparisons)
These results indicate a direct link between discontinuous cell surface 
localization ot MUC1 and the increased cell aggregation in response to 
galectin-3 and B27.29 mAb. In keeping with this. MUC1 was observed to be 
absent at the cell-cell contact point within the cell aggregates in the cells 
treated either with galectin-3 or mAb B27.29 (Picture 5-2). The left picture 
show cell aggregates composed of cells labelled with Dio(green) or Dil(Red) 
florescence, the middle picture show the MUC1 distribution (blue florescence)
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absent between the cell-cell contact point, the right picture show combination 
results of the left and the middle picture.
control
+ Gal-3
+B27.29
Dil/DiO MUC1 Dil/DiO/MUCI
Picture 5-2. Absence of MUC1 at the cell-cell contact point within the cell 
aggregates of HCA1.7+ . HCA1.7+ cells pre-labelled with Dio (green) and 
Dil (red) were incubated with or without Ipg/ml recombinant galectin-3 or 
B27.29 antibody at 370C before the cells were fixed and the MUC1 
localization(blue) was determined by immunohistochemistry. Representative 
images of the MUC1 localization in single and cell aggregates are shown. Bar 
=10 pm.
Thus, polarization of cell surface MUC1 in response to galectin-3 binding 
exposes the smaller cell surface adhesion molecules that increases homotypic 
cell aggregation.
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5.4.4 Investigation of the cell surface adhesion molecules in galectin-3- 
mediated cell aggregation.
E-Cadherin is a member of the Cadherin family that are largely responsible 
for epithelial cell-cell interaction in the maintenance of epithelial 
phenotype(269) and has previously been shown to be an important adhesion 
molecule in epithelial cell-cell interactions (174, 180). It was found here that 
the presence of the MAB1838 anti-E-Cadherin mAb at 2.5 to 20 jLig/ml caused 
a dose-dependent reduction of the spontaneous aggregation of HT29 but not 
HT29-5F7 cells (Fig 5-16).
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HT29
Anti-E-Cadherin (|jg/ml)
Fig 5-16. Involvement of cell surface E-cadherin in gaIectin-3-induced 
cell aggregation. The presence of anti-E-Cadherin antibody (at 
concentrations between 2.5 and 20pg/ml) reduces spontaneous cell 
aggregation of HT29 but has little effect on that of HT29-5F7 cells. Data are 
expressed as mean ± SE of triplicate determinations from three independent 
experiments, (one-way ANOVA followed by NewTnan-Keuls' test for 
multiple comparisons)
However, the presence of this antibody at 20pg/ml inhibited HT29-5F7 cell 
aggregation induced by galectin-3 (Fig 5-17). This suggests the involvement 
of the cell surface E-Cadherin in spontaneous aggregation of HT29 and in 
galectin-3-mediated HT29-5F7 cell aggregation.
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Fig 5-17. Involvement of cell surface E-cadherin in galectin-3-induced cell 
aggregation. Anti-E-Cadherin antibody at 20fag/ml prevents HT29-5F7 cell 
aggregation-induced by (1 pg/ml) galectin-3. Data are expressed as mean ± 
SE of triplicate determinations from three independent experiments. (Two- 
way ANOVA followed by Newman-Keuls' test for multiple comparisons)
This is supported by the discovery that suppression of E-Cadherin expression 
by siRNA resulted significant reduction of spontaneous HT29-5F7 cell 
aggregation and also prevented the increase of cell aggregation in response to 
galectin-3 (Fig5-18, Fig5-19). We found that treatment of HT29-5F7 cells for 
2 or 3 days with E-Cadherin siRNA, but not with the control non-targeting 
siRNA. caused 74% or 82% reduction of E-Cadherin expression comparing 
with normal control separately(Fig 5-18).
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Fig 5-18. SiRNA E-Cadherin knock-down. HT29-5F7 cells were treated 
with E-Cadherin siRNA or control non-targeting siRNA for two or three days 
before the cellular E-Cadherin expression was determined by E-Cadherin 
immunoblotting.
Galectin-3 at 1 pg/ml does not induce HT29-5F7 cell aggregation after E- 
Cadherin siRNA knock-down after 72 hours though Galectin-3 increase 28±6% 
(p=0.0016) HT295F7 cell aggregation of Con-siRNA groups (Fig 5-19).
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Fig 5-19. Involvement of cell surface E-cadherin in galectin-3-induced cell 
aggregation. SiRNA suppression of E-Cadherin prevents galectin-3-mediated 
HT29-5F7 cell aggregation. Data are expressed as mean ±SEM of triplicate 
determinations from three independent experiments, (one-way ANOVA 
followed by Newman-Keuls' test for multiple comparisons)
We found that E-Cadherin shows strong localization at the cell-cell contacts in 
the cell aggregates (Picture5-3). The left two pictures show the single or 
aggregate cells labelled with Dio(Green) /Dil (Red). The right two pictures 
show that E-Cadherin(blue) distribute around the single cells(upper-right 
picture) and accumulate between the cell-cell contact points of the cell 
aggregates!Lower-right picture).
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Picture 5-3. Involvement of cell surface E-cadherin in galectin-3-induced 
cell aggregation. E-Cadherin localization in single and cell aggregates. 
HT29-5F cells pre-treated with or without 1 pg/ml galectin-3 were analysed 
for E-Cadherin expression by anti-E-Cadherin immunohistochemistry. E- 
Cadherin shows strong localization at the cell-cell contacts in the cell 
aggregates (arrowed). Bar = 10pm.
These findings together imply a critical role of the cell surface E-Cadherin in 
galectin-3-mediated cell-cell aggregation.
Using anti-E-Cadherin antibody(lpg/ml) 1:400 against E-Cadherin on cell 
surface ot the fixed HT29 and HT295F7 cells followed by a secondary 
antibody FITC anti-mouse IgG 1:400 incubation. E-Cadherin expression on 
the cell surface was tested by FACS. We found that HT29 and HT29-5F7 
cells have similar levels of cell surface E-Cadherin and similar anti-E- 
Cadherin antibody accessibility (Fig 5-20).
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Fig 5-20. Expression of cell surface E-cadherin on HT29 and HT295F7 
cells. HT29 and HT29-5F7 cells show similar E-Cadherin cell surface 
expressions assessed by flow cytometry. Open histogram: E-Cadherin; shaded 
histogram: immunoglobulin isotype control.
Thus, the inability of the anti-E-Cadherin antibody to prevent HT29-5F7 cell 
aggregation is most likely due to a functional “concealment" of the cell 
surtace E-Cadherin in HT29-5F7 cells, e.g by the presence of adjacent MUC1. 
The blockade by the anti-E-Cadherin antibody of galectin-3-mediated HT29- 
5F7 cell aggregation (Fig 5-17) is in support of this. The fact that the blockade 
of anti-E-Cadherin antibody on galectin-3-mediated aggregation is only partial 
implies the likely involvement of other cell surface adhesion molecules, 
which, like E-Cadherin, may be exposed following MUC1 polarization in 
response to galectin-3 binding.
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5.4.5 Effect of Galectin-3-induced cell aggregation on Anoikis.
As cell aggregation has previously been shown to enhance the ability of cells 
to avoid Anoikis initiation, we assessed the effect of galectin-3-induced cell 
aggregation on Anoikis. After 3 days culture under suspension conditions, 
nearly 4-fold more cells in the cell aggregates obtained from the galectin-3- 
treated cells were viable than those obtained from the BSA-treated controls 
(Fig 5-21).
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Fig 5-21. Galectin-3-induced cell aggregation enhances survival of cells 
from escaping Anoikis. Galectin-3-induced cell aggregation increases 
survival of HT29-5F7 cells under anchorage-independent conditions. HT29- 
5F7 cells treated with or without 1 pg/ml galectin-3 or BSA by culture of the 
cells in suspension for 3 days at 37°C. After separation of the cells using a cell 
‘strainers’, the viability of cells was assessed as described in the Methods 
section. The data are presented as mean ± SEM of triplicate determinations 
from two independent experiments.
This indicates that the increase of cell aggregation in response to galectin-3 
greatly enhances the survival of the cells under anchorage-independent 
conditions. A modest 36% increase of the cell viability was also observed in 
the cell population that passed through the 40pm cell strainers (referred to as
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“single” cells in Fig5-21) from the galectin-3-treated cells compared with the 
BSA-treated controls. As HT29-5F7 cells are 15~ 20 p m in diameter, this 
small increase is highly likely due to the inclusion of small cell aggregates, 
e.g. those formed by 2 to 3 cells, in this cell population. Many small cell 
aggregates were indeed observed in this population by microscopy (Picture 5- 
4).
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Picture5-4. Images of the strained cell population after straining.
Assessments of Anoikis showed no significant difference between the two 
strained cell populations obtained from galectin-3-treated and BSA-treated 
controls within 48 hr culture of the cells under suspension conditions (Fig5- 
22.5-24).
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Fig5-22. Galectin-3-induced cell aggregation enhances survival of cells 
from escaping Anoikis. No significant difference between the two strained 
cell populations obtained from galectin-3-treated and BSA-treated controls 
within 48 hr culture of the cells under suspension conditions, (one-way 
ANOVA followed by Newman-Keuls' test for multiple comparisons)
However, significantly fewer cells in the population of cell aggregates 
obtained from the galectin-3-treated cells were undergoing Anoikis than from 
the BSA treated controls (Fig 5-23.Fig5-24).
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Fig 5-23. Galectin-3-induced cell aggregation enhances survival of cells by 
escaping Anoikis. Galectin-3-induced cell aggregation is associated with 
increased resistance of the cells to Anoikis. The data are presented as mean ± 
SEM of triplicate determinations from two independent experiments, (one­
way ANOVA followed by Newman-Keuls' test for multiple comparisons)
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Fig 5-24. Galectin-3-induced cell aggregation enhances survival of cells 
from escaping Anoikis. Representative flow cytometry plots from the anoikis 
assessments of HT29-5F7 cells cultured in suspension in the presence of 1 
pg/ml galectin-3 or BSA for 2 days at 370C. Annexin-V positive and PI 
negative (early apoptotic, at the bottom right in the bivariate correlation plot) 
and Annexin-V positive and PI positive (late apoptotic, at the top right in the 
correlation plot) cells are considered as apoptotic cells.
A 20% (70.0±0.4% vs 56.1±1.8%. p=0.02). 65% (82.8±1.4% vs 28.7±8.0%. 
p=0.0001) and 29% 63.4±5.9% vs 44.9±6.2%, p=0.02) reduction of Anoikis 
were seen in the cell aggregates obtained from the galectin-3 treated than from 
the BSA-treated control cells after 12, 24 and 48 hr, respectively (Fig 5-23).
This indicates that the galectin-3-induced cell aggregates is associated with 
resistance of the cells to Anoikis initiation.
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5.5. Discussion
This study shows that the presence of galectin-3 at concentrations that can be 
found in the circulation of patients with metastasis increases cancer cell 
homotypic aggregation by interaction with cancer-associated MUC1 
expressing the TF disaccharide. The interaction between galectin-3 and 
MUC1 causes MUC1 cell surface clustering and exposes smaller cell surface 
adhesion molecules including E-Cadherin. The galectin-3-MUC1-induced cell 
aggregation enhances the survival of the cells under anchorage-independent 
conditions by preventing initiation of anoikis. This has important implications 
for our understanding of the molecular mechanisms that underlie cancer 
metastasis.
Survival of tumour cells in the blood/lymphatic circulation is crucial in cancer 
cell metastatic spread (5, 267). After invasion of the tumour cells into the 
blood circulation from the primary tumour sites, only a very small fraction 
(less than 1 in 10,000 cells) of the invaded cells survive to produce metastasis 
at distant sites (14, 54). Prolonging the survival of tumour cells in the 
circulation has been shown previously to directly to increase metastasis (56). 
Earlier studies have also demonstrated that cells in aggregated form have a 
much higher survival rate in the circulation than single cells(13, 14). 
Intraportal injection of aggregated DHD/K12/TRb colon cancer cells into 
syngeneic BD IX rats produced over 4-times more liver metastases than 
injection with the same numbers of single cells (12). Thus, an increase of
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tumour cell aggregation as a result of the increased interaction between 
circulating galectin-3 and cancer-associated MUC1 in the bloodstream of 
cancer patients provides a survival advantage to the circulating tumour cells 
and enhances their metastatic potential.
Although earlier studies have revealed the association of cell aggregation in 
survival of the cells under anchorage-independent conditions, the molecular 
mechanism that underlies such survival advantage is not fully understood. 
There is evidence that this may be at least partly due to the enhanced ability of 
aggregated cells to escape anoikis (86). Anoikis is a specific type of apoptotic 
process induced by loss of cell adhesion or inadequate cell-matrix 
interactions^0) and has been proposed to be the dominant mechanism in 
removing disseminating tumour cells from the circulation^ 1). Resistance to 
anoikis is considered to be a hallmark of metastatic cancer cells(52). Our 
discovery that galectin-3-MUC1-induced cell aggregation is associated with 
enhanced ability of the cells to escape initiation of anoikis supports a role of 
anoikis resistance in the survival advantage of cell aggregation under 
anchorage-independent conditions.
The increased formation of cancer cell aggregates by galectin-3- 
MUC1 interaction may also influence physical trapping of the circulating 
tumour cells in the micro-vasculature. Mechanical as well as ‘"seed-soil" 
compatibility factors are both known to contribute to the ability of specific 
types of cancer cells to spread to various target organs (5, 52, 247). It is 
thought that the initial docking of specific cancer cells to the target organ is 
predominantly controlled by mechanical factors and that this is then followed 
by regulation of specific cell adhesion molecules on the cell surface(247).
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Thus, an increase of tumour cell homotypic aggregation as a result of the 
increased interaction between circulating galectin-3 and cancer-associated 
MUC1 in the bloodstream of cancer patients is likely to enhance physical 
trapping of the circulating tumour cells in the microvasculature at target organ 
and this also enhances metastasis.
It has been shown previously that cell surface-associated galectin-3 acts as a 
cell adhesion molecule and increases cancer cell homotypic aggregation by 
interaction with TF antigen expressed by unknown cell surface molecules on 
adjacent cancer cells under anchorage independent conditions(44, 116). As 
cell surface-associated galectin-3 is relatively small in size, it is likely that 
such interaction may occur only after MUC1 cell surface polarization and 
exposure of the cell surface-associated galectin-3.
Thus, the interaction between circulating galectin-3 and TF-expressing MUC1 
on the surface of disseminating cancer cells promotes cell-cell aggregation 
and embolus formation and enhances survival of disseminating tumour cells in 
the circulation. These findings, together with our previous demonstration that 
the interaction between circulating galectin-3 and cancer-associated MUC1 
enhances cancer-endothelial adhesion(248), indicates that the increased 
circulation of galectin-3 often found in cancer patients can promote several 
important steps of the metastatic cascade. Targeting the action of circulating 
galectin-3 may represent an effective therapeutic approach for preventing 
metastasis.
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CHAPTER 6
6. Effects of TF-binding peanut agglutinin in edible peanuts on 
factors associated with metastasis
6.1. Hypothesis
The discovery that galectin-3—TF/MUC1 interaction promotes metastasis led 
us to hypothesize that the presence of other TF binding proteins, such as the 
peanut agglutinin (PNA) from peanuts, in the bloodstream of cancer patients 
may also act similarly to galectin-3 and promote metastasis.
6.2. Aims:
• To assess the effect of PNA on cancer cell adhesion to and migration 
through the monolayer of endothelial cells.
• To assess the effect of PNA on cancer cell homotypic aggregation, 
survival and anoikis under anchorage-independent conditions.
6.3. Introduction:
A few lectins in foodstuffs recognize the TF antigen. These include the edible 
mushroom lectin ABL {Agaricus bisporus lectin)/ABA (A. bisporus 
agglutinin) (270), jackfruit lectin jacalin (271) and peanut agglutinin (109).
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Peanut agglutinin (PNA) is a protein component of the common peanut 
Arachis hypogaea and binds highly specifically to the oncofetal Thomsen- 
Friedenreich (GaplAGalNAc, T or TF) antigen. PNA has a molecular weight 
of 110,000 dalton with 4 subunits and does not contain covalently bound 
sugar (272). Peanut lectin increases proliferation in colon cancer cell lines and 
cultured human colonic mucosal biopsies in vitro (108, 109, 112), causing a 
40% increase in rectal mucosal proliferation in individuals who ate peanuts 
and had TF over-expression in their colonic epithelia in vivo (273). Earlier 
studies in our group have shown that PNA, which is a tightly globular protein, 
resists enzymatic attack and is highly resistant to cooking and digestion and 
rapidly appears in an active form (up to 5 pg/ml) in the systemic blood 
circulation after peanut ingestion (274). As interaction between the cancer- 
associated TF antigen and endogenous galactoside-binding galectin-3, whose 
concentration is increased in the bloodstream of cancer patients, has been 
shown to increase cancer cell adhesion and metastasis (268), we have 
hypothesised that the appearance of PNA in the blood circulation of cancer 
patients who eat peanuts may, like endogenous galectin-3, influence the 
metastatic behaviour (cancer cell homotypic aggregation and heterotypic 
aggregation) of disseminating tumour cells.
6.4. Materials and methods
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Materials: Biotin-conjugated peanut agglutinin (PNA) was purchased from 
Vector Laboratories Ltd (Peterborough, UK). O-glycanase was obtained from 
Prozyme Inc (Oxford, UK).
Cell lines: Human colon cancer HT29-5F7 cells were obtained and cultured 
as described in Chapter 3 (Yu, Andrews et al., 2007). Macrovascular 
HUVECs and human micro vascular lung endothelial cells (HMVEC-L) were 
from Cambrex BioSciences and were cultured in EGM endothelial growth 
medium (EGM Bulletkit) and EGM-2 medium (EGM-2 Bulletkit, Cambrex 
BioSciences), respectively. Cells that had been passaged less than five times 
were used in the experiments. Human colon cancer SW620 cells were cultured 
in complete DMEM medium containing 10% PCS. MUC1 positive 
transfectants HCA1.7+ human breast epithelial cells and MUC1 negative 
revertants HCA1.7- were as described previously in Chapter 3 (174).
Cell aggregation
Subconfluent cells were released from the culture plates with NECDS and 
were dispersed in serum-free DMEM containing 0.5mg/ml bovine serum 
albumin (BSA). Two 0.5 ml (IX 106 cells) aliquots of the cell suspension 
were incubated, separately, with 5j.il/mJ DIO and Dil Cell Labelling Solution 
for 30 mins at 37°C. The DIO- and Dil-labelled cells were then mixed in the 
presence or absence of PNA in DMEM and incubated at 37°C for 1 In- 
followed by analysis with flow cytometry.
Cancer cell adhesion to endothelial monolayer
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Subcontinent cancer cells were released from the culture plates with NECDS 
and were dispersed in serum-free DMEM containing 0.5mg/ml bovine serum 
albumin (BSA). 0.5 ml (IX 106 cells) aliquots of the cell suspension were 
incubated with Calcein AM lOpl/ml for 30 min at 37°C. The Calcein AM- 
labelled cells were then mixed in the presence or absence of 2.5pg/ml PNA, 
PNA inhibitor (Asialomucin pre-incubated with PNA for 20 minutes before 
being added to cells at 37°C), in DMEM. The cell suspension was then added 
to a monolayer of HMVEC-L (pre-seeded in a 96-well white cell culture plate 
and cultured for 3 days in EBM2 endothelial growth medium at 37°C) for 1 hr 
at 37°C. The culture medium was then removed and the cells were washed 
twice with 200plAvell PBS each time to remove the non-adhesion cells. After 
addition of lOOpl PBS/well, the cell adhesion was determined by fluorescent 
density using a TECAN infinite F200 micro-plate reader.
Cell viability in single and aggregated cells under anchorage-independent 
conditions
96- or 24-well plates were coated twice with 200 pl/well (96-well plates) or 5 
ml/well (6-well plates) of lOmg/ml poly-2-hydroxyethyl methacrylate (poly- 
HEMA, Sigma) in 95% ethanol overnight at room temperature. After 
washing, the cells were treated with 2.5pg/ml PNA or BSA under suspension 
culture in serum-free medium for various times at 37°C. The cells in 
suspension were collected and passed three times through a 40-pm cell 
strainer (BD Biosciences). The viability of the cells that did and did not pass 
through the strainers was measured by the CellTiter-Glo'5' Luminescent Cell 
Viability Assay (Promega).
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Cell anoikis in single and aggregated cells under anchorage-independent 
conditions
For the measurement of cellular anoikis, after separation of the cells by cell 
strainers as above, the cells were re-suspended in FITC-Annexin-V 1 xbinding 
buffer and the apoptotic cells were measured by a FITC-Annexin-V apoptosis 
detection kit (Cambridge Biosciences, Cambridge, UK) by flow cytometry 
according to the manufacturer's instructions.
Reduction of TF expression by O-glycanase treatment
HT295F7 cells (lxl06/ml in O-Glycanase Ixbuffer) were incubated with 
0,02U/ml O-glycanase in O-Glycanase Ixbuffer for 3 hrs at 37°C. The cells 
were then lysed directly with 100pi SDS-sample buffer for 20 mins. The cell 
lysates were then seperated on 4% gel and analysed for TF expression by 
PNA blotting with biotin-PNA (1:1000) and extrAvidin Peroxidase (1:2000).
Impact of enzymatic removal of TF on PNA-mediated cell aggregation
HT295F7 cells were incubated with 0.02U/ml O-glycanase for 2.5 hrs at 37°C 
then labeled with 0.5pg/ml DiO or Dil for 30 minutes at 37°C. After washing 
with PBS and re-suspension in serum-free DMEM, the cells were incubated 
with PNA 2.5pg/ml for 1 hr at 37°C before cell aggregation was assessed by 
flow cytometry, as described in Chapter 3.
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6.5. Results:
6,5.1. PNA increases cancer cell homotypic aggregation.
Pre-treatment of HT29-5F7 cells with PNA at physiological concentrations 
(Wang et ah, 1998) increased HT29-5F7 cell aggregation in a dose-dependent 
way (Fig 6-1).
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Fig6-1. The presence of PNA increases homotypic aggregation of human 
colon cancer HT29-5F7 cells. PNA treatment induces a dose-dependent 
increase ot HT29-5F7 cell aggregation. Data are expressed as mean ± SEM of 
triplicate determinations from three independent experiments. **p<0.01, 
***p<0.001 (one-way ANOVA followed by Newman-Keuls' test for multiple 
comparisons).
At 1 pg/ml and 4 pg/ml PNA caused 21% (p=0.0004) and 41% (pO.OOOl) 
increase of HT29-5F7 cell aggregation, respectively. Fig 6-2 shows 
representative flow cytometry plots from the aggregation assessment of 
human colon cancer HT29-5F7 in the presence or absence of 8pg/ml PNA. At
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8 ng/ml PNA caused 39% HT295F7 cells aggregation (Fig 6-2 right panel) 
after 1.5 hrs incubation at 37°C compared to 24% FIT295F7 cells spontaneous 
aggregation (Fig 6-2 left panel) in the control group.
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Fig 6-2 Representative flow cytometry plots from the aggregation assessment 
of human colon cancer FIT29-5F7 in the presence or absence of 8pg/ml PNA. 
The top right in each bivariate correlation plot represents the cell population 
containing both DiO- and Dil-labelled cells that are defined in this study as 
cell aggregates.
We then assessed the effect of PNA on aggregation of other human colon 
cancer SW620 cells. Cell surface binding of anti-MUCl B27.29 antibody 
followed by flow cytometry showed high expression ofMUCl by SW620 
cells (Fig 6-3).
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FL1-H
Fig 6-3. SW620 cells express high level of cell surface MUC1 assessed by 
flow cytometry. Green histogram: MUC1; Blue shaded histogram: 
immunoglobulin iso type control.
The presence of PNA caused a dose-dependent increase of SW620 cell 
aggregation (Fig 6-4). At 4 ug/ml, PNA induced 11% increase of cell 
aggregation compared with non-treated controls (p=0.0026).
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Fig 6-4. PNA increases homotypic aggregation of SW620 cells. PNA
treatment induces a dose-dependent increase of SW620 cell aggregation. Data 
are expressed as mean ± SEM of triplicate determinations from T independent 
experiments. **p<0.01, ***p<0.001 (one-way ANOVA followed by 
Newman-Keuls' test for multiple comparisons).
To see it the effect of PNA on cell aggregation is linked with its interaction 
with MUC1, the effects of PNA on MUC1 positively (HCA1.7+) and 
negatively transfected (HCA1.7-) human breast epithelial HBL-100 cells were 
assessed. Pre-treatment of the cells with PNA. at 1, 2, 3. 4 pg/ml. caused 
dose-dependent increase of aggregation of HCA1.7+ but not HCA1.7- cells 
compared to a control treated with BSA (Fig 6-5). At 3 ug/ml. PNA induced 
656±117% increase of HCA1.7+ cell aggregation.
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Fig 6-5. PNA induces homotypic aggregation of MUC1 in positively but 
not negatively transfected human breast epithelial cells. PNA increases 
HCA1.7+ but not HCA1.7- cell aggregation. Data are expressed as mean ± 
SEM of triplicate determinations from four independent experiments. Data 
are expressed as mean ± SEM of triplicate determinations from two 
independent experiments. *p<0.05, **p<0.01, ***p<0.001 (one-way
ANOVA followed by Newman-Keuls' test for multiple comparisons).
6.5.2. PNA-mediated cell aggregation increased cell survival under 
anchorage-independent conditions
HT295F7 cells were detached with NECDS and suspended in serum-free 
DMEM (5><107ml). then treated with or without 2.5 pg/ml PNA or BSA by 
culture in suspension in a Poly-HAMA coated plate for 3 days at 37°C. After 
separation ot the cells by cell strainers, the viability of the cells was assessed. 
After 3 days* culture under suspension conditions, nearly 2 times more cells in
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the cell aggregates obtained from the PNA-treated cells were viable than those 
obtained from the BSA-treated controls (Fig 6-6).
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Fig 6-6 PNA-induced cell aggregation enhances survival of cells. PNA- 
induced cell aggregation increases survival of HT29-5F7 cells under 
anchorage-independent conditions. HT29-5F7 cells were treated with or 
without 2.5|ig/ml PNA or BSA by culture in suspension in a Poly-HAMA 
coated plate for 3 days at 37°C. After separation of the cells by cell strainers, 
the viability of the cells was assessed as described in the Methods section. The 
data are presented as mean ± SEM of triplicate determinations from two 
independent experiments (one-way ANOVA to compare means).
These results indicate that the increased aggregation of cells in response to 
PNA greatly enhances their survival under anchorage-independent conditions.
6.5.3. Effect of PNA-mediated aggregation on anoikis:
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To see if the increased survival of the cell aggregates is associated with 
inhibition of cell anoikis, anoilds in the single and aggregated cell populations 
was analysed for caspase 3/7 activation and Annexin-V cell surface binding.
After 2 days' incubation of the cells under suspension conditions, significantly 
fewer cells in the cell aggregates obtained from PNA-treated cells were 
undergoing apoptosis than amongst the BSA-treated controls (36 ± 3% vs 63 ± 
6%, p=0.027), whilst apoptosis of the cells that passed through the cell 
strainers ("single' cells) from PNA-treated and untreated cells showed no 
statistically significant difference (Fig 6-7). For example, cell aggregates from 
2.5 pg/ml PNA-treated cells showed 46% less anoikis (p=0.027) than those 
from BSA-treated controls under 48 hrs suspension culture.
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Fig 6-7. PNA-induced cell aggregates show resistance to anoikis initiation.
HT29-5F7 cells treated with or without 2.5 fig/ml PNA or BSA followed by 
culture of the cells in suspension for 3 days at 37°C. After separation of the 
cells by cell strainers, the apoptosis of cells was assessed by Annexin-V 
binding with FACs as described in the Methods section. The data are 
presented as mean ± SEM of triplicate determinations from two independent 
experiments (one-way ANOVA to compare means).
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Fig 6-8. PNA-induced cell aggregates show resistance to anoikis initiation.
Representative flow cytometry plots from the anoikis assessments of HT29- 
5F7 cells cultured in suspension in the presence of 2.5 pg/ml PNA or BSA for 
2 days at 37°C. Annexin-V positive and PI negative reveal early apoptotic 
cells (bottom right in the bivariate correlation plot) and Annexin-V positive 
and PI positive reveal late apoptotic cells (at the top right in the correlation 
plot).
This indicates that the PNA-induced cell aggregates are associated with 
increased resistance of the cells to anoikis initiation.
6.5.4. Effects of PNA on HT29-5F7 cell adhesion to HMVEC-L
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To determine the effect of PNA on HT295F7 colon cancer cell adhesion to the 
monolayer of HMVEC-Ls, we pre-treated the HT29-5F7 cells with PNA at 
several concentrations as seen in the systemic circulation after eating 200g 
peanuts in human subjects (274). Pre-treatment of the cells with PNA 
significantly increased adhesion ofHT29-5F7 cells to HUVECs in a dose- 
dependent way (Fig 6-9). At 4 pg/mf a 67% increased adhesion (pO.OOOl) 
was seen.
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Fig 6-9 Effects of PNA on HT29-5F7 cell adhesion to HMVEC-L. PNA
induces a dose-dependent increase of HT29-5F7 cell adhesion to the 
monolayer ot HMVEC-L. Data are expressed as the percentage of the adhered 
cells compared to that in the controls (mean ± SEM of triplicate 
determinations from three independent experiments). *p<0.05, **p<0.01,
***p<0.001 (one-way ANOVA followed by Newman-Keuls' test for multiple 
comparisons).
To determine the role of TF expression in PNA-mediated cell-cell interaction 
we treated HT295F7 cells with 0.02 U/ml O-glycanase for three hours at 
37°C. Subsequent analysis of the cell surface TF expression with Biotinylated- 
PNA by flow cytometry showed a 50% reduction of TF on the cell surface 
(Fig 6-10).
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Fig 6-10. Cell surface TF expression in HT295F7 cells in response to 
treatment of the cells with O-Glycanase. HT295F7 cells incubated with 0.02 
U/ml O-Glycanase for 3 hrs at 37°C (red) shows a reduction of TF expressions 
(compared to the untreated cells (green)) by flow cytometry. Blue: 
background control without Biotin-PNA and secondary antibody.
Further investigation is needed to see the effect of TF removal from the cell 
surface on PNA-mediated cell-cell interactions.
6.6. Discussion:
Peanut agglutinin at concentrations similar to that observed in the blood 
circulation of people who ingested 200g peanuts induces homotypic 
aggregation and heterotypic adhesion to vascular endothelial cells in vitro.
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The cell aggregates induced by PNA show increased survival and resistance to 
anoikis initiation under anchorage-independent conditions.
TF antigen expression occurs in about 90% of all types of human cancer cells. 
Cancer-associated MUC1 (97) and the cancer-associated high molecular 
weight splice variant of the adhesion molecule CD44v6 (99) are so far the 
known cell-surface glycoproteins that carry the unsubstituted TF antigen. It 
was found here that pre-treatment of the cells with PNA, at 1, 2, 3, 4 pg/ml, 
caused dose-dependent increases of aggregation of MUC1 positively 
transfected HCA1.7+ but not MUC1 negatively transfected HCA1.7- cells. 
This indicates that the expression of MUC1 is crucial in PNA-mediated cell 
aggregation. Our earlier studies have shown that the MUC1 molecule in 
HCA1.7+ transfectants also carries many copies of unsubstituted TF antigen 
(Yu et ah, 2007). Thus, it is highly likely that the increased cell-cell 
interactions induced by PNA shown in this study are through binding of PNA 
to TF on cell surface MUC1.
Anoikis is a specific type of apoptotic process induced by loss of cell adhesion 
or inadequate cell-matrix interactions (50) and has been proposed to be the 
dominant mechanism in removing disseminating tumour cells from the 
circulation (51). Resistance to anoikis is considered to be a hallmark of 
metastatic cancer cells (52). Previous studies have shown that squamous cell 
carcinoma cells, colonic epithelial cells and malignant pleural mesothelioma 
cells in aggregated forms have a higher ability to resist anoikis initiation (86- 
88). PNA-mediated cell aggregation in the bloodstream of cancer patients 
could increase the formation of tumour emboli, thus tumour cell survival in
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the circulation. This, together with the enhanced ability of the cancer cells to 
adhere to vascular endothelial cells by PNA, supports a detrimental effect of 
the presence of peanuts in the diet of patients on patients' survival.
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Chapter 7
7. Summary of the main findings of the study
a) Recombinant galectin-3 at pathologically relevant concentrations 
seen in the circulation of cancer patients increases cancer cell heterotypic 
adhesion to vascular endothelial cells under static as well as under fluid flow 
conditions.
b) Recombinant galectin-3 induces cancer cell trans-endothelial 
migration.
c) Recombinant galectin-3 induces cancer cell homotypic aggregation 
under anchorage-independent conditions.
d) The aggregation induced by galectin-3 is associated with increased 
survival and resistance of the cells to anoikis initiation in response to 
suspension.
e) The effect of galectin-3 on cancer cell homotypic aggregation and 
heterotypic adhesion to endothelium is via binding of galectin-3 to the 
Thomsen-Friedenreich carbohydrate antigen on the transmembrane mucin 
protein MUC1.
f) The galectin-3-MUCl interaction induces MUC1 cell surface 
polarization that results in exposure of the cell surface adhesion molecules 
including E-cadherim CD44 and ligand for E-selectin.
g) Pre-incubation of galectin-3 with cancer cells before tumour cell 
inoculation into immunodeficient mice decreases the latency of experimental
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metastasis.
li) The TF-binding peanut agglutinin induces cancer cell homotypic 
aggregation and heterotypic adhesion on vascular endothelial cells in cell 
culture and promotes tumour cell survival under suspension conditions.
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Chapter 8
8. General discussion and implications for future studies
8.1. Discussion
The results presented in this thesis show that recombinant galectin-3 at 
pathologically-relevant circulating galectin-3 concentrations increases cancer 
cell homotypic aggregation and heterotypic adhesion to vascular endothelium 
and trans-endothelium invasion under static and fluid flow conditions, and 
increases experimental metastasis in athymic nude mice as a result of its 
interaction with TF antigen on cancer-associated MUC1. The galectin-3- 
TF/MUC1 interaction causes MUC1 cell surface polarization and exposure of 
the cell surface adhesion molecules(Fig8-l and Fig8-2).
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Fig 8-1. Model of the effect of mucl expression on cancer cell adhesion to 
vascular endothelium. MUC1 over expression around the cell surface 
prevent cancer cell adhesion to vacular endothelium..
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Fig 8-2. Model of the mucl-galectin-3 interaction in promotion of cancer 
cell homotypic adhesion to vascular endothelium and cancer cell 
homotypic aggregation. MUC1-galectin-3 interaction causes MUC1 cell 
surface polarization and exposure of the cell surface adhesion molecules, 
which causing increased cancer-endothelial adhesion and cancer cell 
aggregation.
It was already known that the cell surface-associated galectin-3 is involved in 
many cell-cell and cell-matrix interactions (120. 211) and promotes cancer 
development and metastasis (211). Cancer cell-associated galectin-3 is 
reported to play an important role in tumour cell heterotypic adhesion to 
endothelium(l 16), cancer cell homotypic aggregation( 121). and cancer cell 
invasion(233, 234). The bivalent and multivalent properties of galectins 
enable them to bridge two of the same or different cell types, which allows 
homo- or heterotypic cell-cell interactions, and also interaction of the cells
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with extracellular matrix proteins (120). Although the concentration of 
circulating galectin-3 was previously known to be increased in the serum of 
patients with many cancers (209, 235, 237) (238), the functional significance 
of this increased galectin-3 concentration was previously unknown. The 
results from this study suggest that the increased circulation of galectin-3 
plays an important role in promoting tumour cell haematogenous spread to 
remote organs. Thus, blocking the actions of circulating galectin-3 in the 
bloodstream of cancer patients may represent a novel therapeutic approach for 
preventing metastasis.
Tumour recurrence and metastasis are the big problem in cancer patients after 
surgical treatments of the primary tumour. Circulating tumour cells (CTCs) 
can be present in patients for 7-20 years without evidence of clinical disease 
after mastectomy (275). CTCs seem to be non-proliferating cells that persist 
during chemotherapy and are linked to cancer progression (276). An increase 
of CTCs in patients is associated with a higher risk of relapse and a poor 
prognosis (277). The number of circulating tumour cells before any treatment 
is an independent predictor of progression-free survival and overall survival in 
patients with metastatic breast cancer (278). Furthermore, detection of 
elevated CTCs at any time during therapy is an accurate indication of 
subsequent disease progression and mortality for metastasis breast cancer 
patients (279). Patients with >5 CTCs/7.5 mL have shorter mean overall 
survival than those with <5 CTCs/7.5 mL (278, 279). This study suggests that 
the aggregation induced by galectin-3 is associated with increased survival 
and resistance of the cells to anoikis initiation in response to suspension. Thus,
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blocking the interaction of circulating galectin-3 with MUC1 in the 
bloodstream of cancer patients may reduce CTC survival.
Peanut agglutinin binds highly specifically to the TF antigen and has been 
shown in our previous studies to appear rapidly in the bloodstream after 
peanut ingestion in a human subject (Wang et ah, 1998). The work described 
in this thesis shows that the presence of PNA at concentrations seen in the 
serum of people who eat 200g of peanuts increases cancer cell homotypic 
aggregation and heterotypic adhesion in cell culture and enhances tumour cell 
survival under anchorage-independent conditions. These in vitro data suggest 
that the presence of PNA in the bloodstream of cancer patients who eat 
peanuts may represent a detrimental exogenous factor in cancer cell spread. 
Although further studies are needed, these preliminary data suggest that a 
recommendation to avoid peanuts in the diet of cancer patients might help to 
increase the overall survival of those patients.
8.2. Implications for Future Studies
This study reveals a molecular mechanism that promotes metastasis. It has 
also raised a number of interesting questions which require further 
investigation, A research project is currently ongoing investigating the 
expressions of the other galectin members in the circulation of cancer patients 
and healthy people. As members of the galectin family are widely expressed 
by many cell types, it is possible that some other galectins members are also 
altered in the circulation of cancer patients and that these may also act like
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galectin-3 and promote metastasis.
It is noted that pre-incubation of galectin-3 with the MUC1 negatively 
transfected cells before tumour cell injection into nude mice resulted in about 
20% decrease of the metastasis-associated animal survival. This indicates that 
galectin-3 may have other ceil surface ligands. Galectin-3 recognizes 
galactoside-terminated glycans which are known to be expressed by many cell 
surface molecules (TableS-1). Many of those cell surface molecules are 
known to be involved in signal transduction and cell adhesion (232). The cell 
surface-associated galectin-3 has been shown previously to interact with 
laminin, carcinoembryonic antigen, and lysosome-associated membrane 
glycoproteins, and increases human colon cancer cell adhesion to extracellular 
matrix(280). A recent study demonstrated that cell-associated galectin-3 
regulates fibronectin polymerization and tumor cell motility by binding to the 
branched N-glycan ligands and stimulate focal adhesion remodeling, FAK and 
PI3K activation, local F-actin instability, and alphaS beta 1 translocation to 
fibrillar adhesions(281). Hence, an interaction between circulating galectin-3 
and some of these cell surface molecules may also be involved in galectin-3- 
mediated metastasis promotion.
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Table8-1 Ligands recognized by galeetin-3
Lisands Function associated with galectin-3 binding
Laminin
Collagen IV 
Fibronectin Vitronectin 
Hensin 
Elastin
Mac-2BP (gp 90) 
Cubilin
Cell/ECM adhesion
Modulates cell/ECM adhesion 
Modulates cell/ECM adhesion 
Modulates cell/ECM adhesion 
Maintains terminal differentiation of epithelial cells 
Promotes adhesion of cells to elastin 
Promotes cell/cell and cell/ECM adhesion 
Adhesions and endocytosis 
Cell/ECM adhesion
Colon cancer mucins 
Carcino-embrionic 
antigen (CEA) 
Advanced 
glycosilation end 
products (AGE) 
aipiintegrins 
aMpl (CD1 lb/18. 
Mac-1 antigen)(human 
macrophage) 
N-glycans on 
alpha3betal integrin 
CD66a/CD66b (human 
neutrophils)
CD98 (Jurkat cells)
CD4+/CD8+(T
lymphocytes)
FcgRII (human 
eosinophilic leukemia 
cells)
NCA-160 (human 
neutrophils)
Neural cell adhesion 
molecules (NCAM) 
MAG, LI
Cell/cell and cell/ECM adhesion 
Cell/cell and cell/ECM adhesion
Mediates endocytosis of AGE
Modulates cell/ECM adhesion
Modulates cell/ECM adhesion
subsequently activating alpha3betal-integrin-Racl 
signaling to promote lamellipodia formation(282) 
Induces activation NADFI oxidase and adhesion of 
cells to ECM
Induces uptake of extracellular Ca2+ and 
modulates cell 
ECM adhesion
Inhibits apoptosis and modulates cell/ECM 
adhesion
Downregulates of IL-5 gene expression
Induces an oxidative burst in neutrophils 
Modulates cell/ECM adhesion
IgE (rat basophilic _ .
leukemia cells) riggers degranulation and serotonin release
Lamp-1, Lamp-2 
(tumor cells) 
Lipopolysaccharides 
(LPS) (bacteria) 
Mgat5-modi tied N- 
glycans
Modulates cell/cell, cell/ECM adhesion
Adhesion of pathogen organisms to host ECM and 
cells
regulates fibronectin matrix remodeling in tumor 
cells(28l)
Table was adapted from Ochieng J. et al(2004) (232).
The likely involvement of circulating galectin-3 in metastasis shown in this 
study implies that circulating galectin-3 inhibitors could help to reduce cancer
183
cell metastatic spread and increase survival. Thus, developing novel galectin-3 
inhibitors that could be administered directly into the blood circulation of 
cancer patients may represent a promising therapeutic approach for the 
prevention of metastasis.
Cancer cells are normally shown to carry shorter and less branched O-linked 
carbohydrate chains, with increased sialylation and reduced sulfation (Boland 
and Deshmukh 1990; Lloyd, Burchell et al. 1996; Rhodes 1996). But the 
expressions of the glycosyltransferase alone may not account for the altered 
glycosylation changes in cancer cells as discussed in section 1,2.3 of chapterl. 
Redistribution of the glycotransferases in the Golgi apparatus (130) (131) and 
the inappropriate Golgi pH may be responsible for altered glycosylation 
potential (132-134). Further investigations of the mechanisms that lead to the 
expression of TF/MUC1 will help to design new therapeutic agnets to prevent 
circulating galectin-3-mediated metastasis promotion.
The discovery that PNA at relevant concentrations increases tumour cell 
aggregation and adhesion to vascular endothelial cells suggests that the 
presence of peanuts in the diet of cancer patients may represent an 
unfavourable factor in patients' survival. An epidemiological investigation 
into this hypothesis has produced supporting data (see Appendix2).
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Appendix 1
Effect of MUC1 expression and MUCl-gaIectin-3 interaction on 
metastasis in vivo in nude mice (conducted by Prof Xiuli Guo et al in 
Shangdong University of China)
Methods: Eight-week-old female BALB/c athymic (m/Vm/+) nude mice were 
obtained from the Shanghai SLAC Laboratory Animals (Shanghai Institute for 
Biological Sciences) and maintained and used in accordance with the animal 
care protocol approved by Shandong University.
Suspensions (1.0 x 106 cells/mL with PBS) of ACA19+ and ACA19“ cells 
were passed through a 20-pm nylon mesh and incubated with or without 
galectin-3 (1 pg galectin-3 per 0.25 x 106 cells) with gentle shaking (30-60 
rpm) for 1 h at 37°C before injection of the whole-cell suspension into the 
lateral tail vein of the experimental mice. Forty-eight experimental animals 
were randomly divided into four groups: 11 animals per group were injected 
with or without galectin-3-pretreated ACA19- and 13 animals per group were 
injected with or without galectin-3-treated ACA19+ cells. The animals were 
maintained under standard conditions and observed daily. Two animals per 
group were randomly picked and sacrificed under ether anesthesia at days 20, 
40, 60, and 80 (only the two ACA19+groups at the last time point), and tumor 
metastases in lung, liver, and kidney were assessed by light microscopy. The 
remainder of the animals (five animals per group) were killed when 
considered by an independent blinded observer to be moribund, and the 
animal survival time from metastasis-associated death was recorded.
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Immediate dissections of these animals were also done, and metastasesto lung, 
liver, and kidney were examined by light microscope.
Results and discussion:
Forty-seven of the 48 experimental animals developed metastasis after 
inoculation of ACA19+ or ACA19 cells with or without galectin-3 
pretreatment. Metastatic foci were seen in the lungs but not in the other organs. 
At day 20. several metastatic foci in the edges of the lung lobes appeared in 
animals injected with ACA19-. Metastatic foci were not visible in those 
injected with ACA19+ at day 20 but were visible at day 40(Fig4-27C , Fig4- 
27D.Table4-l)
Fig4-27. Effects of MUC1 and MUCl-galectin-3 on ACA19 cell metastasis 
in athymic mice.O macroscopic appearance of representative lungs 40 d 
after tumor cell injections. Arrows, metastatic foci. D, H&E staining of 
representative lung sections from animals 40 d after tumor cell injection. 
Arrows, metastatic lesions. Bar, 200 pm.
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Table S1. the numbers of metastatic foci on surface of the lungs in two of the 
sacrificed experimental animals in each group
Animal groups Average numbers of foci
Day 20 day 40 day 60 day 80
ACA19+ 2±0 19±4 36±5 66±10
ACA19+/Gal3 18±3 41 ±6 70±6 131±13
ACA19- 32±8 99±5 166±46
ACA19-/Gal3 172±23 217±11 192±18
Table 4-1. Metastatic foci on the surface of the lungs of the experimental 
animals. The numbers of metastatic foci on the surface of lungs in the two 
sacrificed experimental animals at day 20, 40, 60 and 80 in each group were 
counted under a dissecting microscope. The data are expressed as mean 
numbers (the actual numbers for each animal are shown in the brackets) of the 
metastatic foci. It was noted that there were huge variations of the sizes of the 
metastatic foci in each experimental animals.
Animals bearing ACA19+ cells survived significantly longer (164 ± 52 days) 
than those bearing ACA19“ cells (85 ± 22 days; P = 0.006; Fig4-28).
1.00
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Fig4-28. Effects of MUC1 and MUC l-galectin-3 on ACA19 cell metastasis 
in athymic mice. A, animals injected with ACA19+ cells have markedly 
increased survival compared with those injected with ACA19" cells.
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Pretreatment of ACA19+ cells with galectin-3 resulted in 35% reduction in 
animal survival (107 ± 31 days; P = 0.05:Fig4-29).
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250
Fig4-29. Effects of MUC1 and MUC1-galectin-3 on ACA19 cell 
metastasis in athymic mice. Pretreatment of ACA19+ cells with galectin-3 
before injection led to shortened animal survival.
These results provide proof of concept that the effects of MUC1 expression and 
galectin-3-MUCl interaction on cancer cell-endothelial adhesion are associated 
with decreased and increased metastasis, respectively. Pretreatment of AC A19“ 
cells with galectin-3 resulted in a small but statistically nonsignificant reduction 
of animal survival from metastasis-associated death (62 ± 12 days; P = 0.1) 
compared with those injected with ACA19“ cells alone. This suggests that 
recombinant/circulating galectin-3 may interact with other cell-surface 
molecules apart from MUC1 and that such interaction, although not affecting 
endothelial adhesion, may also contributeto metastasis.
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Appendix 2
Little or no peanut consumption
Regular peanut eaters
P=0.045
o
0 5 10
Years of survival without colorectal cancer death
Retrospective analysis of mortality amongst the patients studied in an earlier 
case-controlled epidemiological study conducted by our group (Evens et ah 
2002) shows a weak but significant correlation between regular consumption 
of peanut and poor survival of patients with colorectal cancer (the analysis are 
corrected for age, site of cancer, intakes of calories, alcohol, protein and fat). 
This earlier epidemiological study covered a population of 1,276,092 people 
residing in 62 postal codes and included 512 cancer patients in the Merseyside 
and Cheshire Cancer Registry and 512 matched controls.
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Abstract
Adhesion of circulating tumor cells to the blood vessel 
endothelium is a critical step in cancer metastasis. We show 
in this study that galectin-3, the concentration of which is 
greatly increased in the circulation of cancer patients, 
increases cancer cell adhesion to macrovascular and micro- 
vascular endothelial cells under static and flow conditions, 
increases transendothelial invasion, and decreases the latency 
of experimental metastasis in athymic mice. These effects of 
galectin-3 are shown to be a consequence of its interaction 
with cancer-associated MUC1, which breaks the “protective 
shield” of the cell-surface MUC1 by causing MUC1 polariza­
tion, leading to exposure of smaller cell-surface adhesion 
molecules/ligands including CD44 and ligand(s) for E-selectin. 
Thus, the interaction in the bloodstream of cancer patients 
between circulating galectin-3 and cancer cells expressing 
MUC1 bearing the galectin-3 ligand TF (Gal01,3GalNAc-) 
promotes metastasis. This provides insight into the molecular 
regulation of metastasis and has important implications for 
the development of novel therapeutic strategies for prevention 
of metastasis. [Cancer Res 2009;69(17):6799-806]
Introduction
One of the critical steps in cancer metastasis is the adhesion of 
disseminating tumor cells to the blood vessel endothelium in distant 
organs. This process is thought to be regulated by the mechanical 
properties of the cancer cells and also by the specific expression of 
various adhesion molecules and/or ligands to adhesion molecules 
on the surface of cancer cells and endothelial cells (1).
MUC1 is a large transmembrane mucin protein that is expressed 
on the apical surface of most secretory epithelia. The extracellular 
domain of MUC1 consists of variable numbers of 20-amino-acid 
tandem repeat (VNTR) peptides that are heavily glycosylated (up to 
50% of the molecule weight) with complex O-glycans (2). The 
expression of MUC1 is increased up to 10-fold in epithelial cancers 
(3), and this increased MUC1 expression is associated with high 
metastatic potential and poor prognosis (4, 5). The cancer- 
associated MUC1 loses its apical membrane polarization, becoming 
expressed over the entire cell surface (6, 7), and shows reduced
Note: Supplementary data for this article are available at Cancer Research Online 
(http://cancerres.aacrjournals.org/).
Requests for reprints: Lu-Gang Yu, The Henry Wellcome Laboratory, School of 
Clinical Sciences, University of Liverpool, Liverpool L69 3GE, United Kingdom. Phone: 
-1-1-151-794-6820: Fax: 44-151-794-6825: E-mail: lgyu@Hv.ac.uk.
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expression of complex O-glycans and increased expression of 
short oligosaccharides such as GalNAco- (Tn antigen), sialylated 
GalNAcn- (sialyl-Tn), and Galpi.SGalN’Aca-. the oncofetal 
Thomsen-Friedenreich (TF) antigen (8). The TF antigen, which 
is concealed by more extensive glycosylation and sialylation in 
normal epithelium, is revealed on -90% of human epithelial 
cancer cells (9). Cancer-associated MUC1 and the cancer- 
associated high molecular weight splice variant of the adhesion 
molecule CD44v6 (10) are probably the major cell-surface 
glycoproteins that carry the unsubstituted TF antigen, but the 
secreted mucin, MUC2, has also been shown to earn- the 
unsubstituted TF in LSLiM6 human colon cancer cells (4). In 
gastric and colorectal adenocarcinomas, MUC1 is the predom­
inant carrier of TF (11, 12), and the expression of TF on MUC1 
correlates with increased pathologic tumor-node-metastasis 
staging, histologic grading, and unfavorable prognosis (13, 14).
Because of its huge size and length (protruded >10 times higher 
above the cell surface than the typical cell-surface molecules), 
overexpression of MUC1 promotes tumor cell release from primary 
tumor sites by inhibiting E-cadherin-mediated cell-cell and 
integrin-mediated cancer-matrix interactions (6, 7). Binding of 
cell-surface MUC1 by intercellular adhesion molecule-1 increases 
cancer cell interaction with B lymphocytes (15), fibroblasts (16), 
and endothelial cells (17) in cell culture under static conditions. 
Cell-surface MUC1 is also involved in signal transduction via 
interaction of its cytoplasmic tail with important intracellular 
signaling proteins, such as p53 and (Vcatenin, and suppresses 
cellular apoptosis in response to DNA damage (18, 19).
Galectin-3 is a galactoside-binding protein that is expressed in 
many cell types (20) and is found inside cells, extracellularly (but 
still cell surface associated) and in the circulation. Intracellular 
galectin-3 is an apoptosis inhibitor and mRNA splicing promoter, 
whereas extracellular cell surface-associated galectin-3 acts as an 
adhesion molecule during cell-cell interactions and is associated 
with metastasis (20. 21). For example, galectin-3 expressed on 
the surface of breast cancer cells as well as on endothelial cells 
promotes adhesion of breast cancer cells to endothelium by 
interaction with cancer-associated TF antigen expressed by 
unknown cell-surface molecules (22, 23). Concentrations of 
circulating galectin-3 are markedly increased in the sera of cancer 
patients, and patients with metastatic disease have higher 
concentrations of circulating galectin-3 than those with localized 
tumors (24-26).
Recently, we reported that MUC1 is a natural ligand of galectin-3 
in human cancer cells and that binding of recombinant galectin-3 
to cancer-associated MUCl, via the TF antigen, induces MUC1 
cell-surface polarization and increases the adhesion of human 
epithelial cells to human umbilical vein endothelial cells (HUVEC)
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under static cell culture conditions (27). Previous investigations 
have indicated that the great size and length of MUC1 allows 
it to form a protective shield on the cell surface and inhibit cell-cell 
and cell-matrix interactions (6, 7). We therefore suggested that 
interaction between circulating galeetin-3 and cancer-associated 
MUC1 in the bloodstream of cancer patients may break the 
“protective shield” of MUC1 and reveal smaller cell-surface 
adhesion molecules/ligands that enhance cancer cell-endothelial 
adhesion and, hence, promote metastasis (27).
The present study provides in vitro and in vivo evidence that 
strongly supports this hypothesis. It shows that overexpression of 
cell-surface MUC1 is associated with reduced cancer cell-endothelial 
adhesion under static and flowr conditions and with decreased 
cancer cell transendothelial invasion and increased survival of 
athymic nude mice inoculated i.v. with malignant melanoma cells. 
The interaction of cell surface MUC1 with recombinant galectin-3 at 
pathologically-relevant circulating galectin-3 concentrations mark­
edly reduces the protective effects of cell surface MUC1 on cancer 
cell adhesion, trans-endothelial invasion and metastasis-free sur­
vival as a consequence of MUC1 cell surface polarization and 
subsequent exposure of cell-surface adhesion molecules/ligands 
including CD44 and ligand(s) for E-selectin.
Materials and Methods
Materials. Recombinant hill-length human galectin-3 and monoclonal 
antibodies (in,\b) against human CD44H (BBA10) and E-selectin (BBA16) were 
from R&D Systems. B27.29 anti-MUCl mAb was kindly provided by Hr. Mark 
Reddish (Biomira, Inc.). Xonenzymatic Cell Dissociation Solution was from 
Sigma Vybrant DiO Cell-Labeling Solutions were from Molecular Probes.
Cell lines. Human colon cancer HT29 and HT29-5F7 cells were obtained 
and cultured as described previously (27). Macrovascular HUVECs and 
human microvascular lung endothelial cells (HMVEC-L) were from 
Cambrex BioSciences and were cultured in EGM endothelial growth 
medium (EGM Bulletkit) and EGM-2 medium (EGM-2 Bulletkit. Cambrex 
BioSciences), respectively. Cells that had been passaged less than five times 
were used in the experiments. ML’Cl transfection of human melanoma 
A375 cells with full-length cDN'A encoding MUC1 resulted in the MUCT 
positive transfectants ACAI9\ and the subsequent bulk selection of the 
MUCl-negative revertants ACA19 was as described previously (6).
Cancer cell-endothelial adhesion. Cancer cell-endothelial adhesion 
was done as described previously (27). At the end of the experiments, 
the samples were blinded and the tluorescently labeled cells remaining 
on the endothelial monolayer were counted in 10 randomly selected fields 
of view using fluorescent microscopy (Olympus B51). The ability of the 
cells to be labeled by the fluorescent dye was different between any 
two human cell lines tested in our pilot experiment. As comparison of
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Figure 1. Effects of MUC1 and MUC1- 
galectin-3 on cancer cell-HUVEC adhesion 
under static conditions. A, ACA19* cells adhere 
less than ACA19 cells to HUVECs.
Columns, mean of triplicate determinations 
from three independent experiments; bars, SE.
B, pretreatment of the cells with galectin-3 
increases ACA19*, but not ACA19 , cell 
adhesion to HUVECs. Columns, mean
of three independent experiments; bars, SE.
C, siRNA MUC1 suppression in ACA19’ cells. 
Representative blots of three experiments.
D, MUC1 suppression increases ACA19+ 
cell adhesion (left) and abolishes 
galectin-3-induced cell adhesion (right). 
Columns, mean of three independent 
experiments; bars. SE. *, P < 0.05; **. P < 0.01; 
***, P < 0.001.
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Figure 2. Effects of MUC1 and 
MUC1-galectin-3 on cancer 
cell-HMVEC-Ls adhesion under static 
conditions and on cancer cell-HUVEC 
adhesion underflow conditions. A, ACA19* 
cells adhere less than ACA19 cells to 
HMVEC-Ls. Columns, mean of three 
independent experiments; bars. SE.
B, galectin-3 (1 iit^roL) increases ACA19\ 
but not ACA19 , cell adhesion to 
HMVEC-Ls. Columns, mean of two 
independent experiments; bars, SE.
C. ACA19+ cells adhere less than ACA19 
cells to HUVECs at 0.05-Pa shear 
stress flow conditions. Columns, mean of 
seven independent experiments;
bars, SE. D, galectin-3 (1 ng/mL) treatment 
increases adhesion of ACA19*, but not 
ACA19 , cells to HUVECs under flow 
conditions. Columns, mean of five 
ACA19* and six ACA19“ independent 
assessments; bars, SE. *, P < 0.05;
", P < 0.01; ***, P < 0.001.
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the cell adhesion between different MUCl-expressing cells is an important 
part of this study, the actual number of the fluorescently labeled cells adhered 
to endothelial monolayer, rather than the reading of the fluorescent density, 
was used as the end point
MUC1 small interfering RXA knockdown. ACA19' cells were trans­
fected with 100 nmol/L MUC1 small interfering RNA (siRNA) or scrambled 
control nontargeting siRNA (siCONTROL. Dharmacon) for 48 h at 37°C. The 
cells were lysed and the expression of MUC1 was assessed by MUC1 
immunoblotting with the B27.29 anti-MUCl antibody.
Cell adhesion under flow conditions. HUVECs, cultured in flattened 
glass capillaries for 24 h at 37°C to allow the cells to form monolayers as 
described previously (28), were unstimulated or stimulated with 10 ng/mL 
tumor necrosis factor-a (TNF-a) for 24 h at 37eC before the introduction of 
cancer cells. ACA19* - cells were incubated with or without 1 pg/mL 
galectin-3 for 30 min at 37°C. The cells were then perfused through glass 
capillaries at a flow rate to dehver 0.05-Pa shear wall stress. After 4 min of 
washing with PBS, the capillaries were video-recorded and the number of 
adherent cells was quantified and expressed as the number of adherent cells 
per square millimeter per 106 cells perfused.
Cell-surface expressions of E-selectin and CD44. Cells released with 
Nonenzymatic Cell Dissociation Solution were fixed with 2% paraformal­
dehyde for 0.5 h, blocked with 5% normal goat serum/PBS for 0.5 h, and 
incubated with antibodies against E-selectin or CD44H for 1 h at room 
temperature. After application of fluorescein-conjugated secondary anti­
body for 0.5 h, the expression of cell-surface E-selectin or CD44 was 
analyzed by flow cytometry.
Transendothelial invasion. HUVECs were cultured in Transwell inserts 
with 8-pm-pore filters (BD Falcon) for 3 d to allow tight formation of cell 
monolayers. Monolayer integrity was monitored by measuring trans­
endothelial electrical resistance using a volt-ohm meter (EVOM, World 
Precision Instruments), and monolayers with transendothelial electrical 
resistance >800 fl/cm2 were used for transendothelial assessment. 
Epithelial cells, labeled with DiO, were incubated with or without 
galectin-3 for 30 min at 37°C before application of the cells to the HUVECs 
for 16 h at 37°C. The cells at the upper side of the Transwell membrane 
were removed with a cotton sw’ab and fluorescent cells migrated to the
bottom side of the Transwell membrane were counted using an Olympus 
B51 fluorescence microscope.
Metastasis and survival. Eight-week-old female BALB/c athymic {nu / 
nu*) nude mice were obtained from tire Shanghai SLAC Laboratory Animals 
(Shanghai Institute for Biological Sciences) and maintained and used in 
accordance with the animal care protocol approved by Shandong University.
Suspensions (5.0 x 10h cells/ml. with PBS) of ACA19* and ACA19 cells 
were passed through a 20-pm nylon mesh and incubated with or without 
galectin-3 (1 pg galectin-3 per 0.25 x I0b cells) with gentle shaking 
(30-60 rpm) for 1 h at 37°C before injection of the whole-cell suspension 
into the lateral tail vein of the experimental mice. Forty-eight experimental 
animals were randomly divided into four groups: 11 animals per group 
were injected with or without galectin-3-pretreated ACA19 and 13 
animals per group were injected with or without galectin-3-treated ACA19' 
cells. The animals W'ere maintained under standard conditions and 
observed daily. Two animals per group were randomly picked and sacrificed 
under ether anesthesia at days 20, 40, 60, and 80 (only the two ACA19' 
groups at the last time point), and tumor metastases in lung, liver, and 
kidney were assessed by light microscopy. The remainder of the animals 
(five animals per group) were killed wrhen considered by an independent 
blinded observer to be moribund, and the animal survival time from 
metastasis-associated death was recorded. Immediate dissections of these 
animals were also done, and metastases to lung, liver, and kidney were 
examined by light microscopy.
Statistical analysis. Paired or unpaired t test for single-comparison, 
one-way ANOVA followed by Newman-Keuls’ test for multiple comparisons,
test, and Kaplan-Meier analysis followed by log-rank test (StatsDirect for 
Windows, StatsDirect) ware used where appropriate. Differences were 
considered significant when P < 0.05.
Results
Cancer cell-endothelial adhesion is inhibited by MUC1 
expression but increased by ML’Cl-galectin-3 interaction.
A375 human melanoma cells transfected with MUC1 (ACA19*)
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□ Control (BSA)
37C Pro-fixed
Figure 3. Galectin-3 and B27.29 anti-MUCI mAb both induce increased 
adhesion to HUVECs of live, but not prefixed, ACA19* or ACA19 cells. Live or 
paraformaldehyde-prefixed ACA19W~ cells were pretreated with 1 ng/mL 
recombinant galectin-3, B27.29 mAb, bovine serum albumin (BSA), or control 
mouse IgG before adhesion to HUVECs. Columns, mean of four independent 
experiments; bars, SE. *, P < 0.05.
showed significantly less adhesion to unstirnulated and TNF-a- 
prestimulated HUVECs compared with the MUCl-negative rever- 
tants (ACA19 ; Fig. M). To determine the effect of circulating 
galectin-3 on cancer cell adhesion to endothelium, we pretreated the 
cells with recombinant galectin-3 at several pathologically relevant 
circulating galectin-3 concentrations. Earlier investigation by lurisci 
and colleagues (24) has shown that the concentration of circulating 
galectin-3 increases up to 5-fold in the sera of cancer patients with 
melanoma, breast, or gastrointestinal cancer (range, 20-950 ng/mL) 
compared with healthy people. Our own investigation has indicated 
that the concentrations of circulating galectin-3 in the sera of 
colorectal cancer patients are > 14-fold higher (up to 5 pg/mL) than 
in healthy people.5 We found that pretreatment of the cells with 
galectin-3 at concentrations >100 ng/mL resulted in significant 
increase of ACA19*, but not ACA19^, cell adhesion to HUVECs 
(Fig. IB). Immuno/lectin blots of ACA19* and ACA19- cells with 
B27.29 anti-MUCI mAb and TF-binding DNA showed that MUC1 in 
ACA19* cells is abundantly decorated with TF antigens (Supplemen­
tary Fig. SI). Suppression of MUC1 expression by siRNA in ACA19+ 
cells w'as associated with 47% increased adhesion of the cells to 
HUVECs, and this prevented the increase of cell adhesion in response 
to galectin-3 (Fig. 1C and D). Thus, the presence of extracellular free 
galectin-3, by its interaction with MUC1, counteracts the antiadhesive 
effect of MUC1 expression on cancer cell adhesion.
To determine w'hether MUCl-galectin-3 interaction has similar 
effects on cell adhesion in cancer cells that naturally express 
MUC1, we compared the adhesion of human colon cancer HT29 and 
HT29-5F7 cells in the presence or absence of recombinant galectin- 
3. HT29-5F7 is a HT29 subline selected by its resistance to 
5-fluorouracil and has much greater MUC1 than the parental 
HT29 cells (ref. 29; Supplementary Fig. S2). HT29 cells showed signi- 
ficantly more adhesion to unstimulated and TXF-a-prestimulated
J H. Barrow, J.M. Rhodes, and L.G. Yu, in preparation.
HUVECs than HT29-5F7 cells (Supplementary Fig. S3A). Pretreat­
ment of the cells with galectin-3 significantly increased adhesion of 
HT29-5F7, but not HT29, cells to HUVECs, and this effect was 
abolished by the presence of TF-expressing asialofetuin (Supple­
mentary Fig. S3).
We also assessed whether galectin-3 may have been secreted into 
the medium by the cancer cells, but we found no detectable 
endogenously secreted galectin-3 (<0.325 ng/mL. the detectable 
limit of the assay) in the medium during the 1.5-hour assessment 
period. Thus, the contribution of endogenously secreted galectin-3 
to recombinant galectin-3-mediated cell adhesion in these assess­
ments is minimal.
To see w'hether the effects of MUCl-galectin-3 interaction on 
cancer cell adhesion to HUVECs also occur with microvascular 
endothelium, a model that is probably closer to the in vivo situation 
in metastasis, we analyzed cell adhesion to HMVEC-L. Again, 
ACA19* cells showed significantly less adhesion to unstimulated 
and TNF-a-prestimulated HMVEC-Ls than ACA19~ cells (Fig. 2A). 
Pretreatment of the cells with galectin-3 (1 pg/mL) increased 
adhesion of ACA19+ cells but not of ACA19 cells (Fig. 2j5).
Collectively, these results indicate that MUC1 expression 
prevents cancer cell adhesion to macrovascular and microvascular 
endothelium and that MUCl-galectin-3 interaction reduces this 
protective effect of MUC1.
Cancer cell-endothelial adhesion under flow' conditions is 
inhibited by MUC1 expression but increased by MUCl- 
galectin-3 interaction. Under shear flow conditions, very few 
ACA19+ or ACA19” cells showed adhesion to unstimulated 
HUVECs, but their adhesion was markedly increased when 
HUVECs were pretreated with TNF-ot (Fig. 2C). Moreover. 
ACA19+ cells showed 68% less adhesion than ACA19 cells to 
TNF-a-stimulated HUVECs under such conditions. Pretreatment 
of the cells with 1 pg/mL galectin-3 resulted in 55% increased 
adhesion of ACA19' cells but not of ACA19 cells (Fig. 2D). Thus, 
the effects of MUC1 expression and galectin-3-MUCl interaction 
on cancer cell-endothelial adhesion seen under static conditions 
also hold true under flow' conditions.
(ialectin-3 and B27.29 anti-MUCI mAb have similar effects 
on MUC1 cell-surface polarization and on cell adhesion. We 
have previously shown that galectin-3-MUCl interaction induces 
change in MUC1 cell-surface localization (27). To see w’hether this 
change in MUC1 localization is associated with altered cell 
adhesion to endothelium, we compared MUC1 cell-surface 
clustering in response to galectin-3 and cell adhesion to HUVECs.
It w'as found that 10% (48 of 500) ACA19* cells showed 
spontaneous clustering of MUC 1 on the cell surface, as illustrated 
by discontinuity of MUC1 cell-surface staining when cultured in 
suspension for 1 h at 37°C. After pretreatment with galectin-3 
(1 pg/mL) at 37 °C for 1 h, 40% more (68 of 500; P < 0.05) cells 
showed MUC I cell-surface polarization than control cells. Intro­
duction of B27.29 anti-MUCI mAb also resulted in significant 
increase (128 of 500; P < 0.01) in the number of cells showing MUC1 
cell-surface polarization. This effect of B27.29 on MUC 1 cell-surface 
polarization is in keeping with previous reports that the presence 
of 214D4 anti-MUCI mAb, which also recognizes the VNTR region 
of MUC1, induces MUC1 cell-surface polarization in MUC1- 
transfected human melanoma cells (6). The B27.29 mAb recognizes 
the PDTRPAP epitope in the VNTR region of MUC1 (30). and 
nuclear magnetic resonance analysis has indicated an enhanced 
binding affinity of B27.29 to MUC1 in the presence of short sugar 
chains within the VNTR region (31).
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It was found that the increases of MUC1 cell-surface polarization 
in response to galectin-3 and to B27.29 mAh are both associated 
with increased adhesion of ACA19* cells to HUVECs (Fig. 3). 
Furthermore, introduction of galectin-3 or B27.29 mAh to 
paraformaldehyde-prefixed cells, which could not affect the 
MUC1 cell-surface localization, failed to induce cell adhesion 
to HUVECs compared with the control cells. These results 
support a direct link of discontinuous cell-surface localization of 
MUC1 and increased cell adhesion in response to galectin-3 and 
B27.29 mAb.
Involvement of cancer-associated CD44 and endothelial- 
E-selectin in MUCl-galectin-3-induced cancer cell-endothelial 
adhesion. The presence of 25 pg/mL anti-CD44H mAb (BBA10), 
which recognizes all CD44 isoforms, caused 26% {P < 0.05) 
inhibition of ACA19”, but not ACA19*, adhesion to HUVECs, but 
largely blocked ACA19+ cell adhesion induced by galectin-3 
(Fig. AA). The presence of 25 pg/mL anti-E-selectin antibody, 
however, failed to block the adhesion of either ACA19 or ACA194 
cells and also showed no significant inhibition (P = 0.47) of galectin- 
3-induced ACA19* adhesion (Fig. 4A). The presence of either 
anti-CD44H or anti-E-selectin antibody inhibited HT29 cell 
adhesion to HUVECs (Fig. 4fl). Neither of these antibodies at this 
concentration showed significant inhibition of HT29-5F7 cell 
adhesion to HUVECs, but their presence completely prevented the 
increase of HT29-5F7 cell adhesion in response to galectin-3.
Antibody binding followed by flow cytometry analysis showed 
similar CD44 cell-surface expression and antibody accessibility 
between HT29 and HT29-5F7 and between ACA19" and ACA19+ 
cells (Fig. 4C). Thus, the lack of effect of the anti-CD44Fl antibody 
on the adhesion of HT29-5F7 and ACA19+ cells to HUVECs is likely 
due to the inability of cell-surface CD44 to gain access to its
receptor on HUVECs as a result of functional concealment of cell- 
surface CD44, for example, by the presence of adjacent MUC1. The 
inhibition by the anti-CD44H antibody of galectin-3-induced cell 
adhesion, in which cell-surface CD44 is functionally exposed 
following MUC1 cell-surface polarization, supports this conclusion. 
The relatively modest inhibition of the anti-CD44 antibody at 
25 pg/mL on ACA19 adhesion indicates that cell-surface CD44 
may represent just one of several cell adhesion molecules involved 
in melanoma cell-endothelial adhesion.
We found that anti-CD44H antibody pretreatment of HT29 cells, 
but not of HUVECs, caused a significant inhibition of subsequent 
HT29 cell adhesion to HUVECs (Fig. AD). This indicates the 
involvement of HT29-associated, but not HUVEC-associated, CD44 
molecules in HT29-endothelial interaction and in galectin-3- 
mediated cancer cell-endothelial adhesion. This is in keeping with 
earlier reports of a role for cancer-associated CD44 in the initial 
endothelial adhesion of human prostate, breast, and colon cancer 
cells (32, 33).
Neither HT29/HT29-5F7 nor ACA19~/ACA19+ cells express 
E-selectin on their cell surface (Fig. 4C). The HT29 cell adhesion 
to HUVECs and the HT29-5F7 adhesion to HLVECs induced 
by galectin-3 were, however, inhibited by the presence of the 
anti-E-selectin antibody (Fig. AA and B). This suggests the 
involvement of endothelial-E-selectin in these cell adhesion events. 
The different effects of the anti-E-selectin antibody on HT29/ 
HT29-5F7 and ACA19 adhesions to HUVECs likely reflect 
differences in the expression of E-selectin ligands on the surface 
of HT29 colon and ACA19 melanoma cells.
Cancer cell transendothelial invasion is inhibited by MUC1 
expression and increased by MUCl-galectin-3 interaction. 
ACA19 showed 46% greater trans-HUVEC invasion than ACA19*
Figure 4. Involvement of cell-surface CD44 
and ligand(s) to endothelial-E-selectin in 
galectin-3-induced cancer cell-endothelial 
adhesion. A, the presence of 25 ng/mL 
anti-CD44H, but not anti-E-selectin, mAb 
reduces ACA19 cell adhesion and 
adhesion of ACA19* cells induced by 
1 ug/ml galectin-3. Columns, mean of three 
independent experiments; bars, SE.
B, the presence of 25 ng/mL anti-CD44H or 
anti-E-selectin antibody inhibits HT29 and 
HT29-5F7 cell adhesion and adhesion of 
HT29-5F7 cells induced by 1 ng/mL 
recombinant galectin-3. Columns, mean of 
three independent experiments; bars, SE.
C, cell-surface expression of E-selectin and 
CD44 are similar between HT29 and 
HT29-5F7 cells and between ACA19' and 
ACA19 cells. Green, CD44: red, 
E-selectin; purple, isotype control.
D, pretreatment of HT29 cells, but not of 
HUVECs, with 25 (.ig/mL anti-CD44H 
antibody inhibits HT29 cell adhesion to 
HUVECs. Columns, mean of three 
independent experiments; bars, SE.
*, P < 0.05; ’*, P < 0.01; ***, P < 0.001.
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cells (Fig. 5/1). Pretreatment of the cells with galectin-3 (1 (ig/ml.) 
resulted in 64% increased invasion of ACA19* cells but not of 
ACA19 cells (Fig. 5B). This effect of galectin-3 was completely 
prevented by the presence of lactose (Fig. 5C).
Galectin-3 promotes metastasis of ACA19+ MUC1-expressing 
cells in vivo. Forty-seven of the 48 experimental animals developed 
metastasis after inoculation of ACA19+ or ACA19- cells with or 
without galectin-3 pretreatment. Metastatic foci were seen in the 
lungs but not in the other organs. At day 20, several metastatic foci 
in the edges of the lung lobes appeared in animals injected with 
ACA19 . Metastatic foci were not visible in those injected with 
ACA19+ at day 20 but were visible at day 40 (Fig. 6C and D-, 
Supplementary Table SI). Animals bearing ACA19+ cells survived 
significantly longer (164 ± 52 days) than those bearing ACA19 
cells (85 ± 22 days; P = 0.006; Fig. 6A). Pretreatment of ACA19*
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Figure 5. Effects of MUC1 and MUC1-galectin-3 on cancer cell transendothelial 
invasion. A, ACA19* cells show less trans-HUVEC invasion than ACA19 cells. 
Columns, mean of triplicate determinations from six independent experiments; 
bars, SE. S, galectin-3 (1 ng/mL) pretreatment increases ACA19\ but not 
ACA19 , cell trans-HUVEC invasion. Columns, mean of six independent 
experiments; bars, SE. C, galectin-3-mediated transendothelial invasion of 
ACA19* is inhibited by the presence of (10 ng/mL) lactose. Columns, mean of 
four independent assessments; bars, SE. *, P < 0.05; ***, P < 0.0001.
cells with galectin-3 resulted in 35% reduction in animal survival 
(107 ± 31 days; P - 0.05; Fig. 6B). These results provide proof of 
concept that the effects of MUC1 expression and galectin-3-MUCl 
interaction on cancer cell-endothelial adhesion are associated with 
decreased and increased metastasis, respectively. Pretreatment of 
ACA19 cells with galectin-3 resulted in a small but statistically 
nonsignificant reduction of animal survival from metastasis- 
associated death (62 ± 12 days; P = 0.1) compared with those 
injected with ACA19 cells alone. This suggests that recombinant/ 
circulating galectin-3 may interact with other cell-surface mole­
cules apart from MUC1 and that such interaction, although not 
affecting endothelial adhesion, may also contribute to metastasis.
Discussion
This study show's that overexpression of cell-surface MUC1 is 
associated with reduced cancer cell-endothelial adhesion under 
static and flow' conditions and with decreased cancer cell 
transendothelial invasion and increased survival of athymic nude 
mice inoculated i.v. with malignant melanoma cells. The interac­
tion of cell-surface MUC1 with circulating galectin-3 at patholog­
ically relevant concentrations reduces the protective effects of 
MUC1 on cancer cell adhesion, transendothelial invasion, and 
metastasis. These effects of galectin-3 are mediated by MUC1 cell- 
surface clustering and the consequent exposure of cell-surface 
adhesion molecules including CD44 and the ligand(s) for 
endothelial-E-selectin. Thus, the enhanced molecular interaction 
between circulating galectin-3 and cancer-associated MUC1 in the 
bloodstream of cancer patients, occurring as a result of the 
increased expression of MUC1 by cancer cells, the increased 
expression of the galectin-3-ligand TF antigen by cancer-associated 
MUC1, and the increased concentration of circulating galectin-3. all 
of which are common features in cancer, promotes metastasis.
Cancer cell adhesion to endothelium is a vital step in metastasis 
and is mediated by a range of adhesion molecules and their ligands, 
including selectins and integrins expressed on cancer cells and 
endothelial cells, which in turn are regulated by circulating 
molecules such as cytokines (1). The inhibitory effect of MUC1 
expression and the stimulatory' effect of galectin-3-MUCl interac­
tion on cancer cell-endothelial adhesion shown in this study 
suggest that MUC1 cell-surface polarization, which leads to 
uncovering of the smaller adhesion molecules and/or ligands to 
adhesion molecules, represents an essential first step in the process 
of cancer cell-endothelial adhesion. Given the variable expression 
of MUC1 in different cancer cell lines (34), the lack of inhibitory' 
effect of anti-selectin antibodies on cancer cell-endothelial 
adhesion observed in several previous investigations (35) may be, 
to a large extent, due to the concealment of the cell-surface selectin 
ligands by MUC1.
MUC1 can carry sialyl Lewis-related carbohydrate structures 
that act as ligands for selectins (36). However, an interaction 
between cancer-associated MUC1 and endothelial-E-selectin will 
probably not induce tight cell adhesion, a process that is believed 
to require the involvement of cell-surface integrins as has been w’ell 
established for leukocyte-endothelial adhesion (37). Tight cancer 
cell-endothelial adhesion may only occur after MUC1 cell-surface 
polarization and exposure of integrins and other smaller cell 
adhesion molecules. Our previous demonstration (27) that MUC1 is 
absent at the cancer cell-endothelial contact point supports this.
The protective effect of the MUC1 “shield” and the “deprotective” 
effect of the galectin-3-TF/MUCl interaction on cancer cell 
adhesion provide explanations at the molecular level for several
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Figure 6. Effects of MUC1 and MUC1-galectin-3 
on ACA19 cell metastasis in athymic mice.
A. animals injected with ACAIfT cells have markedly 
increased survival compared with those injected with 
ACA19 cells. B, pretreatment of ACA19* cells 
with galectin-3 before injection led to shortened 
animal survival. C, macroscopic appearance of 
representative lungs 40 d after tumor cell injections. 
Arrows, metastatic foci. O, H&E staining of 
representative lung sections from animals 40 d after 
tumor cell injection. Arrows, metastatic lesions.
Bar, 200 urn.
recent clinical and experimental observations related to metastasis, 
for example, the correlation between increased apical MUC1 cell- 
surface polarization and increased lymphatic invasion, recurrence 
rate, and lower overall survival in breast cancer patients (38). The 
correlation of increased concentrations of circulating anti-TF 
antibodies, which would inhibit galectin-3-mediated TF/MUC1 
interactions, with improved prognosis in gastric cancer (39) is also 
consistent with our model. The association of MUC1 sialylation 
with a better prognosis in breast cancer (40) is also in keeping with 
a reduced galectin-3-TF/MUCl interaction as a consequence of 
concealment of TF by sialic acid, thus inhibiting MUCl-galectin-3 
interaction (27). The significant extension of animal sunival 
induced by i.p. coinjection of an anti-TF antibody with metastatic 
4T1 breast cancer cells (41) could be the consequence of the 
blockade of the galectin-3-TF/MUCl interaction.
Because increased occurrence of the TF glycan is one of the 
commonest glycosylation changes in cancer (9), this study also 
highlights the functional importance of cancer-associated changes 
in cellular glycosylation (42, 43) and indicates a potential for glycan 
profiling in predicting cancer metastasis and prognosis. Further­
more, as the increased concentrations of circulating galectin-3 in 
cancer patients are probably produced not only by the tumor cells 
but also by the peritumoral inflammatory and stromal cells (24). 
this also reinforces the importance of the tumor microenvironment 
for metastasis (44, 45).
It should be emphasized that this study focuses on the role of 
circulating galectin-3 on cancer cell adhesion and metastasis. The 
functional importance of cancer cell-associated galectin-3 in 
metastasis is well documented (20, 21). For example, antisense
suppression of galectin-3 in metastatic LSLLVI6 human colon 
cancer cells before inoculation of the cells into athymic mice 
results in reduced liver colonization and metastasis (46), whereas 
suppression of galectin-3 expression by short hairpin RNA in 
melanoma cells reduces tumor cell invasiveness and capacity to 
form tube-like structures on collagen, so-called vasculogenic 
mimicry (47). Similarly, reduction of galectin-3 expression in highly 
malignant human breast cancer MDA-MB-435 cells leads to loss of 
serum- and anchorage-independent growth in vitro and tumor 
growth in nude mice (48).
Thus, galectin-3 released into the bloodstream of cancer patients 
promotes cancer cell hematogenous dissemination by its interac­
tion with TF-expressing MUC1 on cancer cell surface. This provides 
insight into the molecular regulation of metastasis and has 
important implications for the development of therapeutic 
strategies to prevent metastasis.
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